	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S23-PMC2798111	PMC2798111	12/2010	S23-PMC2798111	['as part of an ongoing Vitamin D supplementation trial of fully Lactating women and their infants, we SOUGHT TO DETERMINE WHETHER a dosing regimen that utilizes an oil emulsion of one drop per day to Deliver 400\u2009iu/day is effective in raising infant 25(Oh)D levels from baseline.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 101), ('QUESTION_ANSWERED_BY_THIS_WORK', 108), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 63, 'lactating'), ('GO_0007567', 'parturition', 199, 'deliver'), ('CHEBI_71657', 'versiconol acetate', 249, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 249, '25(OH)D')]
S74-PMC2821652	PMC2821652	2/2010	S74-PMC2821652	['WHILE there is a MODEL in existence which calculates the predicted change in Serum 25(Oh)D for different doses of Vitamin D supplement, this model was developed using data from men [64], and its applicability to a population of Pregnant females is debatable.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 17)]	2	[('UBERON_0001977', 'blood serum', 77, 'serum'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 83, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 228, 'pregnant')]
S77-PMC2821652	PMC2821652	2/2010	S77-PMC2821652	"[""in developing a definition of adherence by Serum 25(Oh)D levels, SEVERAL ASSUMPTIONS were made a priori about WHAT types of PATTERNS of 25(Oh)D levels would be exhibited by adherent and nonadherent patients BASED ON CURRENT KNOWLEDGE about the Metabolism Of Vitamin D.\nassumption 1\nBASED ON KNOWN pharmacokinetics of Vitamin D [64], adherent patients' 25(Oh)D levels would be expected to rise over time, eventually reaching a steady state after 2 months of therapy; nonadherent patients' 25(Oh)D levels would be expected to be erratic and to exhibit variable PATTERNS that would differ significantly from adherent patients' 25(Oh)D levels over the same dosing interval.""]"	[('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 73), ('EXPLICIT_QUESTION', 110), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 207), ('PROBABLE_UNDERSTANDING', 207), ('SUPERFICIAL_RELATIONSHIP', 207), ('INCOMPLETE_EVIDENCE', 216), ('PROBABLE_UNDERSTANDING', 282), ('SUPERFICIAL_RELATIONSHIP', 282), ('INCOMPLETE_EVIDENCE', 291), ('SUPERFICIAL_RELATIONSHIP', 559)]	12	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 136, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 142, 'D'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 244, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 317, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 325, 'D'), ('CHEBI_71657', 'versiconol acetate', 352, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 358, 'D'), ('CHEBI_71657', 'versiconol acetate', 488, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 488, '25'), ('PR_000011614', 'opioid growth factor receptor', 491, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 494, 'D'), ('CHEBI_71657', 'versiconol acetate', 624, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 624, '25(OH ... D')]
S78-PMC2821652	PMC2821652	2/2010	S78-PMC2821652	"[""THEREFORE, the average of each subject's steady-state 25(Oh)D levels (i.e., levels obtained at least 2 months after initiation of Vitamin D therapy) was calculated, and the subject's baseline 25(Oh)D level was subtracted from that value to obtain a value for the change in 25(Oh)D level during the study (change 25Ohd).""]"	[('PROBABLE_UNDERSTANDING', 0)]	1	"[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 192, '25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 273, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 279, 'D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 312, '25OHD')]"
S74-PMC2963768	PMC2963768	10/2010	S74-PMC2963768	['ALTHOUGH there were no significant associations between maternal dietary intake and infant/toddlers’ 25(Oh)D (data not shown) or Vitamin D deficiency (table 3), a higher proportion of the mothers of infants with 25(Oh)D ≥25 nmol/l consumed Milk, meat, and eggs on at least one occasion during the week preceding the interview (fig.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 101, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 212, '25(OH)D'), ('UBERON_0001913', 'milk', 240, 'milk')]
S87-PMC3004407	PMC3004407	12/2010	S87-PMC3004407	['the mean Vitamin D status of the cohort, AS measured by total circulating 25(Oh)D, was 21.7 ± 9.7\u2009ng/ml (range 3.8 to 73.8; unavailable for 7 participants).']	[('PROBABLE_UNDERSTANDING', 41)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 74, '25(OH)D')]
S48-PMC3257641	PMC3257641	3/2010	S48-PMC3257641	['a NUMBER OF STUDIES within non-Pregnant Adult populations have examined 25(Oh)D levels in RELATION to DIFFERENT dosages, preparations or dosing intervals of oral Vitamin D (reviewed in[33]).']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 102)]	3	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('UBERON_0007023', 'adult organism', 40, 'adult'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 72, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
S81-PMC3257641	PMC3257641	3/2010	S81-PMC3257641	['there was a positive CORRELATION between the maternal 25(Oh)D level and the Fetal Metaphyseal cross-sectional area, with the latter 5% and 14% greater in fetuses of mothers who were Vitamin D insufficient (Serum 25(Oh)D 25-50 nmol/l) and Vitamin D deficient (Serum 25(Oh)D < 25 nmol/l) compared to Vitamin D sufficient mothers (Serum 25(Oh)D > 50 nmol/l) [56].']	[('SUPERFICIAL_RELATIONSHIP', 21)]	1	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('UBERON_0000922', 'embryo', 76, 'fetal'), ('UBERON_0001438', 'metaphysis', 82, 'metaphyseal'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('UBERON_0001977', 'blood serum', 206, 'serum'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 218, 'D'), ('CHEBI_27300', 'vitamin D', 238, 'vitamin D'), ('UBERON_0001977', 'blood serum', 259, 'serum'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 265, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D'), ('UBERON_0001977', 'blood serum', 328, 'serum'), ('CHEBI_71657', 'versiconol acetate', 334, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 334, '25(OH)D')]
S90-PMC3257641	PMC3257641	3/2010	S90-PMC3257641	['in a cross sectional study, caesarean section was almost four-times MORE COMMON in women with Vitamin D insufficiency (Serum 25(Oh)D < 37.5 nmol/l) compared to Vitamin D-sufficient women (Serum 25(Oh)D ≥ 37.5 nmol/l), after adjustment for race, age, education level, insurance status, and Alcohol use (adjusted or 3.84; 95% ci 1.71–8.62) [59].']	[('PROBABLE_UNDERSTANDING', 68)]	1	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0001977', 'blood serum', 119, 'serum'), ('CHEBI_71657', 'versiconol acetate', 125, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 125, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('UBERON_0001977', 'blood serum', 188, 'serum'), ('CHEBI_71657', 'versiconol acetate', 194, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 194, '25(OH)D'), ('CHEBI_30879', 'alcohol', 289, 'alcohol')]
S14-PMC3271033	PMC3271033	1/2012	S14-PMC3271033	['Serum 25-Hydroxyvitamin D (25(Oh)D) is ACCEPTED as the BEST MARKER of Vitamin D status ALTHOUGH it MAY serve PRIMARILY as a MARKER of exposure RATHER than clinical outcomes [2].there are FEW DATA that CORRELATE Serum 25(Oh)D levels with functional outcomes in newborns and small infants.']	[('INCOMPLETE_EVIDENCE', 39), ('IMPORTANT_CONSIDERATION', 55), ('SUPERFICIAL_RELATIONSHIP', 60), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 87), ('INCOMPLETE_EVIDENCE', 99), ('PROBABLE_UNDERSTANDING', 109), ('SUPERFICIAL_RELATIONSHIP', 124), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 143), ('INCOMPLETE_EVIDENCE', 187), ('SUPERFICIAL_RELATIONSHIP', 201)]	10	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 6, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0001977', 'blood serum', 211, 'serum'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 217, '25(OH)D')]
S109-PMC3271033	PMC3271033	1/2012	S109-PMC3271033	['supplementation with 400 iu/day of Vitamin D to these infants LED TO a relatively greater increase in those who were Born with the lowest Vitamin D status and there was no suggestion of any bone Mineral outcome deficits at one week or three months of age in infants with low Cord 25(Oh)D levels.']	[('SUPERFICIAL_RELATIONSHIP', 62)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007567', 'parturition', 117, 'born'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_46662', 'mineral', 195, 'mineral'), ('UBERON_0002240', 'spinal cord', 275, 'cord'), ('CHEBI_71657', 'versiconol acetate', 280, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 280, '25(OH)D')]
S134-PMC3271033	PMC3271033	1/2012	S134-PMC3271033	['greer et al [16] FOUND an increase in 25(Oh)D from 24 to 39 ng/ml at three months of age with the provision of 400 iu/day of Vitamin D to Breast-Fed infants.']	[('INCOMPLETE_EVIDENCE', 17)]	1	[('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 38, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007567', 'parturition', 138, 'breast'), ('UBERON_0000310', 'breast', 138, 'breast'), ('GO_0007631', 'feeding behavior', 145, 'fed')]
S31-PMC3277098	PMC3277098	12/2011	S31-PMC3277098	['this ASSOCIATION persists after adjusting for physical activity and dietary intake SUGGESTING obesity is an INDEPENDENT risk factor for reduced Serum 25(Oh)D and SUPPORTS the notion that Vitamin D deficiency MAY follow from modern lifestyle change.']	[('SUPERFICIAL_RELATIONSHIP', 5), ('INCOMPLETE_EVIDENCE', 83), ('SUPERFICIAL_RELATIONSHIP', 108), ('INCOMPLETE_EVIDENCE', 162), ('INCOMPLETE_EVIDENCE', 208)]	5	[('UBERON_0001977', 'blood serum', 144, 'serum'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 150, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]
S68-PMC3277098	PMC3277098	12/2011	S68-PMC3277098	['the latter study FOUND a high prevalence of Vitamin D deficiency in patients, with 88.9% of having Serum 25(Oh)D <50 nmol/l.']	[('INCOMPLETE_EVIDENCE', 17)]	1	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('UBERON_0001977', 'blood serum', 99, 'serum'), ('CHEBI_71657', 'versiconol acetate', 105, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 105, '25(OH)D')]
S132-PMC3277098	PMC3277098	12/2011	S132-PMC3277098	['RECORDED Serum 25(Oh)D in addition to dietary and supplemental Vitamin D intake and ESTIMATED uv exposure in 466 Pregnant women in the uk [55].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 84)]	2	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]
S181-PMC3277098	PMC3277098	12/2011	S181-PMC3277098	['[64] FOUND that lower Serum 25(Oh)D (of ≤37.5 nmol/l) was ASSOCIATED with both Peanut (or 2.39; 95% ci 1.29–4.45, p = 0.005) and shrimp (or 3.08; 95% ci 1.16–8.19, p = 0.02) sensitization, HOWEVER, OTHER studies of Food allergy are LARGELY LIMITED TO epidemiological data without serological measures of Vitamin D [69,70,71,72].']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 58), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 189), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 198), ('INCOMPLETE_EVIDENCE', 232), ('INCOMPLETE_EVIDENCE', 240)]	6	[('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_71657', 'versiconol acetate', 28, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 28, '25(OH)D'), ('NCBITaxon_10088', 'Mus <genus>', 79, 'peanut'), ('CHEBI_33290', 'food', 215, 'food'), ('CHEBI_27300', 'vitamin D', 304, 'vitamin D')]
S184-PMC3277098	PMC3277098	12/2011	S184-PMC3277098	['this data has the advantage of focussing on the Early Life Period and MAY THEREFORE provide INSIGHT into the aetiological ROLE of Vitamin D. DESPITE the OBSERVED PROTECTIVE ASSOCIATION of Serum 25(Oh)D and allergy, it has been NOTED that the widespread practice of supplementation COINCIDED with the rise in allergic disease [35].']	[('INCOMPLETE_EVIDENCE', 70), ('PROBABLE_UNDERSTANDING', 74), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('ANOMALY_CURIOUS_FINDING', 141), ('INCOMPLETE_EVIDENCE', 153), ('SUPERFICIAL_RELATIONSHIP', 162), ('SUPERFICIAL_RELATIONSHIP', 173), ('ANOMALY_CURIOUS_FINDING', 227), ('SUPERFICIAL_RELATIONSHIP', 281)]	11	[('UBERON_0019248', 'early embryo', 48, 'early life period'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('UBERON_0001977', 'blood serum', 188, 'serum'), ('CHEBI_71657', 'versiconol acetate', 194, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 194, '25(OH)D')]
S199-PMC3277098	PMC3277098	12/2011	S199-PMC3277098	['most of these OBSERVATIONAL studies DID NOT have direct serological measures of 25(Oh)D levels to ACCURATELY CONFIRM Vitamin D status and cross sectional study designs involving older children and Adults fail TO provide EVIDENCE on aetiological FACTORS.']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 98), ('INCOMPLETE_EVIDENCE', 109), ('QUESTION_ANSWERED_BY_THIS_WORK', 209), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 245)]	7	[('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 80, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('UBERON_0007023', 'adult organism', 197, 'adults')]
S115-PMC3347028	PMC3347028	3/2012	S115-PMC3347028	['using the RECENTLY revised institute of medicine’s (iom) 2010 criterion for Vitamin D deficiency of total circulating 25(Oh)D < 20 ng/ml (50 nmol/l) [72], approximately 70% of the african american COMPARED TO 35% of caucasian women in the rhode island study had evidence of Vitamin D deficiency during winter, with slight improvement during summer months compared to winter months in both groups.']	[('INCOMPLETE_EVIDENCE', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 197)]	2	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 118, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 118, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]
S144-PMC3347028	PMC3347028	3/2012	S144-PMC3347028	['there is a strong RELATIONSHIP between maternal and fetal (Cord Blood) circulating 25(Oh)D levels [92,93,94,95] such that maternal Vitamin D deficiency is MIRRORED by neonatal Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('SUPERFICIAL_RELATIONSHIP', 155)]	2	[('UBERON_0002240', 'spinal cord', 59, 'cord'), ('UBERON_0000178', 'blood', 64, 'blood'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 83, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D')]
S184-PMC3347028	PMC3347028	3/2012	S184-PMC3347028	['AS PREDICTED by Vitamin D pharmacokinetics, supplements of 1000 iu/day of Vitamin D to Pregnant women result in a 12.5 to 15.0 nmol/l increase in circulating 25(Oh)D concentrations in both maternal and Cord Serum compared with nonsupplemented controls [75,76,77].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 3)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 158, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 158, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 202, 'cord'), ('UBERON_0001977', 'blood serum', 207, 'serum')]
S226-PMC3347028	PMC3347028	3/2012	S226-PMC3347028	['the health effects data from Vitamin D supplementation trials THUS FAR, WHILE TANTALIZING, are NOT CONCLUSIVE in SHOWING definitive “proof” for Vitamin D AS a POTENTIAL CANDIDATE in the reduction of comorbidities of Pregnancy, YET one CANNOT DISMISS the strong CORRELATION between reduced RISK with increased Serum 25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 62), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 72), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('INCOMPLETE_EVIDENCE', 113), ('PROBABLE_UNDERSTANDING', 154), ('INCOMPLETE_EVIDENCE', 159), ('INCOMPLETE_EVIDENCE', 169), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 227), ('ANOMALY_CURIOUS_FINDING', 227), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235), ('SUPERFICIAL_RELATIONSHIP', 261), ('IMPORTANT_CONSIDERATION', 289)]	13	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy'), ('UBERON_0001977', 'blood serum', 309, 'serum'), ('CHEBI_71657', 'versiconol acetate', 315, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 315, '25(OH)D')]
S112-PMC3356951	PMC3356951	4/2012	S112-PMC3356951	['levels of 25(Oh)D are inversely ASSOCIATED with bmi, waist circumference, and body fat BUT are positively ASSOCIATED with age, lean body mass, and Vitamin D intake.']	[('SUPERFICIAL_RELATIONSHIP', 32), ('ANOMALY_CURIOUS_FINDING', 87), ('SUPERFICIAL_RELATIONSHIP', 106)]	3	[('CHEBI_71657', 'versiconol acetate', 10, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 10, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D')]
S143-PMC3356951	PMC3356951	4/2012	S143-PMC3356951	['[102] among women younger than 75 years, there is a lower RISK for early amd with higher Vitamin D levels, with a threshold EFFECT at 15.22 ng/l Serum 25 (Oh)D.\n\nrecommendation guidelines: endocrine society of clinical practice\n\ndiagnostic procedure\nescp RECOMMEND screening for vdd in Individuals at risk for deficiency and not for patients who are not AT RISK.']	[('IMPORTANT_CONSIDERATION', 58), ('SUPERFICIAL_RELATIONSHIP', 124), ('FUTURE_WORK', 255), ('IMPORTANT_CONSIDERATION', 354)]	4	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0001977', 'blood serum', 145, 'serum'), ('CHEBI_71657', 'versiconol acetate', 151, '25 (OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 151, '25 (OH)D'), ('NCBITaxon_1', 'root', 286, 'individuals')]
S249-PMC3407995	PMC3407995	7/2012	S249-PMC3407995	['evidence of the POTENTIAL benefits of maternal Vitamin D supplementation for foetal/infant Brain health\npublished placebo-controlled intervention trials studying the IMPACT of Vitamin D supplementation in mothers with low Serum 25(Oh)D are RARE [45] because such trials are deemed UNACCEPTABLE by ethics committees.']	[('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 166), ('INCOMPLETE_EVIDENCE', 240), ('IMPORTANT_CONSIDERATION', 281)]	4	[('CHEBI_28384', 'vitamin K', 47, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 47, 'Vitamin D'), ('UBERON_0000955', 'brain', 91, 'Brain'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 228, '25(OH)D')]
S253-PMC3407995	PMC3407995	7/2012	S253-PMC3407995	['a STUDY in black and white Pregnant women residing in the northern united states FOUND that approximately 29% of black Pregnant women and 5% of white Pregnant women had Vitamin D deficiency (Serum 25(Oh)D less than 37.5 nmol/l); WHEREAS 54% of black women and 47% of white women had Vitamin D insufficiency (defined as Serum 25(Oh)D levels 37.5 to 80 nmol/l) [122].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 81), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 229)]	3	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('GO_0007565', 'female pregnancy', 119, 'pregnant'), ('GO_0007565', 'female pregnancy', 150, 'pregnant'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('UBERON_0001977', 'blood serum', 191, 'serum'), ('CHEBI_71657', 'versiconol acetate', 197, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 197, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D'), ('UBERON_0001977', 'blood serum', 319, 'serum'), ('CHEBI_71657', 'versiconol acetate', 325, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 325, '25 ... OH ... D')]
S449-PMC3407995	PMC3407995	7/2012	S449-PMC3407995	['the authors CONCLUDED that Vitamin D supplementation of 4000 iu/day for Pregnant women is SAFE and MOST EFFECTIVE in achieving sufficiency in all women and their neonates regardless of race, WHEREAS the current ESTIMATED average REQUIREMENT is comparatively ineffective at achieving adequate circulating 25(Oh)D concentrations, especially in african americans [179].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 90), ('PROBABLE_UNDERSTANDING', 99), ('SUPERFICIAL_RELATIONSHIP', 104), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 191), ('INCOMPLETE_EVIDENCE', 211), ('IMPORTANT_CONSIDERATION', 229)]	7	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 304, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 304, '25(OH)D')]
S19-PMC3427192	PMC3427192	4/2012	S19-PMC3427192	['Biosynthesis Of Vitamin D.\n\nVitamin D THRESHOLDS\nSerum concentrations of 25(Oh)D are CONSIDERED to be a BIOMARKER and INDICATOR of Vitamin D status.44,45ALTHOUGH Vitamin D insufficiency HAS TRADITIONALLY BEEN defined as a Serum 25(Oh)D concentration of 20 to 29 ng/ml,46a panel of experts from the institute of medicine RECENTLY SUGGESTED that Vitamin D INSUFFICIENCY be redefined AS a Serum 25(Oh)D concentration less than 20 ng/ml.47this RECOMMENDATION was based ON INCONCLUSIVE evidence for the threshold of 29 ng/ml and EVIDENCE for adverse Skeletal EFFECTS at thresholds less than 20 ng/ml.47HOWEVER, this revised definition of Vitamin D insufficiency has generated significant CONTROVERSY48,49AND THUS there is presently NO universally ACCEPTED definition for “optimal” 25(Oh)d concentrations INDEPENDENT of Musculoskeletal health.']	[('PROBABLE_UNDERSTANDING', 38), ('INCOMPLETE_EVIDENCE', 85), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 118), ('ANOMALY_CURIOUS_FINDING', 151), ('IMPORTANT_CONSIDERATION', 186), ('INCOMPLETE_EVIDENCE', 190), ('PROBABLE_UNDERSTANDING', 190), ('INCOMPLETE_EVIDENCE', 320), ('INCOMPLETE_EVIDENCE', 329), ('IMPORTANT_CONSIDERATION', 354), ('PROBABLE_UNDERSTANDING', 381), ('FUTURE_WORK', 440), ('ANOMALY_CURIOUS_FINDING', 465), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 468), ('INCOMPLETE_EVIDENCE', 524), ('SUPERFICIAL_RELATIONSHIP', 554), ('ANOMALY_CURIOUS_FINDING', 595), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 683), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 697), ('PROBABLE_UNDERSTANDING', 703), ('INCOMPLETE_EVIDENCE', 727), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 742), ('INCOMPLETE_EVIDENCE', 742), ('SUPERFICIAL_RELATIONSHIP', 799)]	25	[('GO_0033593', 'BRCA2-MAGE-D1 complex', 0, 'Biosynthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 49, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 73, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 228, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 344, 'vitamin D'), ('UBERON_0001977', 'blood serum', 386, 'serum'), ('CHEBI_71657', 'versiconol acetate', 392, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 392, '25(OH)D'), ('UBERON_0004288', 'skeleton', 545, 'skeletal'), ('CHEBI_27300', 'vitamin D', 633, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 776, '25(OH)'), ('UBERON_0002204', 'musculoskeletal system', 814, 'musculoskeletal')]
S32-PMC3427192	PMC3427192	4/2012	S32-PMC3427192	['HOWEVER, in THESE STUDIES, there were no associations between Cord-Blood 25(Oh)D concentrations and subsequent asthma at 5 y of age.59,66\ncollectively, these studies SUGGEST that the benefits of Vitamin D during early Life MAY BE LIMITED to its EFFECTS on Respiratory infections and Viral-induced wheezing and not asthma per se.17HOWEVER, ALTHOUGH Vitamin D MAY have IMPORTANT ROLES in Immune Regulation during early Life, excessive Vitamin D exposure MAY also be ASSOCIATED with adverse health outcomes.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 166), ('INCOMPLETE_EVIDENCE', 223), ('INCOMPLETE_EVIDENCE', 230), ('SUPERFICIAL_RELATIONSHIP', 245), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 328), ('ANOMALY_CURIOUS_FINDING', 339), ('INCOMPLETE_EVIDENCE', 358), ('IMPORTANT_CONSIDERATION', 367), ('SUPERFICIAL_RELATIONSHIP', 377), ('INCOMPLETE_EVIDENCE', 452), ('SUPERFICIAL_RELATIONSHIP', 464)]	13	[('UBERON_0002240', 'spinal cord', 62, 'cord'), ('UBERON_0000178', 'blood', 67, 'blood'), ('CHEBI_71657', 'versiconol acetate', 73, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 73, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('UBERON_0000104', 'life cycle', 218, 'life'), ('UBERON_0001004', 'respiratory system', 256, 'respiratory'), ('NCBITaxon_1', 'root', 283, 'viral'), ('CHEBI_27300', 'vitamin D', 348, 'vitamin D'), ('GO_0002521', 'leukocyte differentiation', 386, 'immune regulation'), ('UBERON_0002405', 'immune system', 386, 'immune'), ('UBERON_0000104', 'life cycle', 417, 'life'), ('CHEBI_27300', 'vitamin D', 433, 'vitamin D')]
S42-PMC3427192	PMC3427192	4/2012	S42-PMC3427192	['studies of Vitamin D status in school-age children with asthmaauthoryearn(% male)age (years)study designsampleoutcome measuresfindingsbrehm412009616 (60)8.7cross-sectionalmild-to-severe persistent asthmaasthma exacerbationsincreased 25(Oh)D ASSOCIATED with reduced hospitalization, reduced Anti-Inflammatory Medication use and reduced Airway hyperresponsivenessbrehm6920101024 (60)8.9prospective cohortmild-to-moderate persistent asthmahospitalization or emergency Department visitbaseline 25(Oh)D levels < 30 ng/ml ASSOCIATED with higher odds of hospitalization or emergency department over 4 ychinellato70201175 (60)9.6cross-sectionalwell-controlled and POORLY controlled asthmaspirometry, asthma controlpositive CORRELATIONS NOTED between 25(Oh)d and asthma controlchinellato71201145 (60)10cross-sectionalintermittent asthmalung function and Airway hyperresponsivenesslower Serum 25(Oh)D ASSOCIATED with decreased Lung function and increased Airway hyperresponsiveness with exercisefreishtat72201092 (63)11.1cross-sectionalafrican americans with and without asthmaphysician-diagnosed asthmadecreased 25(Oh)D in asthmatics vs. controlsmajak73201148 (67)11.5randomized, double-blind, parallel arm clinical trialnewly diagnosed asthmaasthma exacerbationsfewer exacerbations in children with Vitamin D3Supplementation added to inhaled Budesonidesearing742010100 (64)7cross-sectionalmoderate to severe persistent asthmacorticosteroid use and Airflow limitationdecreased 25(Oh)D ASSOCIATED with lower Lung function and higher Corticosteroid requirementsurashima752010217 (57)10.0randomized, double-blind clinical trialschoolchildren (allcomers), subgroup with physician-diagnosed asthmaasthma exacerbationsreduced risk of asthma exacerbations in the subgroup with asthma after Vitamin D3Supplementation\nother cross-sectional studies of Vitamin D status have also examined the ASSOCIATIONS between 25(Oh)D concentrations and asthma Control in school-age children.']	[('SUPERFICIAL_RELATIONSHIP', 241), ('SUPERFICIAL_RELATIONSHIP', 516), ('PROBLEM_COMPLICATION', 656), ('SUPERFICIAL_RELATIONSHIP', 715), ('ANOMALY_CURIOUS_FINDING', 728), ('SUPERFICIAL_RELATIONSHIP', 891), ('SUPERFICIAL_RELATIONSHIP', 1476), ('SUPERFICIAL_RELATIONSHIP', 1873)]	8	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 233, '25(OH)D'), ('CHEBI_60426', 'dioleoyl phosphatidylglycerol', 290, 'anti-inflammatory medication'), ('UBERON_0001005', 'respiratory airway', 335, 'airway'), ('UBERON_0008247', 'tube foot', 465, 'department'), ('CHEBI_71657', 'versiconol acetate', 490, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 490, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 742, '25(OH'), ('UBERON_0001005', 'respiratory airway', 845, 'airway'), ('UBERON_0001977', 'blood serum', 877, 'serum'), ('CHEBI_71657', 'versiconol acetate', 883, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 885, '(OH ... D'), ('UBERON_0002048', 'lung', 917, 'lung'), ('UBERON_0001005', 'respiratory airway', 945, 'airway'), ('CHEBI_71657', 'versiconol acetate', 1103, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1103, '25(OH)D'), ('CHEBI_52915', 'phosphatediyl group', 1291, 'vitamin D3supplementation'), ('CHEBI_72362', 'phosphatidylethanolamine 44:1-OH', 1334, 'budesonideSearing742010100'), ('UBERON_0001005', 'respiratory airway', 1440, 'airflow'), ('CHEBI_71657', 'versiconol acetate', 1468, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1468, '25(OH)D'), ('UBERON_0002048', 'lung', 1498, 'lung'), ('CHEBI_36916', 'cation', 1523, 'corticosteroid'), ('CHEBI_52915', 'phosphatediyl group', 1774, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 1833, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1894, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1900, 'D'), ('GO_0065007', 'biological regulation', 1928, 'control')]
S60-PMC3427192	PMC3427192	4/2012	S60-PMC3427192	['studies of Vitamin D status in Adults with asthmaauthoryearn(% male)age (years)study designsampleoutcome measuresfindingsblack80200514,091 (55)> 20 ycross-sectionalgeneral us populationlung functionhigher Serum 25(Oh)D ASSOCIATED with increased Lung functionkeet8120116857 (49)23.6cross-sectionalgeneral us populationwheeze, history of asthma, and asthma exacerbationhigher serum 25(Oh)D ASSOCIATED with decreased odds of current wheezing and asthma as well as emergency visits for asthma and asthma exacerbationsli822011435 (38)48.57cross-sectionalnewly diagnosed asthmaticslung function, total Serum igehigher 25(Oh)D ASSOCIATED with greater Lung function with no associations NOTED for igeoren832008290 (26)43cross-sectionalobese patientsasthma and allergic rhinitis25(Oh)D deficiency (< 25 ng/ml) ASSOCIATED with increased odds of atopic dermatitis BUT no associations with asthmasutherland84201054 (43)38.3cross-sectionalpersistent asthmalung function, Airway hyper-responsiveness, Glucocorticoid responsivenessdecreased 25(Oh)D ASSOCIATED with decreased Lung function, increased Airway hyperresponsiveness, and reduced Glucocorticoid responses\n\ngenetics of Vitamin D and asthma\nSOME STUDIES have FOCUSED on Genetic ASSOCIATIONS between Vitamin D and asthma in larger populations.']	[('SUPERFICIAL_RELATIONSHIP', 219), ('SUPERFICIAL_RELATIONSHIP', 388), ('SUPERFICIAL_RELATIONSHIP', 620), ('ANOMALY_CURIOUS_FINDING', 679), ('SUPERFICIAL_RELATIONSHIP', 801), ('ANOMALY_CURIOUS_FINDING', 853), ('SUPERFICIAL_RELATIONSHIP', 1034), ('INCOMPLETE_EVIDENCE', 1184), ('QUESTION_ANSWERED_BY_THIS_WORK', 1202), ('SUPERFICIAL_RELATIONSHIP', 1221)]	10	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0007023', 'adult organism', 31, 'adults'), ('UBERON_0001977', 'blood serum', 205, 'serum'), ('CHEBI_71657', 'versiconol acetate', 211, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 211, '25(OH)D'), ('UBERON_0002048', 'lung', 245, 'lung'), ('CHEBI_71657', 'versiconol acetate', 380, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 380, '25(OH)D'), ('UBERON_0001977', 'blood serum', 596, 'serum'), ('CHEBI_71657', 'versiconol acetate', 612, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 612, '25(OH)D'), ('UBERON_0002048', 'lung', 644, 'lung'), ('CHEBI_33010', 'chromide(1-)', 771, '(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 775, 'D'), ('UBERON_0001005', 'respiratory airway', 958, 'airway'), ('CHEBI_24261', 'glucocorticoid', 987, 'glucocorticoid'), ('CHEBI_71657', 'versiconol acetate', 1026, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 1029, 'OH ... D'), ('UBERON_0002048', 'lung', 1060, 'lung'), ('UBERON_0001005', 'respiratory airway', 1085, 'airway'), ('CHEBI_24261', 'glucocorticoid', 1125, 'glucocorticoid'), ('CHEBI_28384', 'vitamin K', 1163, 'Vitamin D'), ('SO_0000704', 'gene', 1213, 'genetic'), ('CHEBI_27300', 'vitamin D', 1242, 'vitamin D')]
S117-PMC3427250	PMC3427250	8/2012	S117-PMC3427250	['SOME studies SUGGEST that the dietary requirement during Pregnancy and Lactation MAY BE as high as 6000 iu/d[59]and recognize that AT LEAST 1500–2000 iu/d of Vitamin D MAY BE NEEDED in order to maintain a Blood level of 25(Oh)D above 30 ng/ml[24].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 81), ('PROBABLE_UNDERSTANDING', 131), ('INCOMPLETE_EVIDENCE', 168), ('FUTURE_WORK', 175)]	6	[('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('GO_0007595', 'lactation', 71, 'lactation'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('UBERON_0000178', 'blood', 205, 'blood'), ('CHEBI_71657', 'versiconol acetate', 220, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 220, '25(OH)D')]
S189-PMC3552819	PMC3552819	12/2012	S189-PMC3552819	['MANY participants DEMONSTRATED a rapid rise in [25(Oh)D] during the first week, which is SIMILAR TO the response to an acute dose of ultraviolet radiation exposure [25]; BUT distinct from the more gradual EFFECTS of OTHER forms of exogenous Vitamin D Intake (e.g., oral D2 Ingestion [10]).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('SUPERFICIAL_RELATIONSHIP', 205), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 216)]	6	[('CHEBI_71657', 'versiconol acetate', 48, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 48, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('GO_0007631', 'feeding behavior', 251, 'intake'), ('CHEBI_37987', 'Cy3 dye', 270, 'D2'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 270, 'D2'), ('GO_0007631', 'feeding behavior', 273, 'ingestion')]
S56-PMC3613945	PMC3613945	2/2013	S56-PMC3613945	['OF more immediate clinical INTEREST, PERHAPS, was our OBSERVATION that this Allele was also CORRELATED with the response of Serum 25(Oh)D levels to long-term Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 27), ('INCOMPLETE_EVIDENCE', 37), ('ANOMALY_CURIOUS_FINDING', 54), ('SUPERFICIAL_RELATIONSHIP', 92)]	5	[('SO_0001023', 'allele', 76, 'allele'), ('UBERON_0001977', 'blood serum', 124, 'serum'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 130, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S20-PMC3641012	PMC3641012	4/2013	S20-PMC3641012	['SIMILARLY, the 25(Oh)D THRESHOLD to define Vitamin D sufficiency is DEBATED; the iom set 50\xa0nmol/l as a lower limit of sufficiency [7], YET OTHER expert bodies such as the american academy of pediatrics have SUGGESTED that Pregnant women attain Serum 25(Oh)D >80\xa0nmol/l [14].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 136), ('ANOMALY_CURIOUS_FINDING', 136), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 140), ('INCOMPLETE_EVIDENCE', 208)]	7	[('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 223, 'pregnant'), ('UBERON_0001977', 'blood serum', 245, 'serum'), ('CHEBI_71657', 'versiconol acetate', 251, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 251, '25(OH)D')]
S55-PMC3641012	PMC3641012	4/2013	S55-PMC3641012	['Serum aliquots were frozen at −20°c and shipped at ambient temperature from bangladesh to toronto for measurement of Serum 25(Oh)D concentration, a WELL-ESTABLISHED BIOMARKER of systemic Vitamin D status [17].']	[('PROBABLE_UNDERSTANDING', 148), ('SUPERFICIAL_RELATIONSHIP', 165)]	2	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 123, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]
S128-PMC3641012	PMC3641012	4/2013	S128-PMC3641012	['Vitamin D supplementation had a substantial, statistically significant EFFECT on maternal and neonatal Vitamin D status at the time of Delivery, as reflected in the overall 25(Oh)D distributions (figure\xa02; table\xa04) as well as the proportion of participants considered to have low 25(Oh)D using cut-offs (table\xa02).']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007567', 'parturition', 135, 'delivery'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 176, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 179, 'D'), ('CHEBI_71657', 'versiconol acetate', 280, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 280, '25(OH)D')]
S163-PMC3641012	PMC3641012	4/2013	S163-PMC3641012	['ALTHOUGH δ25(Oh)D was inversely ASSOCIATED with baseline Vitamin D status, and ABOUT 24% of the variance in δ25(Oh)D in the Vitamin D group was EXPLAINED by baseline 25(Oh)D, this ASSOCIATION APPEARED TO BE due to regression to the mean, SINCE similar TRENDS were observed in both the Vitamin D and placebo groups.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 32), ('INCOMPLETE_EVIDENCE', 79), ('PROBABLE_UNDERSTANDING', 144), ('SUPERFICIAL_RELATIONSHIP', 180), ('ANOMALY_CURIOUS_FINDING', 192), ('PROBABLE_UNDERSTANDING', 238), ('SUPERFICIAL_RELATIONSHIP', 252)]	8	[('CHEBI_33010', 'chromide(1-)', 12, '(OH)D'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 111, '(OH)D'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 166, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 166, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 285, 'vitamin D')]
S33-PMC3668200	PMC3668200	5/2013	S33-PMC3668200	['RECENTLY, aap RECOMMENDATION of 400 iu/day for Vitamin D supplementation was DOCUMENTED to maintain a 25(Oh)D Serum concentration higher than 50 nmol/l in exclusively Breast-Fed infants15).']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 14), ('INCOMPLETE_EVIDENCE', 77)]	3	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 102, '25(OH)D'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('GO_0007567', 'parturition', 167, 'breast'), ('UBERON_0000310', 'breast', 167, 'breast'), ('GO_0007631', 'feeding behavior', 174, 'fed')]
S126-PMC3691177	PMC3691177	6/2013	S126-PMC3691177	['ALTHOUGH the Vitamin D doses used in this trial were greater than the current RECOMMENDED intake for Pregnant women of 400 iu/day during Pregnancy in the united kingdom[14],[17], and 600 iu in the united states[25], ONLY a small percentage of offspring had Cord 25(Oh)D levels in the sufficient range (13% daily group, 3% bolus group).']	[('ANOMALY_CURIOUS_FINDING', 0), ('FUTURE_WORK', 78), ('INCOMPLETE_EVIDENCE', 216)]	3	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnant'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 257, 'cord'), ('CHEBI_71657', 'versiconol acetate', 262, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 262, '25(OH)D')]
S134-PMC3691177	PMC3691177	6/2013	S134-PMC3691177	['the FINDINGS of OUR STUDY are specific to a population of Vitamin D deficient women (half had baseline 25(Oh)D levels below 25 nmol/l) and two specific forms of Prenatal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16)]	2	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 103, '25(OH)D'), ('GO_0007565', 'female pregnancy', 161, 'prenatal'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S15-PMC3702245	PMC3702245	6/2013	S15-PMC3702245	['IN GENERAL, Cord Blood 25(Oh)D concentrations are APPROXIMATELY 60%–89% of the maternal value.11,17,35,41–47THEREFORE, maintaining optimum Vitamin D nutrition during Pregnancy is ESSENTIAL for PREVENTION of hypovitaminosis D in the fetus and Vitamin D deficiency at Birth and in early infancy.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 50), ('ANOMALY_CURIOUS_FINDING', 106), ('IMPORTANT_CONSIDERATION', 179), ('SUPERFICIAL_RELATIONSHIP', 193)]	5	[('UBERON_0002240', 'spinal cord', 12, 'cord'), ('UBERON_0000178', 'blood', 17, 'blood'), ('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 23, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 223, 'D'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D'), ('GO_0007567', 'parturition', 266, 'birth')]
S17-PMC3702245	PMC3702245	6/2013	S17-PMC3702245	['the institute of medicine in the us in its RECENT report RECOMMENDS that a Serum 25(Oh)D concentration of 50 nmol/l (20 ng/ml) is adequate for calcium absorption and bone health in Adults, including Pregnant women, in the us and canada.7HOWEVER, new clinical guidelines from the endocrine society RECOMMEND maintaining a Serum 25(Oh)D concentration >75 nmol/l (30 ng/ml) in order to maximize calcium absorption and bone health, and for POTENTIAL Extraskeletal benefits noted in observational studies.8many RECENT STUDIES13,15–17,48–57that evaluated Vitamin D nutrition during Pregnancy in different geographic locations REPORTED wide VARIATION in Vitamin D status depending on latitude, season, sunlight exposure behavior, and Vitamin D intake (table 1).']	[('INCOMPLETE_EVIDENCE', 43), ('FUTURE_WORK', 57), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('FUTURE_WORK', 297), ('INCOMPLETE_EVIDENCE', 436), ('INCOMPLETE_EVIDENCE', 506), ('INCOMPLETE_EVIDENCE', 620), ('DIFFICULT_TASK', 634)]	8	[('UBERON_0001977', 'blood serum', 75, 'serum'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 81, '25(OH)D'), ('UBERON_0007023', 'adult organism', 181, 'adults'), ('GO_0007565', 'female pregnancy', 199, 'pregnant'), ('UBERON_0001977', 'blood serum', 321, 'serum'), ('CHEBI_71657', 'versiconol acetate', 327, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 327, '25(OH)D'), ('UBERON_0001431', 'distal carpal bone 2', 446, 'extraskeletal'), ('CHEBI_27300', 'vitamin D', 549, 'vitamin D'), ('GO_0007565', 'female pregnancy', 576, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 647, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 727, 'vitamin D')]
S19-PMC3702245	PMC3702245	6/2013	S19-PMC3702245	['there is a high prevalence of Vitamin D deficiency [Serum 25(Oh) D <50 nmol/l], and as shown intable 1, most women studied (>80%) have Serum 25(Oh)D concentrations <75 nmol/l, which are CONSIDERED “INSUFFICIENT”.8mean Serum 25(Oh)D concentrations are highest and the prevalence of Vitamin D deficiency is lowest in sun-enriched populations,51,57WHILE the lowest mean Serum 25(Oh)d and the highest prevalence of Vitamin D deficiency are REPORTED in sunshine-deprived populations.16,17,50,55,56the high prevalence of low Vitamin D ASSOCIATED with sunshine deprivation and INADEQUATE corrective Vitamin D intake SHOULD RAISE PUBLIC HEALTH CONCERN about the INCREASED RISK of adverse health EFFECTS of low Vitamin D status for the mother and fetus and poor Vitamin D nutrition in the infant at Birth.']	[('INCOMPLETE_EVIDENCE', 186), ('PROBLEM_COMPLICATION', 198), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 343), ('INCOMPLETE_EVIDENCE', 436), ('SUPERFICIAL_RELATIONSHIP', 529), ('IMPORTANT_CONSIDERATION', 570), ('FUTURE_WORK', 609), ('IMPORTANT_CONSIDERATION', 616), ('IMPORTANT_CONSIDERATION', 622), ('IMPORTANT_CONSIDERATION', 654), ('SUPERFICIAL_RELATIONSHIP', 687)]	11	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 58, '25(OH) D'), ('UBERON_0001977', 'blood serum', 135, 'serum'), ('CHEBI_71657', 'versiconol acetate', 141, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 141, '25(OH)D'), ('UBERON_0001977', 'blood serum', 218, 'serum'), ('CHEBI_30778', 'gallic acid', 224, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 230, 'D'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D'), ('UBERON_0001977', 'blood serum', 367, 'serum'), ('CHEBI_30778', 'gallic acid', 373, '25(OH)'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 519, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 592, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 702, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 753, 'vitamin D'), ('GO_0007567', 'parturition', 790, 'birth')]
S21-PMC3702245	PMC3702245	6/2013	S21-PMC3702245	['a Serum 25(Oh)D concentration <25 nmol/l (10 ng/ml), which is ASSOCIATED with INCREASED RISK of osteomalacia in Adults,7is common during Pregnancy, AS INDICATED by RECENT REPORTS from many parts of the world.1for example, Serum 25(Oh)D < 25 nmol/l during Pregnancy HAS BEEN REPORTED in 17%–18% of the caucasian population in the uk,48,4961% of a mixed population in new zealand,5432%–42% in the indian population,15,4559%–84% of a nonwestern population in the netherlands,1441% of the kuwaiti population,1680% of the iranian population,17and 75% of the arab population in the united arab emirates.1HOWEVER, there are LIMITED STUDIES on the ASSOCIATION between such low levels of Vitamin D status and Skeletal integrity in Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 62), ('IMPORTANT_CONSIDERATION', 78), ('PROBABLE_UNDERSTANDING', 148), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 164), ('INCOMPLETE_EVIDENCE', 171), ('INCOMPLETE_EVIDENCE', 265), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 597), ('INCOMPLETE_EVIDENCE', 617), ('SUPERFICIAL_RELATIONSHIP', 640)]	10	[('UBERON_0001977', 'blood serum', 2, 'serum'), ('CHEBI_71657', 'versiconol acetate', 8, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 8, '25(OH)D'), ('UBERON_0007023', 'adult organism', 112, 'adults'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 228, '25(OH)D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 679, 'vitamin D'), ('UBERON_0004288', 'skeleton', 700, 'skeletal'), ('GO_0007565', 'female pregnancy', 722, 'pregnant')]
S44-PMC3702245	PMC3702245	6/2013	S44-PMC3702245	['with INCREASING INTEREST in the ROLE of Vitamin D in Glucose Homeostasis, the ASSOCIATION between maternal Serum 25(Oh)D concentration in early Pregnancy and the risk of Gestational diabetes mellitus was investigated in a study from the national institutes of health, bethesda, md.85the authors FOUND that maternal Vitamin D deficiency [serum 25(Oh)D < 50 nmol/l] was ASSOCIATED with a higher risk of Gestational diabetes mellitus (adjusted odds ratio 2.66; ci 1.01–7.02).']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 78), ('INCOMPLETE_EVIDENCE', 295), ('SUPERFICIAL_RELATIONSHIP', 368)]	5	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0042593', 'glucose homeostasis', 53, 'glucose homeostasis'), ('UBERON_0001977', 'blood serum', 107, 'serum'), ('CHEBI_71657', 'versiconol acetate', 113, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 113, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0007565', 'female pregnancy', 170, 'gestational'), ('CHEBI_27300', 'vitamin D', 315, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 343, '25(OH)D'), ('GO_0007565', 'female pregnancy', 401, 'gestational')]
S45-PMC3702245	PMC3702245	6/2013	S45-PMC3702245	['CONSISTENT with THIS report, a systematic review and meta-analysis of seven observational studies performed between 2008 and 2011 FOUND Serum 25(Oh)D < 50 nmol/l to be ASSOCIATED with Gestational diabetes BUT with an overall lower odds ratio of 1.61 (ci 1.19–2.17).86another meta-analysis of maternal Vitamin D status and Pregnancy outcomes,87which included 24 studies up to 2012, FOUND an overall INCREASED RISK of Preeclampsia (odds ratio 2.09; ci 1.50–2.90) and Gestational diabetes (odds ratio 1.38; ci 1.12–1.70).']	[('INCOMPLETE_EVIDENCE', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 168), ('ANOMALY_CURIOUS_FINDING', 205), ('INCOMPLETE_EVIDENCE', 381), ('IMPORTANT_CONSIDERATION', 398)]	7	[('UBERON_0001977', 'blood serum', 136, 'serum'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 142, '25(OH)D'), ('GO_0007565', 'female pregnancy', 184, 'gestational'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('GO_0007565', 'female pregnancy', 322, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 416, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 465, 'gestational')]
S54-PMC3702245	PMC3702245	6/2013	S54-PMC3702245	['Monocytes cultured in Vitamin D-deficient Plasma (Serum 25(Oh)D < 30 nmol/l) SHOWED significantly decreased Tolllike Receptor-mediated Expression of Cathelicidin (p < 0.05) compared with those conditioned in Vitamin D-sufficient Plasma (Serum 25(Oh)D > 75 nmol/l).93CONSISTENT with these in vitro FINDINGS, OBSERVATIONAL clinical DATA FOUND an ASSOCIATION between Vitamin D status in Cord Blood and the RISK of Lower Respiratory Tract infection in the first year of Life.94the risk of Respiratory syncytial Virus bronchiolitis in the first year of Life is increased by six-fold (ci 1.6–24.9) in infants with Cord Blood 25(Oh)D < 50 nmol/l compared with infants with 25(Oh)D > 75 nmol/l.']	[('INCOMPLETE_EVIDENCE', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 264), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 264), ('INCOMPLETE_EVIDENCE', 297), ('INCOMPLETE_EVIDENCE', 307), ('FUTURE_WORK', 330), ('INCOMPLETE_EVIDENCE', 335), ('SUPERFICIAL_RELATIONSHIP', 344), ('IMPORTANT_CONSIDERATION', 403)]	9	[('CL_0000576', 'monocyte', 0, 'Monocytes'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 42, 'plasma'), ('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D'), ('PR_000001660', 'prostaglandin F2-alpha receptor', 108, 'tolllike receptor'), ('GO_0010467', 'gene expression', 135, 'expression'), ('PR_000006009', 'alpha-catulin', 149, 'cathelicidin'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 229, 'plasma'), ('UBERON_0001977', 'blood serum', 237, 'serum'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 243, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 364, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 384, 'cord'), ('UBERON_0000178', 'blood', 389, 'blood'), ('UBERON_0004905', 'articulation', 411, 'lower respiratory tract'), ('UBERON_0000104', 'life cycle', 466, 'life'), ('UBERON_0001004', 'respiratory system', 485, 'respiratory'), ('NCBITaxon_1', 'root', 507, 'virus'), ('UBERON_0000104', 'life cycle', 548, 'life'), ('UBERON_0002240', 'spinal cord', 608, 'cord'), ('UBERON_0000178', 'blood', 613, 'blood'), ('CHEBI_71657', 'versiconol acetate', 619, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 619, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 666, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 666, '25(OH)D')]
S56-PMC3702245	PMC3702245	6/2013	S56-PMC3702245	['IN CONTRAST, an OBSERVATIONAL study REPORTED an increased RISK of infantile eczema and pneumonia in ASSOCIATION with maternal Serum 25(Oh)D > 75 nmol/l in the last trimester.76HOWEVER, another RECENT STUDY with a larger sample size from the same institution DID NOT FIND an ASSOCIATION between maternal 25(Oh)d > 75 nmol/l in late Pregnancy and eczema or asthma at 12 months and three and six years of age.97there was no report on the ASSOCIATION between maternal Vitamin D status and Respiratory infections in the latter study.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 36), ('IMPORTANT_CONSIDERATION', 58), ('SUPERFICIAL_RELATIONSHIP', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('INCOMPLETE_EVIDENCE', 193), ('INCOMPLETE_EVIDENCE', 258), ('SUPERFICIAL_RELATIONSHIP', 274), ('SUPERFICIAL_RELATIONSHIP', 435)]	10	[('UBERON_0001977', 'blood serum', 126, 'serum'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 132, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 303, '25(OH)'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 303, '25(OH'), ('GO_0007565', 'female pregnancy', 331, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 464, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 485, 'respiratory')]
S63-PMC3702245	PMC3702245	6/2013	S63-PMC3702245	['a review of the FEW previous randomized controlled TRIALS of Vitamin D supplementation during Pregnancy INDICATES that doses of 400–1600 iu/day were INSUFFICIENT in achieving a mean Serum 25(Oh)D concentration ≥50 nmol/l in most of the studies.41in a RECENT Vitamin D supplementation TRIAL from the uk, a multiethnic group of 180 Pregnant women were randomized at 27 weeks’ Gestation to receive a single Oral dose of 200,000 iu of Vitamin D, daily supplementation of 800 iu, or no treatment.33the median Serum 25(Oh)D concentration in the 800 iu/day group at study entry was 26 nmol/l (interquartile range 22–37), and the median 25(Oh)D concentration at delivery following supplementation was 42 nmol/l (interquartile range 31–76).']	[('INCOMPLETE_EVIDENCE', 16), ('FUTURE_WORK', 51), ('INCOMPLETE_EVIDENCE', 104), ('IMPORTANT_CONSIDERATION', 149), ('PROBLEM_COMPLICATION', 149), ('INCOMPLETE_EVIDENCE', 251), ('INCOMPLETE_EVIDENCE', 284)]	7	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('UBERON_0001977', 'blood serum', 182, 'serum'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 188, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('GO_0007565', 'female pregnancy', 330, 'pregnant'), ('GO_0007565', 'female pregnancy', 374, 'gestation'), ('UBERON_0000165', 'mouth', 404, 'oral'), ('CHEBI_27300', 'vitamin D', 431, 'vitamin D'), ('UBERON_0001977', 'blood serum', 504, 'serum'), ('CHEBI_71657', 'versiconol acetate', 510, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 510, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 629, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 629, '25(OH)D')]
S64-PMC3702245	PMC3702245	6/2013	S64-PMC3702245	['ONLY 30% of the women treated with 800 iu/day of Vitamin D achieved a Serum 25(Oh)D concentration >50 nmol/l.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('UBERON_0001977', 'blood serum', 70, 'serum'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 76, '25(OH)D')]
S68-PMC3702245	PMC3702245	6/2013	S68-PMC3702245	['these two studies and older RESEARCH41INDICATE that, in populations with a high prevalence of SEVERE Vitamin D sufficiency, supplementation up to 1600 iu/day MAY BE inadequate to achieve the RECOMMENDED target Serum 25(Oh)D concentration of 50 nmol/l.7in two RECENT STUDIES from india, which used large single-dose supplementation of 120,000 iu at the fifth and seventh month of Gestation15Or at the second and third trimester,69only 25% and 62%, respectively, achieved a Serum 25(Oh)D concentration >50 nmol/l.']	[('INCOMPLETE_EVIDENCE', 28), ('IMPORTANT_CONSIDERATION', 94), ('INCOMPLETE_EVIDENCE', 158), ('FUTURE_WORK', 191), ('INCOMPLETE_EVIDENCE', 259)]	5	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 216, '25(OH)D'), ('GO_0007565', 'female pregnancy', 379, 'gestation15or'), ('UBERON_0001977', 'blood serum', 472, 'serum'), ('CHEBI_71657', 'versiconol acetate', 478, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 478, '25(OH)D')]
S70-PMC3702245	PMC3702245	6/2013	S70-PMC3702245	['OF NOTE, in two of the five studies, the mean concentration of 25(Oh)D after supplementation was <50 nmol/l,33,78and Serum 25(Oh)D WAS NOT MEASURED in ONE STUDY.73all these STUDIES underscore the uncertainty about the amount of Vitamin D supplementation REQUIRED to optimize Vitamin D status in Pregnancy and which would be generalizable worldwide.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 131), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 173), ('IMPORTANT_CONSIDERATION', 254)]	5	[('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 123, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 275, 'vitamin D'), ('GO_0007565', 'female pregnancy', 295, 'pregnancy')]
S72-PMC3702245	PMC3702245	6/2013	S72-PMC3702245	['the institute of MEDICINE7CONSIDERS a Serum 25(Oh)D concentration >50 nmol/l AS acceptable, WHILE the Endocrine society and Vitamin D EXPERTS RECOMMEND >75 nmol/l.8,99a RECENT STUDY among traditional populations in tanzania with type vi (dark) skin color living in a sun-abundant environment RECOMMENDED a mean Serum 25(Oh)D concentration of 115 nmol/l in nonpregnant Adults and 139 nmol/l in Pregnant women.57the question then is: WHAT Serum concentration of 25(Oh)D is “normal” in Adults, including during Pregnancy?']	[('INCOMPLETE_EVIDENCE', 17), ('PROBABLE_UNDERSTANDING', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 92), ('PROBABLE_UNDERSTANDING', 134), ('FUTURE_WORK', 142), ('INCOMPLETE_EVIDENCE', 169), ('FUTURE_WORK', 292), ('EXPLICIT_QUESTION', 432), ('EXPLICIT_QUESTION', 517)]	9	[('UBERON_0001977', 'blood serum', 38, 'serum'), ('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 44, '25(OH)D'), ('UBERON_0005063', 'left ventricular compact myocardium', 102, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('UBERON_0001977', 'blood serum', 311, 'serum'), ('CHEBI_71657', 'versiconol acetate', 317, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 317, '25(OH)D'), ('UBERON_0007023', 'adult organism', 368, 'adults'), ('GO_0007565', 'female pregnancy', 393, 'pregnant'), ('UBERON_0001977', 'blood serum', 437, 'serum'), ('CHEBI_71657', 'versiconol acetate', 460, '25(OH)D'), ('UBERON_0007023', 'adult organism', 483, 'adults'), ('GO_0007565', 'female pregnancy', 508, 'pregnancy')]
S73-PMC3702245	PMC3702245	6/2013	S73-PMC3702245	['WHILE the DEBATE and studies to identify OPTIMAL Serum 25(Oh)D concentration CONTINUE, it is PRUDENT to monitor Vitamin D status and develop STRATEGIES to ensure AT LEAST a minimum Serum 25(Oh)D concentration of 50 nmol/l in Pregnant women, especially in an environment where Vitamin D deficiency is endemic.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 10), ('IMPORTANT_CONSIDERATION', 41), ('FUTURE_WORK', 77), ('FUTURE_WORK', 93), ('IMPORTANT_CONSIDERATION', 93), ('FUTURE_WORK', 141), ('PROBABLE_UNDERSTANDING', 162)]	8	[('UBERON_0001977', 'blood serum', 49, 'serum'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 55, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('UBERON_0001977', 'blood serum', 181, 'serum'), ('CHEBI_71657', 'versiconol acetate', 187, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 187, '25(OH)D'), ('GO_0007565', 'female pregnancy', 225, 'pregnant'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D')]
S74-PMC3702245	PMC3702245	6/2013	S74-PMC3702245	['in studies of Adults and nonpregnant women, a Vitamin D intake of up to 10,000 iu/day is ASSOCIATED with achievement of a Serum 25(Oh)D concentration ≥80 nmol/l without Vitamin D toxicity.103,104from a review of PREVIOUS STUDIES, an additional daily intake of 100 iu of Vitamin D increases the Serum 25(Oh)D concentration by 1–2 nmol/l.7,105THEREFORE, knowing the population baseline Serum 25(Oh)D concentration, IT IS POSSIBLE to ESTIMATE the Vitamin D intake REQUIRED to replete body stores and achieve an expected target Serum 25(Oh)d concentration.']	[('SUPERFICIAL_RELATIONSHIP', 89), ('INCOMPLETE_EVIDENCE', 212), ('PROBABLE_UNDERSTANDING', 338), ('INCOMPLETE_EVIDENCE', 413), ('INCOMPLETE_EVIDENCE', 431), ('IMPORTANT_CONSIDERATION', 461)]	6	[('UBERON_0007023', 'adult organism', 14, 'adults'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('UBERON_0001977', 'blood serum', 122, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 131, 'OH)D'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D'), ('UBERON_0001977', 'blood serum', 294, 'serum'), ('CHEBI_71657', 'versiconol acetate', 300, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 300, '25(OH)D'), ('UBERON_0001977', 'blood serum', 384, 'serum'), ('CHEBI_33010', 'chromide(1-)', 392, '(OH)D'), ('CHEBI_27300', 'vitamin D', 444, 'vitamin D'), ('UBERON_0001977', 'blood serum', 524, 'serum'), ('CHEBI_30778', 'gallic acid', 530, '25(OH)')]
S75-PMC3702245	PMC3702245	6/2013	S75-PMC3702245	['because of CONTROVERSY surrounding Vitamin D REQUIREMENTS during Pregnancy, investigators from south carolina performed a comprehensive, large, randomized controlled study of Vitamin D supplementation in Pregnancy to achieve optimal Vitamin D status, DEFINED as a Serum 25(Oh)D concentration ≥80 nmol/l at Delivery.18BASED on the pharmacokinetics of Vitamin d, the authors INVESTIGATED the SAFETY and EFFECTIVENESS of high-dose Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 11), ('IMPORTANT_CONSIDERATION', 45), ('PROBABLE_UNDERSTANDING', 251), ('PROBABLE_UNDERSTANDING', 315), ('QUESTION_ANSWERED_BY_THIS_WORK', 373), ('IMPORTANT_CONSIDERATION', 390), ('SUPERFICIAL_RELATIONSHIP', 401)]	7	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('UBERON_0001977', 'blood serum', 264, 'serum'), ('CHEBI_71657', 'versiconol acetate', 270, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 270, '25(OH)D'), ('GO_0007567', 'parturition', 306, 'delivery'), ('CHEBI_33229', 'vitamin (role)', 350, 'vitamin'), ('CHEBI_27300', 'vitamin D', 428, 'vitamin D')]
S76-PMC3702245	PMC3702245	6/2013	S76-PMC3702245	['they HYPOTHESIZED that daily Vitamin D3Supplementation of 4000 iu/day would be more effective than 2000 iu and a standard dosing regimen of 400 iu in achieving a Serum 25(Oh)D concentration of >80 nmol/l without any safety ISSUES referable to Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 5), ('IMPORTANT_CONSIDERATION', 223), ('PROBLEM_COMPLICATION', 223)]	3	[('CHEBI_52915', 'phosphatediyl group', 29, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 29, 'vitamin D3supplementation'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 168, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D')]
S125-PMC3717170	PMC3717170	5/2013	S125-PMC3717170	['they have INITIATED a randomized controlled trial of 25(Oh)D3Repletion in Vitamin D–deficient hemodialysis patients TO EVALUATE efficacy and SAFETY and the EFFECTS on inflammation and esa REQUIREMENTS.']	[('INCOMPLETE_EVIDENCE', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 116), ('IMPORTANT_CONSIDERATION', 141), ('SUPERFICIAL_RELATIONSHIP', 156), ('IMPORTANT_CONSIDERATION', 188)]	5	[('CHEBI_76706', 'EC 6.1.* (C-O bond-forming ligase) inhibitor', 53, '25(OH)D3repletion'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 53, '25(OH'), ('PR_000006494', 'disrupted in schizophrenia 1 protein', 59, 'D3repletion'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
S195-PMC3717170	PMC3717170	5/2013	S195-PMC3717170	['moreover, a NUMBER OF STUDIES HAVE SHOWN that prevailing levels of 25(Oh)D3, especially in older subjects, the institutionalized, and in most other countries, are well below those DOCUMENTED in the nhanes survey.58as parts of the Aging Process, the skin becomes less able to make Vitamin D for a given amount of uvb exposure, the Kidneys become less able to produce the active Metabolite 1,25(Oh2)D3, and the Intestine becomes less able to respond to the 1,25(Oh2)D3With respect to calcium absorption.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 180)]	3	[('CHEBI_62946', 'ammonium sulfate', 67, '25(OH)D3'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 67, '25(OH'), ('PR_000001177', 'D(2) dopamine receptor', 73, 'D3'), ('GO_0006915', 'apoptotic process', 230, 'aging process'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('UBERON_0002113', 'kidney', 330, 'kidneys'), ('CHEBI_39382', 'flufenoxuron', 377, 'metabolite'), ('CHEBI_37958', 'dye', 388, '1,'), ('CHEBI_72639', '13-HODE', 390, '25(OH2)D3'), ('UBERON_0000160', 'intestine', 409, 'intestine'), ('CHEBI_37958', 'dye', 455, '1,'), ('CHEBI_86970', 'N-[(15Z)-tetracosenoyl]-tetradecasphing-4-enine-1-phosphoethanolamine', 457, '25(OH2)D3with')]
S35-PMC3773018	PMC3773018	4/2013	S35-PMC3773018	['we grouped the children according to longitudinal trajectory of 25(Oh)D based on if a child had: 1) low Vitamin D status at Birth (< 11ng/ml) AS SUGGESTED by the institute of medicine (26) or 2) low Postnatal Vitamin D status (< 30ng/ml) ACCORDING TO the Endocrine society clinical practice guidelines on Vitamin D insufficiency (27,28).']	[('PROBABLE_UNDERSTANDING', 142), ('INCOMPLETE_EVIDENCE', 145), ('INCOMPLETE_EVIDENCE', 238)]	3	[('CHEBI_71657', 'versiconol acetate', 64, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 64, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007567', 'parturition', 124, 'birth'), ('GO_0007567', 'parturition', 199, 'postnatal'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 255, 'Endocrine'), ('CHEBI_28384', 'vitamin K', 305, 'Vitamin D')]
S17-PMC3809191	PMC3809191	1/2013	S17-PMC3809191	['Serum 25 (Oh) D levels ≤20 ng/ml are ACCEPTED AS the cutoff level for Vitamin D deficiency SINCE this level was the highest level to maintain the Serum pth levels below 45 pg/ml.']	[('INCOMPLETE_EVIDENCE', 37), ('PROBABLE_UNDERSTANDING', 46), ('PROBABLE_UNDERSTANDING', 91)]	3	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 6, '25 (OH) D'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0001977', 'blood serum', 146, 'serum')]
S53-PMC3809191	PMC3809191	1/2013	S53-PMC3809191	['THIS EVIDENCE is CONSISTENT with low Vitamin D levels in either Pregnant or non-Pregnant Individuals in our country as in the rest of the world.11,12HOWEVER we did not FIND significant association of low levels of Serum 25 (Oh) D with elevated RISK for gdm EVEN after adjustment for conventional risk FACTORS for diabetes.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 17), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 147), ('INCOMPLETE_EVIDENCE', 168), ('IMPORTANT_CONSIDERATION', 244), ('ANOMALY_CURIOUS_FINDING', 257), ('SUPERFICIAL_RELATIONSHIP', 301)]	8	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('NCBITaxon_1', 'root', 89, 'individuals'), ('UBERON_0001977', 'blood serum', 214, 'serum'), ('CHEBI_71657', 'versiconol acetate', 220, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 220, '25 (OH) D')]
S53-PMC3814422	PMC3814422	10/2013	S53-PMC3814422	['this variable incorporates the seasonal INFLUENCE on 25(Oh)D. to remove this seasonal INFLUENCE in an ATTEMPT to obtain a MARKER of habitual Vitamin D concentrations for each mother, we used the residuals from the sine–cosine regression model.']	[('SUPERFICIAL_RELATIONSHIP', 40), ('SUPERFICIAL_RELATIONSHIP', 86), ('DIFFICULT_TASK', 102), ('SUPERFICIAL_RELATIONSHIP', 122)]	4	[('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 53, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 149, 'D')]
S134-PMC3814422	PMC3814422	10/2013	S134-PMC3814422	['by way of analogy, in a study of Vitamin D and Adult Lung function we FOUND that, WHILST there were APPARENT ASSOCIATIONS with dietary Vitamin D intake, there was NO EVIDENCE for an association with Blood 25(Oh)D concentrations29.']	[('INCOMPLETE_EVIDENCE', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 82), ('ANOMALY_CURIOUS_FINDING', 82), ('ANOMALY_CURIOUS_FINDING', 100), ('SUPERFICIAL_RELATIONSHIP', 109), ('INCOMPLETE_EVIDENCE', 163)]	6	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('UBERON_0007023', 'adult organism', 47, 'adult'), ('UBERON_0002048', 'lung', 53, 'lung'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('UBERON_0000178', 'blood', 199, 'blood'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 205, '25(OH)D')]
S27-PMC3827489	PMC3827489	10/2013	S27-PMC3827489	['diagnostic criteria of Vitamin D insufficiency or deficiency\nNO CONSENSUS on the definition of Vitamin D deficiency exists; HOWEVER, most clinicians and researchers agree on the following stratifications BASED ON the Serum concentration of 25(Oh)D: deficiency, <50.0 nmol/l or <20.0 ng/ml; insufficiency, 50.0-74.9 nmol/l or 20.0-29.9 ng/ml; and sufficiency, ≥75.0 nmol/l or ≥30.0 ng/ml1,6,16,17).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 61), ('INCOMPLETE_EVIDENCE', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('INCOMPLETE_EVIDENCE', 204), ('PROBABLE_UNDERSTANDING', 204)]	5	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('UBERON_0001977', 'blood serum', 217, 'serum'), ('CHEBI_71657', 'versiconol acetate', 240, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 240, '25(OH)D')]
S184-PMC3873449	PMC3873449	12/2013	S184-PMC3873449	['in 2011, the us endocrine society endorsed the need for at LEAST 600 iu(15 ug)/ day of Vitamin D supplementation for women during Pregnancy and up to 1500–2000 iu/day to maintain 25(Oh)D Blood levels above 30 ng/ml [16].']	[('PROBABLE_UNDERSTANDING', 59)]	1	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 179, '25(OH)D'), ('UBERON_0000178', 'blood', 187, 'blood')]
S199-PMC3873449	PMC3873449	12/2013	S199-PMC3873449	['it HAS BEEN REPORTED that pre-gravid obese women had significantly lower Serum 25(Oh)D concentrations and dose-DEPENDENT RELATIONS between pre-Pregnancy bmi and maternal Vitamin D status [48].']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 111), ('SUPERFICIAL_RELATIONSHIP', 121)]	3	[('UBERON_0001977', 'blood serum', 73, 'serum'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 79, '25(OH)D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]
S27-PMC4113768	PMC4113768	7/2014	S27-PMC4113768	['conclusions: sex-specific ASSOCIATIONS of 25(Oh)D3With Serum Lipids MAY exist in elderly subjects, and an adequate Vitamin D status MAY have a beneficial IMPACT on dyslipidaemia in elderly women.']	[('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 132), ('SUPERFICIAL_RELATIONSHIP', 154)]	4	[('CHEBI_86970', 'N-[(15Z)-tetracosenoyl]-tetradecasphing-4-enine-1-phosphoethanolamine', 42, '25(OH)D3with'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 42, '25(OH'), ('PR_000006480', 'type I iodothyronine deiodinase', 48, 'D3with'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('CHEBI_18059', 'lipid', 61, 'lipids'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
S378-PMC4113768	PMC4113768	7/2014	S378-PMC4113768	['the national academies press : washington, dc, usa, 2011).we INVESTIGATED WHETHER DIFFERENT levels of habitual Calcium Intake INFLUENCED Serum 25(Oh)D and indices of Vitamin D activation and Catabolism during winter and in the context of both adequate and inadequate Vitamin D intakes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 74), ('EXPLICIT_QUESTION', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 82), ('SUPERFICIAL_RELATIONSHIP', 126)]	5	[('CHEBI_22313', 'alkaline earth metal atom', 111, 'calcium'), ('GO_0007631', 'feeding behavior', 119, 'intake'), ('UBERON_0001977', 'blood serum', 137, 'serum'), ('CHEBI_71657', 'versiconol acetate', 143, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 143, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('GO_0009056', 'catabolic process', 191, 'catabolism'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D')]
S381-PMC4113768	PMC4113768	7/2014	S381-PMC4113768	['results: repeated measures anova SHOWED that there was no significant ( p = 0.2) time × Vitamin D treatment × Calcium intake grouping interaction effect on mean Serum 25(Oh)D concentration over the 15-week intervention period.']	[('INCOMPLETE_EVIDENCE', 33)]	1	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 110, 'calcium'), ('UBERON_0001977', 'blood serum', 161, 'serum'), ('CHEBI_71657', 'versiconol acetate', 167, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 167, '25(OH)D')]
S747-PMC4113768	PMC4113768	7/2014	S747-PMC4113768	['25(Oh)D assay standardization is, THEREFORE, ESSENTIAL to the development of EVIDENCED-BASED clinical and PUBLIC HEALTH guidelines for Vitamin D.\nmethods: Vitamin D standardization program (vdsp) is an international program designed to promote the standardized laboratory measurement of 25(Oh)D. it was established in 2010 by the us nih office of dietary supplements in collaboration with us national institute of standards and technology (nist), cdc, and ghent university.']	[('PROBABLE_UNDERSTANDING', 34), ('IMPORTANT_CONSIDERATION', 45), ('INCOMPLETE_EVIDENCE', 77), ('IMPORTANT_CONSIDERATION', 106)]	4	[('CHEBI_71657', 'versiconol acetate', 0, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 6, 'D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 155, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 287, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 287, '25(OH)D')]
S1132-PMC4113768	PMC4113768	7/2014	S1132-PMC4113768	['overall, 98% of the subjects supplemented with 400,000 iu of Vitamin D had their level of 25(Oh)D above 20 ng/ml at week 8, WHILE 84% and 52% of patients receiving 200,000 iu or 100,000 iu reached that level after 12 weeks of treatment.']	[('ANOMALY_CURIOUS_FINDING', 124)]	1	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 90, '25(OH)D')]
S1399-PMC4113768	PMC4113768	7/2014	S1399-PMC4113768	['the strongest suppressive EFFECT was seen on Cyp11A1, 3Β-Hsd and Cyp19A1 where the Vitamin D treatment decreased the Gene Expression to 30% compared to control.']	[('SUPERFICIAL_RELATIONSHIP', 26)]	1	[('PR_000006110', 'cytochrome P450 27, mitochondrial', 45, 'CYP11A1'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '3β-HSD'), ('PR_000006101', 'cytochrome P450 1A1', 65, 'CYP19A1'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0010467', 'gene expression', 117, 'gene expression'), ('SO_0000704', 'gene', 117, 'gene')]
S1670-PMC4113768	PMC4113768	7/2014	S1670-PMC4113768	['the difference in mean Serum 25(Oh)D concentration at follow-up vs. baseline REMAINED statistically significant after exclusion of 14 participants who were taking supplemental Vitamin D at follow-up and/or who had increased their sun exposure since time of diagnosis ( p = 0.005), and after exclusion of 17 participants whose baseline sample was taken from march to july inclusive ( p = 0.0003).']	[('INCOMPLETE_EVIDENCE', 77)]	1	[('UBERON_0001977', 'blood serum', 23, 'serum'), ('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 29, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D')]
S1673-PMC4113768	PMC4113768	7/2014	S1673-PMC4113768	['differences in mean Serum 25(Oh)D concentration between the two time points were not EXPLAINED by differences in use of Vitamin D supplements, self-reported sun exposure or season of sampling at follow-up vs. baseline.']	[('PROBABLE_UNDERSTANDING', 85)]	1	[('UBERON_0001977', 'blood serum', 20, 'serum'), ('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 26, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
S1828-PMC4113768	PMC4113768	7/2014	S1828-PMC4113768	['in SOME of the elderly subjects lower Plasma 25(Oh)D levels coexisting with high alkaline phosphatase activity MAY INDICATE developing osteomalacia.taking INTO ACCOUNT lower Plasma 25(Oh)D, 1,25(Oh)D and calcium levels among the MAJORITY of centenarians, the sufficient Vitamin D and calcium supplementation SHOULD be systematically APPLIED also in the oldest old.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 111), ('INCOMPLETE_EVIDENCE', 115), ('INCOMPLETE_EVIDENCE', 155), ('PROBABLE_UNDERSTANDING', 229), ('FUTURE_WORK', 308), ('SUPERFICIAL_RELATIONSHIP', 333)]	7	[('UBERON_0001969', 'blood plasma', 38, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 45, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 174, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 181, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D')]
S1975-PMC4113768	PMC4113768	7/2014	S1975-PMC4113768	['there was a positive CORRELATION between the total amount of Vitamin D obtained from Food and the Serum 25(Oh)D concentration ( r = 0.218, p = 0.004).']	[('SUPERFICIAL_RELATIONSHIP', 21)]	1	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_33290', 'food', 85, 'food'), ('UBERON_0001977', 'blood serum', 98, 'serum'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 104, '25(OH)D')]
S1978-PMC4113768	PMC4113768	7/2014	S1978-PMC4113768	['conclusion: in the absence of Vitamin D Synthesis by sunlight, Vitamin D obtained from Food has a significant INFLUENCE on the Serum 25(Oh)D concentration in children.']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0009057', 'macromolecule catabolic process', 40, 'synthesis'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_33290', 'food', 87, 'food'), ('UBERON_0001977', 'blood serum', 127, 'serum'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 133, '25(OH)D')]
S1984-PMC4113768	PMC4113768	7/2014	S1984-PMC4113768	['the PRESENT STUDY AIMS TO EXAMINE the ASSOCIATIONS of Serum 25-Hydroxy Vitamin D levels [25(Oh)D, a BIOMARKER of Vitamin D in blood] with clrd and outcomes using data from a large-scale prospective cohort study in the u.s.\nmethods: a total of 15,772 (m: 7,414, f: 8,358) subjects aged ≥20 year old who participated in the u.s. third national health and nutrition examination survey, had measures of serum 25(Oh)D at baseline (1988–1994), and had been followed up through december of 2006 were analyzed.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 100)]	5	[('UBERON_0001977', 'blood serum', 54, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 60, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 405, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 405, '25(OH)D')]
S2398-PMC4113768	PMC4113768	7/2014	S2398-PMC4113768	['eligible studies included Pregnant women and their offspring, and one or more RELEVANT exposures (either assessment of Vitamin D status (dietary intake, sunlight exposure, circulating 25(Oh)D) or supplementation of participants with Vitamin D or Vitamin D containing Food e.g., oily fish) and outcomes (offspring birth weight, Birth length, Head circumference, bone mass, anthropometry and body composition, risk of asthma and atopy, small for Gestational dates, Preterm Birth, type 1 diabetes, low Birth weight, Serum calcium concentration, Blood pressure and rickets).']	[('IMPORTANT_CONSIDERATION', 78)]	1	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 184, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 190, 'D'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D'), ('CHEBI_33290', 'food', 267, 'food'), ('GO_0007567', 'parturition', 327, 'birth'), ('UBERON_0000033', 'head', 341, 'head'), ('GO_0007565', 'female pregnancy', 444, 'gestational'), ('GO_0007565', 'female pregnancy', 463, 'preterm birth'), ('GO_0007567', 'parturition', 499, 'birth'), ('UBERON_0001977', 'blood serum', 513, 'serum'), ('UBERON_0000178', 'blood', 542, 'blood')]
S2517-PMC4113768	PMC4113768	7/2014	S2517-PMC4113768	['THESE FINDINGS SUGGEST that; (1) there is no additional BENEFIT to calcium absorption or bone mineralisation from a Blood level for 25(Oh)D above ~75 nmol/l; (2)DESPITE adequate Vitamin D and regular physical activity lower dietary Calcium intake is STILL a PREDICTOR of lower total body bmd and bmc; and (3) in certain population groups with baseline 25(Oh)D > 75 nmol/l, Vitamin D supplementation of 50,000 iu/month does not significantly increase 25(Oh)D concentrations over a 12 month period, but POSSIBLY PREVENTS seasonal decline.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 56), ('ANOMALY_CURIOUS_FINDING', 161), ('IMPORTANT_CONSIDERATION', 250), ('SUPERFICIAL_RELATIONSHIP', 258), ('INCOMPLETE_EVIDENCE', 501), ('SUPERFICIAL_RELATIONSHIP', 510)]	8	[('UBERON_0000178', 'blood', 116, 'blood'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 132, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 232, 'calcium'), ('CHEBI_71657', 'versiconol acetate', 352, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 352, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 373, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 450, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 450, '25(OH)D')]
S2646-PMC4113768	PMC4113768	7/2014	S2646-PMC4113768	['median maternal 25(Oh)D was 61 nmol/l (iqr 43–88 nmol/l), and ONLY 9.2% of mothers were using Vitamin D supplementation (at LEAST 400 iu/day) in late Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 62), ('PROBABLE_UNDERSTANDING', 124)]	2	[('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 16, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy')]
S3047-PMC4113768	PMC4113768	7/2014	S3047-PMC4113768	['the main DETERMINANTS of Cord 25(Oh)D [adjusted mean difference in nmol/l (95% ci)] were summer season of sampling [19.2 (17.4, 20.9), p < 0.0001], maternal 25(Oh)D concentrations at 15 weeks [0.3 (0.26, 0.34), p < 0.0001] and the maternal use of a Vitamin D containing supplement at 15 weeks [2.5 (0.6, 4.42), p = 0.011].']	[('SUPERFICIAL_RELATIONSHIP', 9)]	1	[('UBERON_0002240', 'spinal cord', 25, 'cord'), ('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 30, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 157, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D')]
S3200-PMC4113768	PMC4113768	7/2014	S3200-PMC4113768	['use of Vitamin D supplements, living in an institution and season of Blood sampling were significant independent predictors of 25(Oh)D concentrations using linear regression models, while non-use of Vitamin D containing supplements, season and low physical activity PREDICTED Vitamin D deficiency using logistic regression models.']	[('SUPERFICIAL_RELATIONSHIP', 266)]	1	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('UBERON_0000178', 'blood', 69, 'blood'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 127, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D')]
S3274-PMC4113768	PMC4113768	7/2014	S3274-PMC4113768	['a pre-specified sub-group analysis was conducted TO DETERMINE whether effects of the intervention on co-primary outcomes were modified by the presence or absence of Vitamin D deficiency (Serum 25(Oh)D < 50 nmol/l) at baseline.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 49)]	1	[('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('UBERON_0001977', 'blood serum', 187, 'serum'), ('CHEBI_71657', 'versiconol acetate', 193, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 193, '25(OH)D')]
S3328-PMC4113768	PMC4113768	7/2014	S3328-PMC4113768	['when ADDITIONAL EVIDENCE on EFFECTS RELATED to Vitamin D from OBSERVATIONAL studies with respect to Serum 25(Oh)D level or personal uvb irradiance, the ROLE of skin pigmentation, and laboratory studies of mechanisms, hill’s criteria for causality in a biological system (hill ab.']	[('FUTURE_WORK', 5), ('SUPERFICIAL_RELATIONSHIP', 28), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 62), ('SUPERFICIAL_RELATIONSHIP', 152)]	5	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('UBERON_0001977', 'blood serum', 100, 'serum'), ('CHEBI_71657', 'versiconol acetate', 106, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 106, '25(OH)D')]
S11-PMC4169453	PMC4169453	9/2014	S11-PMC4169453	['conclusions\nVitamin D supplementation at a dose of 400 iu/d was not sufficient to maintain 25(Oh)D >20 ng/ml in nursing women, WHILE 1200 iu/d APPEARED more EFFECTIVE, but had no effect on Breastfed offspring Vitamin D status, or changes in the bone mass and the body composition OBSERVED in both during breastfeeding.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('ANOMALY_CURIOUS_FINDING', 127), ('ANOMALY_CURIOUS_FINDING', 143), ('SUPERFICIAL_RELATIONSHIP', 157), ('INCOMPLETE_EVIDENCE', 280)]	5	[('CHEBI_28384', 'vitamin K', 12, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 91, '25(OH)D'), ('GO_0007567', 'parturition', 189, 'breastfed'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
S68-PMC4169453	PMC4169453	9/2014	S68-PMC4169453	['Serum 25(Oh)D <20 ng/ml DEFINED the Vitamin D deficiency state, WHEREAS ≥30 ng/ml REFLECTED Vitamin D sufficiency[7].']	[('PROBABLE_UNDERSTANDING', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 64), ('SUPERFICIAL_RELATIONSHIP', 82)]	3	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
S88-PMC4169453	PMC4169453	9/2014	S88-PMC4169453	['sample size calculation\nto detect a statistically significant difference in Serum 25(Oh)D level (primary outcome) by 4 ng/ml between the intervention groups after Vitamin D supplementation at least 64 mother-infant pairs per group were REQUIRED at 80% power using a two-sided t-test at α\u200a=\u200a0.05.']	[('IMPORTANT_CONSIDERATION', 236)]	1	[('UBERON_0001977', 'blood serum', 76, 'serum'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S135-PMC4169453	PMC4169453	9/2014	S135-PMC4169453	['the EFFECT of group (Vitamin D dose) x time INTERACTION ( p \u200a=\u200a0.12) and the EFFECT of group ( p \u200a=\u200a0.45) on infants’ Serum 25(Oh)D levels was not statistically significant, WHILE the EFFECT of time was statistically significant ( p<0.0001) (fig.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('ANOMALY_CURIOUS_FINDING', 174), ('SUPERFICIAL_RELATIONSHIP', 184)]	6	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001977', 'blood serum', 118, 'serum'), ('CHEBI_71657', 'versiconol acetate', 124, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 124, '25(OH)D')]
S162-PMC4169453	PMC4169453	9/2014	S162-PMC4169453	['HOWEVER, maternal total body fat mass was comparable between groups, significant negative CORRELATIONS were noted between maternal 25(Oh)D level and maternal fat mass (r\u200a=\u200a−0.49, p \u200a=\u200a0.00001), Android fat mass (r\u200a=\u200a−0.53, p \u200a=\u200a0.00001), and gynoid fat mass (r\u200a=\u200a−0.43, p \u200a=\u200a0.00001) after 6 months of Vitamin D supplementation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 90)]	2	[('CHEBI_71657', 'versiconol acetate', 131, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 131, '25(OH)D'), ('UBERON_0001428', 'intermedium', 194, 'android'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D')]
S174-PMC4169453	PMC4169453	9/2014	S174-PMC4169453	['in OUR STUDY maternal median 25(Oh)D levels (∼15 ng/ml) at the baseline visit, INDICATING Vitamin D deficiency.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 79)]	2	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 29, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S184-PMC4169453	PMC4169453	9/2014	S184-PMC4169453	['there is GROWING EVIDENCE SHOWING Serum 25(Oh)D levels higher than 30 ng/ml, or EVEN higher than 40 ng/ml as EFFECTIVE for expression of Extra-Skeletal EFFECTS RELATED to proper Vitamin D status[1],[34],[35].']	[('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 26), ('ANOMALY_CURIOUS_FINDING', 80), ('SUPERFICIAL_RELATIONSHIP', 109), ('SUPERFICIAL_RELATIONSHIP', 152), ('SUPERFICIAL_RELATIONSHIP', 160)]	6	[('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 40, '25(OH)D'), ('UBERON_0001431', 'distal carpal bone 2', 137, 'extra-skeletal'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D')]
S190-PMC4169453	PMC4169453	9/2014	S190-PMC4169453	['from a clinical POINT OF VIEW, the IMPACT of 1200 iu/d Vitamin D dose on the maternal 25(Oh)D concentration was very subtle.']	[('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 35)]	2	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D')]
S200-PMC4169453	PMC4169453	9/2014	S200-PMC4169453	['though supplementation at a dose of 2000 iu/d was PREVIOUSLY REPORTED to increase maternal 25(Oh)D to 30–39 ng/ml[35],[38],[39], it STILL MIGHT be insufficient for Vitamin D-deficient women[40],[41].']	[('INCOMPLETE_EVIDENCE', 50), ('INCOMPLETE_EVIDENCE', 61), ('IMPORTANT_CONSIDERATION', 132), ('INCOMPLETE_EVIDENCE', 138)]	4	[('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 91, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
S206-PMC4169453	PMC4169453	9/2014	S206-PMC4169453	['NEVERTHELESS, we SHOULD KEEP IN MIND that each 400 iu/d of Vitamin D MAY increase Serum 25(Oh)D level by 2.8 ng/ml[17].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 24), ('INCOMPLETE_EVIDENCE', 69)]	4	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0001977', 'blood serum', 82, 'serum'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D')]
S210-PMC4169453	PMC4169453	9/2014	S210-PMC4169453	['INTERESTINGLY, the fish Intake was not associated with Serum 25(Oh)D level in that study, DESPITE fish being CONSIDERED a rich source of Vitamin D. ON THE OTHER HAND, a mean skin synthesis of Vitamin D was 200–650 iu/d at the summer peak, but it accounted for ONLY 10–25% of total basal Vitamin D input[37].']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 90), ('INCOMPLETE_EVIDENCE', 109), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 148), ('ANOMALY_CURIOUS_FINDING', 260)]	5	"[('GO_0007631', 'feeding behavior', 24, 'intake'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('CHEBI_74268', ""N(1)-methylguanosine 5'-monophosphate"", 61, '25(OH)d'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 61, '25(OH)d'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 287, 'vitamin D')]"
S22-PMC4251419	PMC4251419	12/2014	S22-PMC4251419	['in case-control studies, participants with one of these Autoimmune diseases TEND to report lower past sun exposure, and/or have lower Vitamin D status (measured as the Blood concentration of the intermediary Metabolite, 25(Oh)D, seefigure 1), than healthy controls (see for example recent reviews [12,13]).']	[('SUPERFICIAL_RELATIONSHIP', 76)]	1	[('UBERON_0001442', 'skeleton of manus', 56, 'autoimmune'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('UBERON_0000178', 'blood', 168, 'blood'), ('CHEBI_39382', 'flufenoxuron', 208, 'metabolite'), ('CHEBI_71657', 'versiconol acetate', 220, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 220, '25(OH)D')]
S85-PMC4302429	PMC4302429	1/2015	S85-PMC4302429	['results\n\nVitamin D3 Serum concentrations DEPENDED on dietary Vitamin D3 content\nthe analysis of the Vitamin D3 Metabolite 25-Oh-D3 in Serum samples obtained after six weeks of experimental diet REVEALED that the Vitamin D3 content in the diet determined the Vitamin D Serum concentrations of the Mice.']	[('SUPERFICIAL_RELATIONSHIP', 41), ('INCOMPLETE_EVIDENCE', 194)]	2	[('CHEBI_33237', 'vitamin D4', 9, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 9, 'Vitamin D3'), ('UBERON_0001977', 'blood serum', 20, 'serum'), ('CHEBI_33279', 'vitamin D5', 61, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 61, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 100, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 100, 'vitamin D3'), ('CHEBI_39382', 'flufenoxuron', 111, 'metabolite'), ('CHEBI_86945', 'syringaldehyde acetate', 122, '25-OH-D3'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 122, '25-OH-D3'), ('UBERON_0001977', 'blood serum', 134, 'serum'), ('CHEBI_33279', 'vitamin D5', 212, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 212, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('UBERON_0001977', 'blood serum', 268, 'serum'), ('NCBITaxon_10088', 'Mus <genus>', 296, 'mice')]
S23-PMC4380518	PMC4380518	9/2014	S23-PMC4380518	['we DEFINED Vitamin D deficiency as <50 nmol/l, a COMMON cut-point in the literature.5,22,23\n\nstatistical analyses\nfirst, we analyzed bivariate associations between 25(Oh)D category and pnv use as well as covariates including maternal age, race/ethnicity, smoking, education and bmi.']	[('PROBABLE_UNDERSTANDING', 3), ('PROBABLE_UNDERSTANDING', 49)]	2	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 164, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 164, '25(OH)D')]
S52-PMC4380518	PMC4380518	9/2014	S52-PMC4380518	['shea et al studied 2500 elderly Adults and FOUND that lack of pnv use was ASSOCIATED with higher odds of Vitamin D insufficiency (<75 nmol/l) in both black (5.2 (95% ci: 3.5, 7.7)) and white participants (or 2.6, 95% ci: 2.0, 3.2), HOWEVER these subjects were much older and not Pregnant.26a SMALL turkish STUDY of 79 Pregnant women SHOWED significantly higher 25(Oh)D levels among women reporting pnv use in the third trimester,27BUT this study DID NOT include women of african descent and DID NOT have the power to address POTENTIAL INTERACTION by bmi.']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 232), ('INCOMPLETE_EVIDENCE', 292), ('INCOMPLETE_EVIDENCE', 333), ('PROBLEM_COMPLICATION', 431), ('INCOMPLETE_EVIDENCE', 446), ('INCOMPLETE_EVIDENCE', 491), ('INCOMPLETE_EVIDENCE', 525), ('SUPERFICIAL_RELATIONSHIP', 535)]	10	[('UBERON_0007023', 'adult organism', 32, 'adults'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 279, 'pregnant'), ('GO_0007565', 'female pregnancy', 318, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 361, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 361, '25(OH)D')]
S110-PMC4396835	PMC4396835	1/2015	S110-PMC4396835	['25-Hydroxyvitamin D in children with asd RELATED to iq\nthere was no relation between iq and Vitamin D level, that is, the group with intellectual disability did not display lower 25(Oh)D levels compared to those without.']	[('SUPERFICIAL_RELATIONSHIP', 41)]	1	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 0, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 179, '25(OH)D')]
S130-PMC4396835	PMC4396835	1/2015	S130-PMC4396835	['HOWEVER, the LACK OF effect of season of sampling (= season of Birth in OUR STUDY) on 25(Oh)D levels in our african/middle east group, all having low Vitamin D status throughout the year, HAS also BEEN REPORTED in women with african/middle east origin living in norway [59].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 72), ('INCOMPLETE_EVIDENCE', 188), ('INCOMPLETE_EVIDENCE', 202)]	5	[('GO_0007567', 'parturition', 63, 'birth'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
S169-PMC4396835	PMC4396835	1/2015	S169-PMC4396835	['three DIFFERENT independent findings POINT towards a ROLE for Vitamin D in the development of asd: (1) increased risk for asd in offspring of migrants, especially from countries with a dark-skinned population and from cultures where women use covered clothing; (2) low 25(Oh)D levels in groups of newborn children, who later have developed asd, and in groups of children and Adults with asd; and (3) an ASSOCIATION between season of Birth and asd, in OUR STUDY not extending to the high-risk groups of migrants, SUGGESTING that these groups are exposed to suboptimal Vitamin D levels the whole year.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 6), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 53), ('SUPERFICIAL_RELATIONSHIP', 403), ('QUESTION_ANSWERED_BY_THIS_WORK', 451), ('INCOMPLETE_EVIDENCE', 512)]	6	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 269, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 269, '25(OH)D'), ('UBERON_0007023', 'adult organism', 375, 'adults'), ('GO_0007567', 'parturition', 433, 'birth'), ('CHEBI_27300', 'vitamin D', 567, 'vitamin D')]
S56-PMC4598849	PMC4598849	10/2015	S56-PMC4598849	['in THIS STUDY with a large sample, adjustment for more confounders and using non-linear models, we FOUND that there was an inverted u-shaped RELATIONSHIP between Cord Blood 25(Oh)D and Birth weight, SUGGESTING that the newborn with low or high levels of fetal Vitamin D are both in INCREASED risk of growth restriction and higher levels of fetal Vitamin D HAVE not been shown to confer greater BENEFITS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 99), ('SUPERFICIAL_RELATIONSHIP', 141), ('INCOMPLETE_EVIDENCE', 199), ('IMPORTANT_CONSIDERATION', 282), ('IMPORTANT_CONSIDERATION', 356), ('IMPORTANT_CONSIDERATION', 394)]	7	[('UBERON_0002240', 'spinal cord', 162, 'cord'), ('UBERON_0000178', 'blood', 167, 'blood'), ('CHEBI_71657', 'versiconol acetate', 173, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 173, '25(OH)D'), ('GO_0007567', 'parturition', 185, 'birth'), ('CHEBI_27300', 'vitamin D', 260, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 346, 'vitamin D')]
S137-PMC4684854	PMC4684854	12/2015	S137-PMC4684854	"[""as discussed, individual Vitamin D indices CAN be INFLUENCED by various DETERMINANTS DESPITE specific levels of supplementation; it is THUS the author's RECOMMENDATION that a personalized medical approach be taken via individual screening for 25(Oh)D as a routine part of Preconception and Prenatal care.""]"	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 50), ('SUPERFICIAL_RELATIONSHIP', 72), ('ANOMALY_CURIOUS_FINDING', 85), ('PROBABLE_UNDERSTANDING', 135), ('FUTURE_WORK', 153)]	6	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 243, '25(OH)D'), ('GO_0007565', 'female pregnancy', 272, 'preconception'), ('GO_0007565', 'female pregnancy', 290, 'prenatal')]
S76-PMC4690051	PMC4690051	12/2015	S76-PMC4690051	['using stepwise selection (0.20 for entry, 0.05 to stay) to remove the insignificant variables, we retained 25(Oh)D status in the model while assessing the following POSSIBLE CONFOUNDERS: race (aa or ea), maternal iq, use of tobacco products or Alcohol during Pregnancy, maternal dietary Intake of Vitamin D, age, pre-Pregnancy bmi, total number of completed Pregnancies, Gestational hypertension or Gestational diabetes, insurance status, level of maternal education, marital status, child’s age at cv2, and Gestational age at Birth.']	[('INCOMPLETE_EVIDENCE', 165), ('PROBLEM_COMPLICATION', 174)]	2	[('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 107, '25(OH)D'), ('CHEBI_30879', 'alcohol', 244, 'alcohol'), ('GO_0007565', 'female pregnancy', 259, 'pregnancy'), ('GO_0007631', 'feeding behavior', 287, 'intake'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin D'), ('GO_0007565', 'female pregnancy', 317, 'pregnancy'), ('GO_0007565', 'female pregnancy', 358, 'pregnancies'), ('GO_0007565', 'female pregnancy', 371, 'gestational'), ('GO_0007565', 'female pregnancy', 399, 'gestational'), ('GO_0007565', 'female pregnancy', 508, 'gestational'), ('GO_0007567', 'parturition', 527, 'birth')]
S170-PMC4690051	PMC4690051	12/2015	S170-PMC4690051	['DUE TO phlebotomy limits in infants and THE BURDEN of other candle procedures, this candle sub-study lacks repeated measures of 25(Oh)D status for participants and lacks individual assessments of Parathyroid hormone status or Vitamin D receptor ( vdr ) genotype.']	[('PROBLEM_COMPLICATION', 0), ('IMPORTANT_CONSIDERATION', 40)]	2	[('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 128, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 196, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]
S18-PMC4691762	PMC4691762	12/2015	S18-PMC4691762	['Vitamin D deficiency (currently defined as 25Ohd3<50\u2005nmol/l) has become MORE COMMON in modern communities over time, PRESUMABLY DUE TO INADEQUATE sun exposure resulting from indoor activities and skin cancer CONCERNS.13vitamin d deficiency is common in victoria, australia and also APPEARS TO BE increasing among Pregnant women14and infants.6in addition, the prevalence of infant Vitamin D deficiency was fourfold higher among fully Breastfed infants than fully formula Fed (p<0.001) EVEN at 12\u2005months after solid Food had been introduced.15\nUNLIKE OTHER countries in the northern hemisphere, australia does not RECOMMEND universal Vitamin D supplementation.']	[('PROBABLE_UNDERSTANDING', 72), ('PROBABLE_UNDERSTANDING', 117), ('PROBABLE_UNDERSTANDING', 128), ('IMPORTANT_CONSIDERATION', 135), ('IMPORTANT_CONSIDERATION', 208), ('ANOMALY_CURIOUS_FINDING', 282), ('ANOMALY_CURIOUS_FINDING', 484), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 542), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 549), ('FUTURE_WORK', 612)]	10	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_63058', '(2R,3S)-EHNA', 43, '25OHD3'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 43, '25OHD3'), ('GO_0007565', 'female pregnancy', 313, 'pregnant'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D'), ('GO_0007567', 'parturition', 433, 'breastfed'), ('GO_0007631', 'feeding behavior', 470, 'fed'), ('CHEBI_33290', 'food', 514, 'food'), ('CHEBI_27300', 'vitamin D', 632, 'vitamin D')]
S68-PMC4691762	PMC4691762	12/2015	S68-PMC4691762	"[""Vitamin D deficiency : infant 25Ohd3 levels and Metabolites including the c3-epimer of 25Ohd3 will be measured using liquid chromatography-tandem mass spectrometry.22the method will be referenced to the joint commission for traceability in laboratory medicine's RECOMMENDED reference standard to provide accuracy for the Vitamin D result.""]"	[('FUTURE_WORK', 262)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 30, '25OHD3'), ('CHEBI_25212', 'metabolite', 48, 'metabolites'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 87, '25OHD3'), ('CHEBI_27300', 'vitamin D', 321, 'vitamin D')]
S69-PMC4691762	PMC4691762	12/2015	S69-PMC4691762	"[""participant's Vitamin D status will be defined by their Blood 25Ohd3 level, AS: severely deficient <12.5\u2005nmol/l; moderately deficient 12.5–25\u2005nmol/l; mild deficiency 26–49\u2005nmol/l; sufficient ≥50\u2005nmol/l; and elevated >220\u2005nmol/l.23\nparent baseline questionnaire : to check that potential environmental and OTHER CONFOUNDING factors are balanced between the two randomisation groups, baseline parent questionnaires will collect data on: parental smoking, medication use, parental ancestry, ethnicity, education, employment, occupation, family history of allergy, use of supplements including Vitamin A, d and cod Liver oil, number of siblings; and pet ownership.""]"	[('PROBABLE_UNDERSTANDING', 76), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 305), ('PROBLEM_COMPLICATION', 311)]	3	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0000178', 'blood', 56, 'blood'), ('CHEBI_63058', '(2R,3S)-EHNA', 62, '25OHD3'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 62, '25OHD3'), ('CHEBI_27300', 'vitamin D', 590, 'vitamin A'), ('UBERON_0002107', 'liver', 611, 'liver')]
S106-PMC4691762	PMC4691762	12/2015	S106-PMC4691762	['we will not be monitoring Serum 25(Oh)D for safety reasons nor considering the association between 25(Oh)D and outcome frequency given that 400\u2005Iu HAS BEEN SHOWN to be SAFE in term babies,1926preterm infants27and is the current RECOMMENDED dose in the usa, canada, the uk and europe.18\n\ndiscussion\nthe results of the vitality trial will determine WHETHER Vitamin D supplementation has a ROLE in optimising infant Immune health in the first year of Life, reducing the risk of allergic disease and Respiratory diseases.']	[('INCOMPLETE_EVIDENCE', 147), ('IMPORTANT_CONSIDERATION', 168), ('FUTURE_WORK', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 347), ('SUPERFICIAL_RELATIONSHIP', 387)]	5	[('UBERON_0001977', 'blood serum', 26, 'serum'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 32, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 99, '25(OH)D'), ('CHEBI_17883', 'hydrogen chloride', 144, 'IU'), ('CHEBI_27300', 'vitamin D', 355, 'vitamin D'), ('UBERON_0002405', 'immune system', 413, 'immune'), ('UBERON_0000104', 'life cycle', 448, 'life'), ('UBERON_0001004', 'respiratory system', 496, 'respiratory')]
S95-PMC4719746	PMC4719746	1/2016	S95-PMC4719746	"['=\u20090.24independent variabler2adj.b95\xa0% cib95\xa0% cir2adj.b95\xa0% cib95\xa0% cilowerupperlowerupperlowerupperloweruppergestational week at inclusion (<15 ref)−0.0010.01ᅟ≥15−0.56−4.43.3 −6.4−10−2.3**−4.6−8.3−0.92* age at inclusion0.03 0.940.551.3** 0.14−0.210.490.03 1.10.641.5**0.700.261.1** parity (para 0 ref)0.020.01ᅟpara1−1.2−5.43.10.24−3.13.6−2.8−7.41.8 −4.4−8.7−0.22* ᅟpara ≥2 −11−17−6.3** −3.2−7.61.3 −9.3−15−3.8** −5.4−110.25geographic region (western europe ref)0.380.16ᅟsouth asia −37−40−33**−28−33−23**−26−31−21**−17−23−11** ᅟmiddle east −34−39−30**−24−29−18**−21−26−15**−9.5−16−2.9** ᅟsub-saharan africa −31−37−25**−20−27−13**−26−34−19**−12−20−3.1** ᅟeast asia −17−24−10**−11−18−3.9**−19−28−11**−11−20−1.6* ᅟother −13−19−6.4**−7.6−14−0.90*−9.0−17−1.3* −1.4−9.66.9season (summer ref)0.030.01ᅟwinter −9.9−14−6.1**−5.2−8.9−1.4**−5.7−9.8−1.6** −1.3−6.13.4geographic region*seasona−11−16−4.8**−15−22−7.4** education level (>12 y ref)0.110.08ᅟ10-12 year −14−18−10**−3.7−7.1−0.30*−11−15−6.8** −1.8−6.12.5ᅟ<10\xa0year −23−28−17**−5.2−10−0.31*−23−29−17**−8.6−15−2.5** Vitamin D supplements (≥10μgbref)0.080.02ᅟno or <10\xa0μg −15−19−11**−11−14−7.7**−8.2−13−3.8**−9.8−14−5.8** pre-Pregnancy bmi (<25\xa0kg/m2ref)−0.001−0.001ᅟ≥25\xa0kg/m2−0.76−4.73.2−0.11−4.44.2\nathe EFFECT of season on 25(Oh)d differed by ethnicity: the interaction term is ""1"" for records with both non-western and winter and ""0"" for western and summer (ref)\nbintake of ≥10\xa0μg Vitamin D daily past two weeks\nbold numbers indicate p \u2009<\u20090.05 (* p \u2009<\u20090.05, ** p \u2009<\u20090.01)\n\nVitamin D status at Gestational week 28\nat the beginning of the third trimester, the prevalence of 25(Oh)D <50\xa0nmol/l among the largest ethnic minority groups was lower than at study inclusion: south asia: 62\xa0%, the middle east: 58\xa0% and sub-saharan africa: 63\xa0%.']"	[('SUPERFICIAL_RELATIONSHIP', 1248)]	1	[('CHEBI_28384', 'vitamin K', 1059, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1168, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 1268, '25(OH)'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1268, '25(OH'), ('CHEBI_27300', 'vitamin D', 1427, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 1435, 'D'), ('CHEBI_28384', 'vitamin K', 1519, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1539, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1618, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 1618, '25 ... OH ... D')]
S152-PMC4719746	PMC4719746	1/2016	S152-PMC4719746	['the SMALL increase of 25(Oh)D OBSERVED among women with a slight deficiency at baseline who did not receive the recommendation, MAY BE RELATED to usual practices in norway of routinely RECOMMENDING a daily intake of 10\xa0μg Vitamin D as part of Antenatal Care [21].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 135), ('FUTURE_WORK', 185)]	5	[('CHEBI_71657', 'versiconol acetate', 22, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 22, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 243, 'antenatal care')]
S44-PMC4764019	PMC4764019	1/2016	S44-PMC4764019	['briefly, at age 5 years, 13% of children Born of mothers in the lowest quartile of Vitamin D status [25(Oh)D <18 ng/ml] exhibited Learning disability, as contrasted with ONLY 4% of children Born of mothers in the highest 25(Oh)D quartile (>29 ng/ml), that is, a better than 3-fold increase in risk of the lowest quartile.']	[('ANOMALY_CURIOUS_FINDING', 170)]	1	[('GO_0007567', 'parturition', 41, 'born'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 101, '25 ... OH ... D'), ('GO_0007612', 'learning', 130, 'learning'), ('GO_0007567', 'parturition', 190, 'born'), ('CHEBI_71657', 'versiconol acetate', 221, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 221, '25(OH)D')]
S23-PMC4785305	PMC4785305	3/2016	S23-PMC4785305	['maternal Vitamin D status during Pregnancy\nvitamin D deficiency during Pregnancy is PREVALENT worldwide, ESPECIALLY in developing countries.8in a systematic review of 18 studies conducted in western countries during the first Trimester, white caucasian Pregnant women were found to have a mean 25(Oh)D level between 29 and 73\u2005nmol/l.9mean 25(Oh)D levels were lower in non-caucasian Pregnant women, ranging between 15.2 and 43\u2005nmol/l.9in addition to ethnicity, higher latitude was a significant predisposing FACTOR for hypovitaminosis d.9similarly, in non-western countries, more than half of the Pregnant women who were beyond their first trimester had 25(Oh)D levels below 75\u2005nmol/l; these include countries such as india,10kuwait,11pakistan12and turkey.13even lower levels (<25\u2005nmol/l) HAVE BEEN REPORTED at Delivery in saudi arabia, iran and the united arab emirates.14furthermore, immigrant women were at PARTICULAR RISK.1516an OBSERVATIONAL study from the netherlands SHOWED significantly lower 25(Oh)D levels during the first Trimester in immigrant Pregnant women (turkish, moroccan and others), compared to western participants.17\n\nASSOCIATION between maternal Vitamin D status and maternal adverse outcomes\nVitamin D insufficiency during Pregnancy is ASSOCIATED with adverse maternal outcomes such as increased risk of Gestational diabetes mellitus (gdm), preeclampsia, caesarean-section Delivery and bacterial vaginosis.18in a recent meta-analysis of observational studies, the risk of gdm was FOUND TO BE increased by 40–84% in Pregnant women with low 25(Oh)D levels, defined as <50\u2005nmol/l or <75\u2005nmol/l, DEPENDING ON the studies.19–21while Preeclampsia risk was significantly increased in Vitamin D insufficient women,22c-section rates were INCONSISTENTLY AFFECTED by Vitamin D status.23HOWEVER, THESE FINDINGS REMAIN LIMITED by the inherent BIASES of OBSERVATIONAL studies, INCONSISTENT adjustment for CONFOUNDERS, in addition to the wide HETEROGENEITY in Vitamin D assays and Vitamin D cut-offs definition.']	[('IMPORTANT_CONSIDERATION', 84), ('IMPORTANT_CONSIDERATION', 105), ('SUPERFICIAL_RELATIONSHIP', 507), ('INCOMPLETE_EVIDENCE', 788), ('IMPORTANT_CONSIDERATION', 909), ('INCOMPLETE_EVIDENCE', 932), ('INCOMPLETE_EVIDENCE', 973), ('SUPERFICIAL_RELATIONSHIP', 1139), ('SUPERFICIAL_RELATIONSHIP', 1259), ('ANOMALY_CURIOUS_FINDING', 1503), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1752), ('SUPERFICIAL_RELATIONSHIP', 1767), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1796), ('INCOMPLETE_EVIDENCE', 1807), ('INCOMPLETE_EVIDENCE', 1822), ('INCOMPLETE_EVIDENCE', 1829), ('PROBLEM_COMPLICATION', 1853), ('INCOMPLETE_EVIDENCE', 1863), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1886), ('PROBLEM_COMPLICATION', 1914), ('DIFFICULT_TASK', 1951)]	22	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 51, 'D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 226, 'trimester'), ('GO_0007565', 'female pregnancy', 253, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 294, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 294, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 345, 'D'), ('GO_0007565', 'female pregnancy', 382, 'pregnant'), ('GO_0007565', 'female pregnancy', 596, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 653, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 653, '25(OH)D'), ('GO_0007567', 'parturition', 810, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 1000, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1000, '25(OH)D'), ('GO_0009294', 'DNA mediated transformation', 1032, 'trimester'), ('GO_0007565', 'female pregnancy', 1055, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1168, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 1215, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1246, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1327, 'gestational'), ('GO_0007567', 'parturition', 1396, 'delivery'), ('GO_0007565', 'female pregnancy', 1538, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 1562, '25(OH)D'), ('GO_0007128', 'meiotic prophase I', 1651, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 1700, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1779, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1968, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D')]
S25-PMC4785305	PMC4785305	3/2016	S25-PMC4785305	['the 2010 institute of medicine (iom) report on dietary reference intakes for Calcium and Vitamin D RECOMMENDED 600\u2005iu to Pregnant women as the recommended daily allowance (rda), the rda being the dose that is projected to allow at least 97.5% of the Pregnant women population to reach the DESIRABLE target 25(Oh)D level ≥50\u2005nmol/l.29this RECOMMENDATION was BASED ON OBSERVATIONAL studies, NONE of which were conducted in the middle east.29CONVERSELY, the Endocrine society 2011 GUIDELINES RECOMMENDED that 1500–2000\u2005iu daily of Vitamin D is NEEDED to reach a target 25(Oh)D level ≥75\u2005nmol/l (a RECOMMENDATION that was graded as weak with moderate quality of evidence).30the american college of obstetricians and gynecologists (acog) does not RECOMMEND screening for Vitamin D level in Pregnancy, and abides by the iom RECOMMENDATIONS.31moreover, the who 2012 guidelines on Vitamin D replacement during Pregnancy DID NOT RECOMMEND vitamin D supplementation as part of Prenatal care.32this was based ON a meta-analysis of Vitamin D trials during Pregnancy, which IDENTIFIED a LIMITED NUMBER of high-quality studies DEMONSTRATING a beneficial EFFECT of supplementation on maternal and neonatal outcomes, and CONCLUDED that FURTHER randomised controlled trials (rcts) ARE NEEDED.33in the uk, HOWEVER, Pregnant women are CONSIDERED AT RISK of Vitamin D deficiency, and supplementation with 400\u2005iu daily is REQUIRED.34\nit is NOT CLEAR WHETHER any of the above RECOMMENDED doses are applicable to non-western populations, with lower baseline Vitamin D levels, such as in lebanon and other middle eastern countries.']	[('FUTURE_WORK', 99), ('IMPORTANT_CONSIDERATION', 289), ('FUTURE_WORK', 338), ('INCOMPLETE_EVIDENCE', 357), ('INCOMPLETE_EVIDENCE', 366), ('INCOMPLETE_EVIDENCE', 389), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 437), ('PROBABLE_UNDERSTANDING', 478), ('FUTURE_WORK', 489), ('FUTURE_WORK', 541), ('IMPORTANT_CONSIDERATION', 541), ('FUTURE_WORK', 594), ('FUTURE_WORK', 742), ('FUTURE_WORK', 818), ('INCOMPLETE_EVIDENCE', 912), ('FUTURE_WORK', 920), ('ANOMALY_CURIOUS_FINDING', 998), ('ANOMALY_CURIOUS_FINDING', 998), ('INCOMPLETE_EVIDENCE', 1061), ('INCOMPLETE_EVIDENCE', 1074), ('INCOMPLETE_EVIDENCE', 1113), ('SUPERFICIAL_RELATIONSHIP', 1140), ('INCOMPLETE_EVIDENCE', 1205), ('FUTURE_WORK', 1220), ('FUTURE_WORK', 1264), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1288), ('IMPORTANT_CONSIDERATION', 1316), ('INCOMPLETE_EVIDENCE', 1316), ('IMPORTANT_CONSIDERATION', 1327), ('IMPORTANT_CONSIDERATION', 1401), ('FULL_UNKNOWN', 1419), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1429), ('FUTURE_WORK', 1454)]	33	[('CHEBI_31341', 'calcium dihydroxide', 77, 'Calcium'), ('CHEBI_28384', 'vitamin K', 89, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 89, 'Vitamin'), ('GO_0007565', 'female pregnancy', 121, 'pregnant'), ('GO_0007565', 'female pregnancy', 250, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 309, 'OH)D'), ('PR_000013502', 'parvalbumin alpha', 311, ')D'), ('UBERON_0005063', 'left ventricular compact myocardium', 455, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 528, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 566, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 566, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 766, 'vitamin D'), ('GO_0007565', 'female pregnancy', 785, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('GO_0007565', 'female pregnancy', 902, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 938, 'D'), ('GO_0007565', 'female pregnancy', 967, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1020, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1044, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1297, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1338, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1535, 'vitamin D')]
S28-PMC4785305	PMC4785305	3/2016	S28-PMC4785305	['rcts of Vitamin D supplementation during Pregnancy\ntwo landmark rcts HAVE BEEN conducted in the usa35and the uk.36hollis et al 35SHOWED that in Pregnant women in the usa, with a baseline 25(Oh)D level around 60\u2005nmol/l, a Vitamin dose of 4000\u2005iu daily allowed 82% of participants to reach a 25(Oh)D level of 80\u2005nmol/l, WHILE ONLY 70% and 50% reached this TARGET in the intermediate (2000\u2005iu daily) and low (400\u2005iu daily) doses, respectively.']	[('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 127), ('ANOMALY_CURIOUS_FINDING', 318), ('ANOMALY_CURIOUS_FINDING', 324), ('FUTURE_WORK', 354)]	5	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('GO_0007565', 'female pregnancy', 144, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 187, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 187, '25(OH)D'), ('CHEBI_33229', 'vitamin (role)', 221, 'vitamin'), ('CHEBI_71657', 'versiconol acetate', 290, '25(OH)D')]
S40-PMC4785305	PMC4785305	3/2016	S40-PMC4785305	['objectives\nthe two primary OBJECTIVES of this trial, comparing the effect of high-dose versus low-dose Vitamin D, are as follows:\nthe proportion of women who will reach the iom defined desirable 25(Oh)D level ≥50\u2005nmol/l at Delivery.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 27)]	1	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 195, '25(OH)D'), ('GO_0007567', 'parturition', 223, 'delivery')]
S86-PMC4785305	PMC4785305	3/2016	S86-PMC4785305	['Vitamin D supplementation ≤200\u2005iu daily.ii\nexclusion criteria:\n25(Oh)D level <25\u2005nmol/l, AS it would be UNETHICAL to randomise Pregnant women to the low dose of Vitamin D, and 25(Oh)D level >75\u2005nmol/l (30\u2005ng/ml), as Vitamin D supplementation with routine Prenatal multivitamins would be sufficient.']	[('PROBABLE_UNDERSTANDING', 89), ('DIFFICULT_TASK', 104)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 63, '25(OH)D'), ('GO_0007565', 'female pregnancy', 127, 'pregnant'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 176, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 182, 'D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'prenatal')]
S156-PMC4785305	PMC4785305	3/2016	S156-PMC4785305	['in addition, women with a 25(Oh)D level >75\u2005nmol/l will be excluded in order to prevent reaching supranormal levels of 25(Oh)D SHOULD they be allocated to the high-Vitamin D dose.']	[('FUTURE_WORK', 127)]	1	[('CHEBI_71657', 'versiconol acetate', 26, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 26, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 122, 'OH)D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
S116-PMC4811107	PMC4811107	3/2016	S116-PMC4811107	['children who are not firstborn, those who are black, and those Born to women with very low 25(Oh)D MAY identify a PRIORITY group for Vitamin D deficiency screening.']	[('INCOMPLETE_EVIDENCE', 99), ('IMPORTANT_CONSIDERATION', 114)]	2	[('GO_0007567', 'parturition', 63, 'born'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 91, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]
S136-PMC4811441	PMC4811441	3/2016	S136-PMC4811441	['also, an increase in 25(Oh)D ≥30 nmol/l was not associated with Pregnancy-induced hypertension.10.1371/journal.pone.0152198.t004\n\ncaption (table-wrap): table 4\nbivariable and multivariable logistic regression analysis of the DETERMINANTS of Pregnancy-induced hypertension.bivariablemultivariableabor95% cipbor95% ciplowerupperlowerupper25(Oh)D t10.0081.0081.0011.0140.0240.0021.0020.9931.0100.709obesity t10.3661.4430.8972.3210.131-0.1690.8440.4641.5380.844nulliparity0.3611.4351.0391.9830.0290.2051.2280.8541.7650.269excessive gwg0.4731.6041.1462.2460.0060.3631.4380.9952.0780.054preexisting medical condition t10.6321.8810.8764.0400.1050.0891.0930.4542.6290.842assisted reproduction0.1821.2000.7881.8280.3950.0841.0880.6561.8030.745tobacco use t1-0.6330.5310.2161.3080.169-0.4470.6400.2621.5630.327height0.0541.0551.0291.083<0.0010.0351.0351.0051.0660.021age ≥40 years t1-0.1410.8680.3732.0240.744-0.1920.8250.3122.1840.699dbp t10.0871.0911.0691.114<0.0010.0881.0921.0671.117<0.001\n25(Oh)d = 25-Hydroxyvitamin D, t1 = first trimester, gwg = Gestational weight gain, dbp = diastolic Blood pressure,\ndichotomous: age ≥40 years, obesity, nulliparity, excessive gwg, preexisting medical condition and assisted reproduction\na.adjusted for multifetal Pregnancy, baseline employment status, Gestational age at t1, month of Conception and northern european country of Birth\n\ndiscussion\nthese results are the primary outcome of the gravid study–TO OUR KNOWLEDGE the FIRST STUDY reporting on the RELATIONSHIP between longitudinal Vitamin D status and its RELATION to pe and Gestational bp trajectory.']	[('SUPERFICIAL_RELATIONSHIP', 225), ('PROBABLE_UNDERSTANDING', 1438), ('INCOMPLETE_EVIDENCE', 1459), ('SUPERFICIAL_RELATIONSHIP', 1488), ('SUPERFICIAL_RELATIONSHIP', 1547)]	5	[('CHEBI_71657', 'versiconol acetate', 21, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 21, '25(OH)D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007565', 'female pregnancy', 241, 'pregnancy'), ('CHEBI_33010', 'chromide(1-)', 338, '(OH)D'), ('CHEBI_63056', 'zinc cation', 984, '25(OH'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 994, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 1043, 'gestational'), ('UBERON_0000178', 'blood', 1084, 'blood'), ('GO_0007565', 'female pregnancy', 1247, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1286, 'gestational'), ('GO_0007620', 'copulation', 1318, 'conception'), ('GO_0007567', 'parturition', 1362, 'birth'), ('CHEBI_27300', 'vitamin D', 1522, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1566, 'gestational')]
S127-PMC4829940	PMC4829940	5/2016	S127-PMC4829940	['HOWEVER, a FEW other STUDIES have explored RELATIONSHIPS between Vitamin D supplementation or circulating 25(Oh)D and methylation at a few Cpg Sites in two to four candidate Genes in Adults[18],[46], and one Genome-wide Dna Methylation study explored ASSOCIATION with Vitamin D deficiency in african children[17].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 251)]	4	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 106, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 106, '25(OH)D'), ('SO_0000036', 'matrix_attachment_site', 139, 'CpG sites'), ('SO_0000704', 'gene', 174, 'genes'), ('UBERON_0007023', 'adult organism', 183, 'adults'), ('SO_0001026', 'genome', 208, 'genome'), ('GO_0006306', 'DNA methylation', 220, 'DNA methylation'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D')]
S47-PMC4859539	PMC4859539	5/2016	S47-PMC4859539	['four multivariable regressions were performed TO ASSESS WHETHER any significant ASSOCIATIONS existed between the natural logarithm of each subject’s cathelicidin concentration and each of the following Vitamin D measurements: (1) child’s current 25(Oh)D at time of follow-up, (2) child’s 25(Oh)d at Birth, (3) maternal 25(Oh)D throughout Pregnancy (visits 3 to 7 as area under the curve), and (4) maternal 25(Oh)D one month before Delivery; all analyses controlled for race/ethnicity, age, gender, and percent fat.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 80)]	3	[('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 246, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 246, '25(OH)D'), ('CHEBI_37972', 'phosphorus-32 atom', 288, '25'), ('CHEBI_17792', 'organohalogen compound', 291, 'OH'), ('GO_0007567', 'parturition', 299, 'birth'), ('CHEBI_71657', 'versiconol acetate', 319, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 319, '25 ... OH ... D'), ('GO_0007565', 'female pregnancy', 338, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 406, '25(OH)D'), ('GO_0007567', 'parturition', 431, 'delivery')]
S97-PMC4859539	PMC4859539	5/2016	S97-PMC4859539	"[""in MODELS 1 and 4, there was also a TREND NOTED with the child’s percent fat being positively ASSOCIATED with Cathelicidin (beta = 0.028, p = 0.052 and beta = 0.025, p = 0.087).10.1371/journal.pone.0152711.t003\n\ncaption (table-wrap): table 3\nmultivariable linear regression models assessing factors associated with natural logarithm for Cathelicidin.model 1 \xa0\xa0independent variablesbetase1p valuerace/ethnicity\xa0\xa0black-0.0390.230.864white---------hispanic-0.1490.2000.459genderfemale---------male0.3180.16 0.047 age0.1450.065 0.028 percent fat0.0280.0140.052child's current 25(Oh)D-0.0050.010.598 model 2 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicityblack0.0350.210.868white---------hispanic-0.1490.210.470genderfemale---------male0.2750.170.104age0.2120.07 0.004 percent fat0.0250.020.087child's 25(Oh)D at Birth-0.0030.010.748 model 3 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicity\xa0\xa0black0.0410.180.821white---------hispanic-0.1220.160.458genderfemale---------male0.0910.140.507age0.1550.07 0.023 percent fat0.0120.010.359maternal 25(Oh)D throughout Pregnancy<-0.000100.999 model 4 \xa0\xa0\xa0independent variablesbetasep valuerace/ethnicity\xa0\xa0black0.0460.1990.816white---------hispanic-0.0800.1850.669genderfemale---------male0.3180.158 0.047 age0.1510.064 0.021 percent fat0.0260.010.069maternal 25(Oh)D 1-month before Delivery0.0030.010.606\n1se represents standard error\n\ndiscussion\nin THIS STUDY of healthy children whose mothers had participated in a Vitamin D supplementation trial during Pregnancy, DESPITE DIFFERENCES in both maternal and childhood Vitamin D status, there were no significant differences in Cathelicidin concentration between the three racial/ethnic groups studied.""]"	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 36), ('ANOMALY_CURIOUS_FINDING', 42), ('SUPERFICIAL_RELATIONSHIP', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 1391), ('ANOMALY_CURIOUS_FINDING', 1508), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1516)]	7	[('CHEBI_3364', 'Canthiumine', 110, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 110, 'cathelicidin'), ('CHEBI_3461', 'Casuarictin', 337, 'Cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 572, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 572, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 801, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 807, 'D'), ('GO_0007567', 'parturition', 812, 'birth'), ('CHEBI_71657', 'versiconol acetate', 1042, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1048, 'D'), ('GO_0007565', 'female pregnancy', 1061, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 1300, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1300, '25(OH)D'), ('GO_0007567', 'parturition', 1323, 'delivery0'), ('CHEBI_27300', 'vitamin D', 1458, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1497, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1559, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 1618, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 1618, 'cathelicidin')]
S112-PMC4930210	PMC4930210	7/2016	S112-PMC4930210	['season of sampling and race were also significantly ASSOCIATED with 25(Oh)D concentration (table 4).10.1371/journal.pone.0157262.g002\n\ncaption (fig): fig 2\nabsolute concentrations of (a) Plasma 25(Oh)D, and (b) Plasma 3-Epi-25(Oh)D3Versus maternal Vitamin D intake (iu/day) in a longitudinal cohort of Pregnant women and their infants in alberta, canada.']	[('SUPERFICIAL_RELATIONSHIP', 52)]	1	[('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 68, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 187, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 194, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 211, 'plasma'), ('CHEBI_34304', 'fenobucarb', 218, '3-epi-25'), ('CHEBI_51048', '(R,R)-diepoxybutane', 226, '(OH)D3versus'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('GO_0007565', 'female pregnancy', 302, 'pregnant')]
S137-PMC4930210	PMC4930210	7/2016	S137-PMC4930210	['another RECENT american longitudinal STUDY of 193 Pregnant women from mid-Pregnancy to Birth SHOWED Consuming a Prenatal Vitamin D supplement (334 iu/day) did not PREVENT precipitous drops in maternal Plasma 25(Oh)D concentration [28].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 93), ('SUPERFICIAL_RELATIONSHIP', 163)]	4	[('GO_0007565', 'female pregnancy', 50, 'pregnant'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 87, 'birth'), ('GO_0007631', 'feeding behavior', 100, 'consuming'), ('GO_0007565', 'female pregnancy', 112, 'prenatal'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 201, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 208, '25(OH)D')]
S164-PMC4930210	PMC4930210	7/2016	S164-PMC4930210	['THUS, it APPEARS that ALTHOUGH winter uvr exposure MAY BE insufficient, VARIATIONS in summer sun exposure will alter fall 25(Oh)D concentration and THUS indirectly INFLUENCE winter Vitamin D levels.']	[('PROBABLE_UNDERSTANDING', 0), ('ANOMALY_CURIOUS_FINDING', 9), ('ANOMALY_CURIOUS_FINDING', 22), ('INCOMPLETE_EVIDENCE', 51), ('DIFFICULT_TASK', 72), ('PROBABLE_UNDERSTANDING', 148), ('SUPERFICIAL_RELATIONSHIP', 164)]	7	[('CHEBI_71657', 'versiconol acetate', 122, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 122, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]
S168-PMC4930210	PMC4930210	7/2016	S168-PMC4930210	['WHILE the current canadian cancer society RECOMMENDATIONS [38] are to avoid sun exposure or failing that, use of sunscreen at all times when out in the sun, our participants undoubtedly were getting sunlight exposure AS SEEN by a seasonal variation in 25(Oh)D.\nin CONCLUSION, we FOUND a 20% rate of Vitamin D insufficiency (<75 nmol/l) in a large, well-nourished cohort of Pregnant women.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 42), ('INCOMPLETE_EVIDENCE', 217), ('INCOMPLETE_EVIDENCE', 220), ('INCOMPLETE_EVIDENCE', 264), ('INCOMPLETE_EVIDENCE', 279)]	6	[('CHEBI_71657', 'versiconol acetate', 252, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 252, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D'), ('GO_0007565', 'female pregnancy', 373, 'pregnant')]
S32-PMC4934634	PMC4934634	11/2015	S32-PMC4934634	['BASED ON lower circulating 25(Oh)D concentrations at a given Vitamin D supplement level in obese and overweight subjects compared to normal weight subjects, ekwaru and coworkers RECENTLY RECOMMENDED that “Vitamin D supplementation be 2–3 times higher for obese subjects and 1.5 times higher for overweight subjects relative to normal weight subjects” [10].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 178), ('FUTURE_WORK', 187)]	3	[('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 27, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]
S160-PMC4934634	PMC4934634	11/2015	S160-PMC4934634	['combining the main comorbidities, for every 10 ng/ml increase in 25(Oh)D at Delivery, the odds ratio was reduced to 0.84 ( p = 0.006) INDICATING fewer adverse Pregnancy outcomes as maternal Vitamin D levels increased.']	[('INCOMPLETE_EVIDENCE', 134)]	1	[('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 65, '25(OH)D'), ('GO_0007567', 'parturition', 76, 'delivery'), ('GO_0007565', 'female pregnancy', 159, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
S164-PMC4934634	PMC4934634	11/2015	S164-PMC4934634	['THUS, it is NOT SURPRISING that this study FOUND no effect of the Vitamin D supplementation on incidences of Preterm Birth, Preeclampsia, or small for Gestation age SINCE 23% of participants had persistent Serum 25(Oh)D below 10 ng/ml which IS CONSIDERED Vitamin D deficiency status by both the iom and endocrine society (table 1).']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 43), ('PROBABLE_UNDERSTANDING', 165), ('INCOMPLETE_EVIDENCE', 241)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'preterm birth'), ('GO_0007128', 'meiotic prophase I', 124, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 151, 'gestation'), ('UBERON_0001977', 'blood serum', 206, 'serum'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 212, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S166-PMC4934634	PMC4934634	11/2015	S166-PMC4934634	[', provided Vitamin D supplement doses DEPENDING ON baseline level of Serum 25(Oh)D levels or placebo [62].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 38)]	1	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0001977', 'blood serum', 69, 'serum'), ('CHEBI_71657', 'versiconol acetate', 75, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 75, '25(OH)D')]
S199-PMC4934634	PMC4934634	11/2015	S199-PMC4934634	['ALTHOUGH Cord Blood 25(Oh)D levels were significantly higher in the supplemented children compared TO the control group, ONLY a small percentage of offspring receiving daily Vitamin D (13%) or bolus Vitamin D (3%) had Cord Blood Vitamin D levels ≥ 50 nmol/l.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 99), ('ANOMALY_CURIOUS_FINDING', 121)]	3	[('UBERON_0009472', 'axilla', 9, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 20, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 218, 'cord'), ('UBERON_0000178', 'blood', 223, 'blood'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]
S14-PMC4944244	PMC4944244	7/2016	S14-PMC4944244	['[3] among primary school children in malaysia had SHOWN lack of Vitamin D with 70.4\xa0% having Serum 25 (Oh) D <50\xa0nmol/l.']	[('INCOMPLETE_EVIDENCE', 50)]	1	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0001977', 'blood serum', 93, 'serum'), ('CHEBI_71657', 'versiconol acetate', 99, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 99, '25 (OH) D')]
S49-PMC4944244	PMC4944244	7/2016	S49-PMC4944244	['they also underwent skin color measurement using the fitzpatrick skin type chart measurement (fstcm) and mexameter (mx) 18; weight and height measurements and Blood test for Vitamin D. hypovitaminosis D was DEFINED as Serum 25(Oh)D\u2009<\u200950\xa0nmol/l.']	[('PROBABLE_UNDERSTANDING', 207)]	1	[('UBERON_0000178', 'blood', 159, 'blood'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 201, 'D'), ('UBERON_0001977', 'blood serum', 218, 'serum'), ('CHEBI_71657', 'versiconol acetate', 224, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 224, '25(OH)D')]
S104-PMC4944244	PMC4944244	7/2016	S104-PMC4944244	['in comparison, our results SHOWED a much lower prevalence of Vitamin D deficiency with 43.9\xa0% having Serum 25(Oh)D <25\xa0nmol/l (table\xa02).']	[('INCOMPLETE_EVIDENCE', 27)]	1	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('UBERON_0001977', 'blood serum', 101, 'serum'), ('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 107, '25(OH)D')]
S131-PMC4944244	PMC4944244	7/2016	S131-PMC4944244	['in order to standardize the level of Vitamin D, cut off point for Serum 25(Oh) D of <50\xa0nmol/l was used for comparison between VARIOUS STUDIES.']	[('INCOMPLETE_EVIDENCE', 127)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 72, '25(OH) D')]
S171-PMC4944244	PMC4944244	7/2016	S171-PMC4944244	['HOWEVER, this ASSUMPTION would not be EFFECTIVE for countries with less exposure to the sun, where low education was ASSOCIATED with lower Serum 25(Oh)D, PERHAPS AS a result of less dietary intake of Vitamin D and less opportunity for sunbathing leisure and vacation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 117), ('INCOMPLETE_EVIDENCE', 154), ('PROBABLE_UNDERSTANDING', 162)]	6	[('UBERON_0001977', 'blood serum', 139, 'serum'), ('CHEBI_71657', 'versiconol acetate', 145, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 145, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]
S203-PMC4944244	PMC4944244	7/2016	S203-PMC4944244	['OUR STUDY SHOWED SIMILAR results where fair skin such as chinese had a higher level of Serum 25(Oh) D. initially, by using simple logistic regression analysis, the skin color type, Melanin index measurement and sun protection score SHOWED CORRELATION with Vitamin D status ( p \u2009<\u20090.05).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 232), ('SUPERFICIAL_RELATIONSHIP', 239)]	5	[('UBERON_0001977', 'blood serum', 87, 'serum'), ('CHEBI_71657', 'versiconol acetate', 93, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 93, '25(OH) D'), ('CHEBI_25179', 'melanins', 181, 'melanin'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D')]
S38-PMC4973215	PMC4973215	8/2016	S38-PMC4973215	['differences in the distributions of Cord Blood 25(Oh)D concentrations by race were evident (figure 1), with a higher proportion of Vitamin D-deficient samples FOUND in the black population.']	[('INCOMPLETE_EVIDENCE', 159)]	1	[('UBERON_0009472', 'axilla', 36, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 47, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S70-PMC4973215	PMC4973215	8/2016	S70-PMC4973215	"[""for white mothers, measurement of maternal Serum 25(Oh)D at <22 weeks' Gestation SHOWED a u-shaped RELATIONSHIP between Vitamin D status and risk of sga, where the highest risk for sga was SEEN with both low and high Vitamin D levels.""]"	[('INCOMPLETE_EVIDENCE', 81), ('SUPERFICIAL_RELATIONSHIP', 99), ('INCOMPLETE_EVIDENCE', 189)]	3	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('GO_0007565', 'female pregnancy', 71, 'gestation'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D')]
S35-PMC4979151	PMC4979151	8/2016	S35-PMC4979151	['there is NO standard classification of Vitamin D status based on 25(Oh)D3Concentrations in Cord Blood; THUS, for the PURPOSE of the PRESENT STUDY we stratified the participants into four groups based on Serum 25(Oh)D concentrations as done earlier [20] :(1) ≥76\xa0nmol/l (high); (2) 50–75\xa0nmol/l (moderate); (3) 30–49\xa0nmol/l (low); (4) <30\xa0nmol/l (very low).']	[('FULL_UNKNOWN', 9), ('PROBABLE_UNDERSTANDING', 103), ('QUESTION_ANSWERED_BY_THIS_WORK', 117), ('QUESTION_ANSWERED_BY_THIS_WORK', 132)]	4	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_73735', 'gadoterate', 65, '25(OH)D3concentrations'), ('PR_000029608', 'DISP complex protein LRCH3', 65, '25 ... OH ... D3concentrations'), ('UBERON_0002240', 'spinal cord', 91, 'cord'), ('UBERON_0000178', 'blood', 96, 'blood'), ('UBERON_0001977', 'blood serum', 203, 'serum'), ('CHEBI_71657', 'versiconol acetate', 209, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 209, '25(OH)D')]
S177-PMC4992225	PMC4992225	8/2016	S177-PMC4992225	['caption (table-wrap): table 4\n\n25(Oh)D concentrations and depression scores in nulliparous and multiparous subgroupsvariables mean (sd)nulliparousmultiparousvitamin D groupcontrol groupn p -valuevitamin D groupcontrol groupn p -value*25(Oh)D at baseline (ng/ml)13.13(6.91)13.25 (6.55)41/510.9312.49 (9.08)9.31 (5.34)34/270.1525(Oh)D at Delivery (ng/ml)18.40 (11.38)12.49 (6.29)33/430.0116.58 (8.54)11.36 (5.47)28/250.02depression score at baseline8.41(3.52)8.73 (3.57)41/510.678.47 (4.35)8.48 (4.30)34/270.99depression score at 38-40w Gestation6.47(3.43)7.98 (3.74)38/460.065.80 (3.62)7.44 (4.28)30/270.12depression score at Postpartum (4w)4.59(3.24)7.27 (4.04)34/450.0024.60 (3.40)7.52 (4.70)30/270.01depression score at Postpartum (8w)4.18(3.79)7.24 (3.79)34/450.0014.20 (3.79)7.07 (4.37)30/270.01\n*mann–whitney u test\nwe EXAMINED the CORRELATION between change in Vitamin D concentrations and change in depression scores at 38–40 weeks of Gestation, 4 and 8 weeks Postpartum.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 824), ('SUPERFICIAL_RELATIONSHIP', 837)]	2	[('CHEBI_71657', 'versiconol acetate', 31, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 31, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 165, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 203, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 203, 'D'), ('CHEBI_71657', 'versiconol acetate', 234, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 240, 'D'), ('CHEBI_33010', 'chromide(1-)', 327, '(OH)D'), ('GO_0007567', 'parturition', 336, 'delivery'), ('GO_0007565', 'female pregnancy', 535, 'gestation6'), ('GO_0007565', 'female pregnancy', 625, 'postpartum'), ('GO_0007565', 'female pregnancy', 722, 'postpartum'), ('CHEBI_27300', 'vitamin D', 867, 'vitamin D'), ('GO_0007565', 'female pregnancy', 942, 'gestation'), ('GO_0007565', 'female pregnancy', 967, 'postpartum')]
S92-PMC5045784	PMC5045784	10/2016	S92-PMC5045784	"[""the CURRENT PRACTICE of TARGETING nutritional Intake of 400\u2009iu per day Vitamin D is sufficient to achieve Serum 25(Oh)D levels >30\u2009ng\u2009ml−1at 36 weeks' corrected age.""]"	[('INCOMPLETE_EVIDENCE', 4), ('FUTURE_WORK', 24)]	2	[('GO_0007631', 'feeding behavior', 46, 'intake'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0001977', 'blood serum', 106, 'serum'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 112, '25(OH)D')]
S71-PMC5062906	PMC5062906	10/2016	S71-PMC5062906	['results\n\ndietary depletion of circulating Plasma 25(Oh)D is DEPENDENT on Genetic background\nTO DETERMINE the extent of Vitamin D depletion in g0dams Fed diet lacking Vitamin d (lvd) compared with dams on control diet (con) (fig.']	[('SUPERFICIAL_RELATIONSHIP', 60), ('QUESTION_ANSWERED_BY_THIS_WORK', 92)]	2	[('UBERON_0001969', 'blood plasma', 42, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('SO_0000704', 'gene', 73, 'genetic'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('GO_0007631', 'feeding behavior', 149, 'fed'), ('CHEBI_33229', 'vitamin (role)', 166, 'vitamin')]
S21-PMC5064894	PMC5064894	10/2016	S21-PMC5064894	['Vitamin D HAS BEEN SHOWN to Modulate the Innate Immune Response in Lung Epithelial Cells [6,7], and Antimicrobial peptides induced by Vitamin D MAY have antiviral EFFECTS BASED on observed activity against Herpes Simplex Virus-1 (Hsv-1) [8], adenovirus [9], human immunodeficiency virus (hiv) [10] and vaccinia [11].']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 144), ('SUPERFICIAL_RELATIONSHIP', 163), ('QUESTION_ANSWERED_BY_THIS_WORK', 171)]	4	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0065007', 'biological regulation', 28, 'modulate'), ('GO_0045087', 'innate immune response', 41, 'innate immune response'), ('UBERON_0002405', 'immune system', 48, 'immune'), ('CL_0000082', 'epithelial cell of lung', 67, 'lung epithelial cells'), ('UBERON_0000115', 'lung epithelium', 67, 'lung epithelial'), ('CHEBI_65381', 'albizoside C', 100, 'antimicrobial'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('PR_000008476', 'orexin', 206, 'herpes simplex virus'), ('NCBITaxon_10088', 'Mus <genus>', 230, 'HSV'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 230, 'HSV-1')]
S30-PMC5064894	PMC5064894	10/2016	S30-PMC5064894	['similarly, a decrease in parent-reported ari was NOTED in children in mongolia given Vitamin D-fortified Milk (300\xa0iu of Vitamin D3) [23], in a setting in which children had very low baseline Serum 25 (Oh) D levels.']	[('ANOMALY_CURIOUS_FINDING', 49)]	1	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('UBERON_0001913', 'milk', 105, 'milk'), ('CHEBI_33279', 'vitamin D5', 121, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 121, 'vitamin D3'), ('UBERON_0001977', 'blood serum', 192, 'serum'), ('CHEBI_71657', 'versiconol acetate', 198, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 198, '25 (OH) D')]
S10-PMC5084041	PMC5084041	10/2016	S10-PMC5084041	['the DETERMINANTS of season-corrected change in 25(Oh)D were origin, sun-Seeking behaviour, clothing style, dietary Vitamin D intake, Vitamin D supplementation and recent travel <35° n. in CONCLUSION, season-corrected 25(Oh)D concentration increased during Pregnancy and DEPENDED PARTLY on lifestyle FACTORS.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 188), ('SUPERFICIAL_RELATIONSHIP', 270), ('INCOMPLETE_EVIDENCE', 279), ('SUPERFICIAL_RELATIONSHIP', 299)]	5	[('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 53, 'D'), ('GO_0007601', 'visual perception', 72, 'seeking'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 133, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 141, 'D'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 217, '25(OH)D'), ('GO_0007565', 'female pregnancy', 256, 'pregnancy')]
S96-PMC5084041	PMC5084041	10/2016	S96-PMC5084041	['in a multivariable logistic regression analysis, DETERMINANTS relating to odds of 25(Oh)D concentrations <30 nmol/l at t1 were of non-north european origin, sampling in spring, never exposing skin when sunny, no Vitamin D supplementation, lower dietary Vitamin D intake and lower age (table 2).']	[('SUPERFICIAL_RELATIONSHIP', 49)]	1	[('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin D')]
S97-PMC5084041	PMC5084041	10/2016	S97-PMC5084041	['among the subgroup ( n = 316) of women Born in africa and asia, DETERMINANTS of 25(Oh)D concentrations <30 nmol/l were not taking Vitamin D supplements, never exposing skin when sunny and lower age (table 2).']	[('SUPERFICIAL_RELATIONSHIP', 64)]	1	[('GO_0007567', 'parturition', 39, 'born'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 80, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
S107-PMC5084041	PMC5084041	10/2016	S107-PMC5084041	['Gestational weight gain, bmi and age were not significantly associated with change in 25(Oh)D. in the subgroup of women Born in africa and asia, only Vitamin D supplementation at t3 was a DETERMINANT of season-corrected change in Vitamin D status during Pregnancy (adjusted r2= 0.115) (table 3).']	[('SUPERFICIAL_RELATIONSHIP', 188)]	1	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('GO_0007567', 'parturition', 120, 'born'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy')]
S90-PMC5085625	PMC5085625	9/2016	S90-PMC5085625	['ACCORDING to barebring et al., AT LEAST a 30 nmol/l increase in Serum 25(Oh)D concentration is ASSOCIATED with lower odds of pe, REGARDLESS OF Vitamin D status in early Pregnancy [13].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('PROBABLE_UNDERSTANDING', 31), ('SUPERFICIAL_RELATIONSHIP', 95), ('INCOMPLETE_EVIDENCE', 129)]	4	[('UBERON_0001977', 'blood serum', 64, 'serum'), ('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 70, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'pregnancy')]
S27-PMC5129897	PMC5129897	10/2016	S27-PMC5129897	['materials and methods\npublications on the RELATIONS between 25(Oh)D concentrations and health outcomes were obtained LARGELY by searchingpubmed.govandscholar.google.comfor terms such as Vitamin D, 25-Hydroxyvitamin D, meta-analysis, Back and Spine disorders, cancer, Cardiovascular disease, Immune System, osteoporosis, Respiratory infection, economic BURDEN, canada, cost, season, mortality, incidence , and risk .']	[('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 117), ('IMPORTANT_CONSIDERATION', 352)]	3	[('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 60, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 197, '25-hydroxyvitamin D'), ('UBERON_0001137', 'dorsum', 233, 'back'), ('UBERON_0001013', 'adipose tissue', 242, 'spine'), ('UBERON_0004535', 'cardiovascular system', 267, 'cardiovascular'), ('UBERON_0002405', 'immune system', 291, 'immune system'), ('UBERON_0001004', 'respiratory system', 320, 'respiratory')]
S70-PMC5129897	PMC5129897	10/2016	S70-PMC5129897	['a meta-analysis of Lung cancer incidence versus 25(Oh)D concentration at the time of enrollment FOUND that relative risk decreased from 1.0 at 20\xa0nmol/l to 0.86 at 40\xa0nmol/l and 0.84 at 50\xa0nmol/l, after which the 95% confidence intervals became very large.47most of the 13 studies were prospective studies with long follow-up times, and ONE STUDY involved smokers who had taken large doses of Vitamin A, which MAY have AFFECTED cancer risk since it competes with Vitamin D.50thus, doubling the calculated change in relative risk to 0.72 at 40\xa0nmol/l and 0.68 at 50\xa0nmol/l and higher SEEMS REASONABLE.']	[('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 337), ('INCOMPLETE_EVIDENCE', 410), ('SUPERFICIAL_RELATIONSHIP', 419), ('ANOMALY_CURIOUS_FINDING', 583), ('PROBABLE_UNDERSTANDING', 583), ('PROBABLE_UNDERSTANDING', 589)]	7	[('UBERON_0002048', 'lung', 19, 'lung'), ('CHEBI_71657', 'versiconol acetate', 48, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 48, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 54, 'D'), ('CHEBI_27300', 'vitamin D', 393, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 463, 'vitamin D')]
S78-PMC5129897	PMC5129897	10/2016	S78-PMC5129897	['a clinical trial involving 8- to 12-year-old schoolchildren in japan receiving 1200 iu/d of Vitamin D3Found a significant reduction in incidence of type a influenza for those who had not been taking Vitamin D supplements (relative risk = 0.36 [95% ci, 0.17–0.79]).33a study in mongolia involving children near 10\xa0y of age with a baseline 25(Oh)D concentration of 18\xa0nmol/l (95% ci, 13–25\xa0nmol/l) FOUND that giving them a loading dose of Vitamin D3Followed by 300 iu/d of Vitamin D, which raised the 25(Oh)D concentration to 47\xa0nmol/l (95% ci, 39–57\xa0nmol/l), resulted in a 3-month adjusted relative risk of acute Respiratory Tract infections (aris) of 0.50 (95% ci, 0.28–0.88).34that study SHOWS that People with low 25(Oh)D concentrations have significant reductions in aris with modest increases in 25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 396), ('INCOMPLETE_EVIDENCE', 689)]	2	[('CHEBI_59712', 'squarate', 92, 'vitamin D3found'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 92, 'vitamin D3found'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 338, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 338, '25(OH)D'), ('CHEBI_83261', 'pyribencarb', 437, 'vitamin D3followed'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 499, '25(OH)D'), ('UBERON_0000065', 'respiratory tract', 612, 'respiratory tract'), ('NCBITaxon_10088', 'Mus <genus>', 700, 'people'), ('CHEBI_71657', 'versiconol acetate', 716, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 800, '25(OH)D')]
S112-PMC5129897	PMC5129897	10/2016	S112-PMC5129897	['a prospective study in korea FOUND that incidence of depressive symptoms was increased for those Individuals with 25(Oh)D concentrations <50\xa0nmol/l compared with those with >50\xa0nmol/l if they had Serum Total Cholesterol levels of < 240\xa0mg/dl (odds ratio [or] = 1.60 [95% ci, 1.23–2.08]) but NOT for those with Serum Total Cholesterol >240\xa0ng/dl (or = 0.97 [95% ci, 0.52–1.81]) after adjustment for confounding variables.75a study in italy conducted a clinical trial with Vitamin D for outpatients of mean age 74 ± 6\xa0years with mdd being treated with antidepressant therapy.76at the start of the 4-week trial, mean hamilton depression rating scale scores were 21.1 for the treated cases and 21.5 for the comparison subjects.']	[('INCOMPLETE_EVIDENCE', 29), ('ANOMALY_CURIOUS_FINDING', 291)]	2	[('NCBITaxon_1', 'root', 97, 'individuals'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 114, '25(OH)D'), ('UBERON_0001977', 'blood serum', 196, 'serum'), ('CHEBI_15891', 'taurine', 202, 'total'), ('CHEBI_16113', 'cholesterol', 208, 'cholesterol'), ('UBERON_0001977', 'blood serum', 310, 'serum'), ('CHEBI_66254', 'topopyrone C', 316, 'total cholesterol'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin D')]
S150-PMC5129897	PMC5129897	10/2016	S150-PMC5129897	['estimate of reduction in economic BURDEN in canada if all inhabitants had 25(Oh)D concentrations >100\xa0nmol/l after several years.outcometotal economic burden in 2016 ($b)reduction due to improving Vitamin D status (%)reduction in economic BURDEN due to improving Vitamin D status ($b)deaths in canada in 201139reduction in deaths, using deaths for 2011cancer7.3151.172,47610,870cvd24.6143.460,9108530dementia16.271.110,000700dm15.7182.871941290ms3.7401.5500 ref.92200osteoporosis (Hip fractures)5.0221.1\xa0\xa0respiratory infections6.1251.557671440total78.615.912.5156,84723,030\nnote: total deaths in canada in 2011 were 242,07488\n$b, billions of dollars; cvd, cardiovascular disease; dm, diabetes mellitus; ms, multiple sclerosis.']	[('IMPORTANT_CONSIDERATION', 34), ('IMPORTANT_CONSIDERATION', 239)]	2	[('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 74, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 263, 'vitamin D'), ('UBERON_0001464', 'hip', 481, 'hip')]
S151-PMC5129897	PMC5129897	10/2016	S151-PMC5129897	['as with all ESTIMATES, these have uncertainties, including the 25(Oh)D concentration–health outcome RELATIONS used; the ESTIMATES of economic BURDENS; whether reducing risk of specific diseases would translate into the same fraction of economic BURDEN; the extent to which changing risk-modifying risk factors such as smoking, alcohol Consumption, diet, and obesity modify the relative reduction due to higher 25(Oh)D concentration; and that the analysis omitted several Vitamin D–sensitive diseases and conditions BECAUSE of LIMITED UNDERSTANDING of the EFFECTS.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 100), ('INCOMPLETE_EVIDENCE', 120), ('IMPORTANT_CONSIDERATION', 142), ('IMPORTANT_CONSIDERATION', 245), ('PROBLEM_COMPLICATION', 515), ('INCOMPLETE_EVIDENCE', 526), ('SUPERFICIAL_RELATIONSHIP', 555)]	8	[('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 63, '25(OH)D'), ('GO_0007631', 'feeding behavior', 335, 'consumption'), ('CHEBI_71657', 'versiconol acetate', 410, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin D')]
S177-PMC5129897	PMC5129897	10/2016	S177-PMC5129897	['for example, 50% of the clinical trials with baseline 25(Oh)D concentration <50\xa0nmol/l FOUND beneficial EFFECTS of Vitamin D on BIOMARKERS of inflammation, WHEREAS ONLY 26% of those with higher baseline 25(Oh)D concentrations did.3the DIFFERENT results with respect to baseline 25(Oh)D concentration MAY BE DUE TO the LIMITED accuracy of clinical trials but COULD also be DUE TO CONSIDERABLY less BENEFIT for those with 25(Oh)D concentrations above 50\xa0nmol/l.']	[('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 128), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 156), ('ANOMALY_CURIOUS_FINDING', 156), ('ANOMALY_CURIOUS_FINDING', 164), ('INCOMPLETE_EVIDENCE', 164), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235), ('INCOMPLETE_EVIDENCE', 300), ('PROBLEM_COMPLICATION', 307), ('INCOMPLETE_EVIDENCE', 318), ('INCOMPLETE_EVIDENCE', 358), ('PROBLEM_COMPLICATION', 372), ('ANOMALY_CURIOUS_FINDING', 379), ('IMPORTANT_CONSIDERATION', 397)]	15	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 203, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 203, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 278, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 284, 'D'), ('CHEBI_71657', 'versiconol acetate', 420, '25(OH)D')]
S192-PMC5129897	PMC5129897	10/2016	S192-PMC5129897	['one was a meta-analysis of observational studies.104the OTHER was a study of cancer incidence by occupation in nordic countries.49\n\nconclusions\nmany People living in canada do not have OPTIMAL 25(Oh)D concentrations AS a result of limited solar uvb exposure and/or not obtaining enough Vitamin D from Food or supplements.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('IMPORTANT_CONSIDERATION', 185), ('PROBABLE_UNDERSTANDING', 216)]	3	[('NCBITaxon_10088', 'Mus <genus>', 149, 'people'), ('CHEBI_71657', 'versiconol acetate', 193, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 193, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 294, 'D'), ('CHEBI_33290', 'food', 301, 'food')]
S21-PMC5155676	PMC5155676	12/2016	S21-PMC5155676	['in nonpregnant Adults, baseline 25(Oh)D concentration, body weight/adiposity and age are IMPORTANT DETERMINANTS of the incremental rise in 25(Oh)D after Vitamin D supplementation (13,14).']	[('IMPORTANT_CONSIDERATION', 89), ('SUPERFICIAL_RELATIONSHIP', 99)]	2	[('UBERON_0007023', 'adult organism', 15, 'adults'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 32, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 38, 'D'), ('CHEBI_30778', 'gallic acid', 139, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 145, 'D'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
S75-PMC5155676	PMC5155676	12/2016	S75-PMC5155676	['percentage of women achieving Vitamin D replete status (>50 nmol/l) according to randomization group and season of Deliveryseason of Deliveryplacebo1000 iu/d Cholecalciferol p comparing randomization groupswinter (december–may)13.975.0<.001summer (june–november)54.290.1<.001 p comparing seasons<.001<.001\n\ndeterminants of maternal 25(Oh)D at 34 weeks of Gestation\nin univariate analysis, maternal age, baseline 25(Oh)D, season of Delivery and compliance with study Medication were significantly ASSOCIATED with 34 week 25(Oh)D in both the Placebo and Vitamin D supplementation groups (table 3).']	[('SUPERFICIAL_RELATIONSHIP', 496)]	1	[('CHEBI_28384', 'vitamin K', 30, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 30, 'Vitamin D'), ('GO_0006260', 'DNA replication', 115, 'DeliverySeason'), ('GO_0006260', 'DNA replication', 133, 'DeliveryPlacebo1000'), ('CHEBI_16113', 'cholesterol', 158, 'Cholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 332, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 355, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 412, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 415, 'OH ... D'), ('GO_0007567', 'parturition', 431, 'delivery'), ('CHEBI_60211', 'compound Z', 466, 'medication'), ('CHEBI_71657', 'versiconol acetate', 520, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 520, '25(OH)D'), ('CHEBI_26130', 'biological pigment', 540, 'placebo'), ('CHEBI_27300', 'vitamin D', 552, 'vitamin D')]
S82-PMC5155676	PMC5155676	12/2016	S82-PMC5155676	['in multiple linear regression analysis, maternal factors significantly ASSOCIATED with greater 25(Oh)D at 34 weeks of Gestation in the Vitamin D supplementation group were lower Pregnancy weight gain (kg) (β = −0.81; 95% confidence interval [ci] −1.39, −0.22; p = .007), higher compliance (%) (β = 0.28; 95%ci 0.072, 0.48; p = .008), higher early Pregnancy 25(Oh)D (nmol/l) (β = 0.28; 95%ci 0.16, 0.40; p< .001), and summer Delivery (summer vs winter) (β = 10.51; 95%ci 6.40, 14.63; p< .001) (figure 2a).']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_71657', 'versiconol acetate', 95, '25(OH)D'), ('GO_0007565', 'female pregnancy', 118, 'gestation'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('GO_0007565', 'female pregnancy', 347, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 357, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 357, '25(OH)D'), ('GO_0007567', 'parturition', 424, 'delivery')]
S84-PMC5155676	PMC5155676	12/2016	S84-PMC5155676	['when achievement of Vitamin D replete status at 34 weeks of Gestation was considered INSTEAD of absolute 25(Oh)D concentration, in multivariate analyses, Delivery in summer (relative risk [rr] = 1.20; 95%ci 1.09, 1.33; p< .001), white ethnicity (rr = 1.27; 95%ci 1.17, 1.37; p< .001), greater compliance with Medication (%) (rr = 1.01; 95%ci 1.00, 1.02; p = .03), and greater early Pregnancy 25(Oh)D concentration (nmol/l) (rr = 1.003; 95%ci 1.001, 1.006; p = .007) were significantly ASSOCIATED with achieving 25(Oh)D >50 nmol/l in the women randomized to Cholecalciferol.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 85), ('SUPERFICIAL_RELATIONSHIP', 485)]	2	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 105, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 111, 'D'), ('GO_0007567', 'parturition', 154, 'delivery'), ('CHEBI_60211', 'compound Z', 309, 'medication'), ('GO_0007565', 'female pregnancy', 382, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 392, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 511, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 511, '25(OH)D'), ('CHEBI_52550', 'theopalauamide', 557, 'cholecalciferol')]
S115-PMC5155676	PMC5155676	12/2016	S115-PMC5155676	['this mechanism MIGHT be IMPORTANT in preventing hypervitaminosis D. HOWEVER, studies comparing the effectiveness of DIFFERING doses of Vitamin D in Pregnancy HAVE SHOWN that 4000 iu/d CAN achieve a higher 25(Oh)D than 400 iu/d (10,28), BUT WHETHER these higher doses are of clinical benefit is YET to be DEMONSTRATED (4,29) and at the general population level, lower doses would be compatible with keeping 25(Oh)D below a concentration which MIGHT be concerning.']	[('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 240), ('ANOMALY_CURIOUS_FINDING', 294), ('INCOMPLETE_EVIDENCE', 304), ('INCOMPLETE_EVIDENCE', 442)]	11	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 65, 'D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 205, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 211, 'D'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 412, 'D')]
S52-PMC5405075	PMC5405075	4/2017	S52-PMC5405075	['DESPITE that there was no difference preserved in the offspring’s 25(Oh)D level at the age of 18months, a statistically significant lower proportion of children, belonged to Vitamins D groups, were sensitized to Mite Antigens, as indicated by specific Ige measurements.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 66, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamins D'), ('CHEBI_46662', 'mineral', 212, 'mite'), ('NCBITaxon_10088', 'Mus <genus>', 212, 'mite'), ('CHEBI_59132', 'antigen', 217, 'antigens'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 252, 'IgE')]
S5-PMC5418719	PMC5418719	5/2017	S5-PMC5418719	['Vitamin D intake of 800\xa0iu/day SAFELY achieved an 88% PROBABILITY of Vitamin D sufficiency at 36\xa0weeks Postmenstrual age in vlbw infants with Cord-blood levels of 25(Oh)D\u2009≥\u200910\xa0ng/ml, and 65% PROBABILITY of Vitamin D sufficiency was OBSERVED in infants with 25 Ohd concentrations\u2009<\u200910\xa0ng/ml at Birth.']	[('IMPORTANT_CONSIDERATION', 31), ('PROBABLE_UNDERSTANDING', 54), ('PROBABLE_UNDERSTANDING', 191), ('INCOMPLETE_EVIDENCE', 232)]	4	"[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0008283', 'cell proliferation', 103, 'postmenstrual'), ('UBERON_0002240', 'spinal cord', 142, 'cord'), ('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 163, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 257, '25 OHD'), ('GO_0007567', 'parturition', 293, 'birth')]"
S19-PMC5418719	PMC5418719	5/2017	S19-PMC5418719	['the AIM of THIS STUDY was TO DETERMINE WHETHER daily Vitamin D supplementation with a high dose of 800\xa0iu is SAFE and EFFECTIVE to increase the proportion of vlbw infants with 25(Oh)D\u2009>\u200930\xa0ng/ml, from 2\xa0weeks of age until hospital discharge.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 39), ('IMPORTANT_CONSIDERATION', 109), ('SUPERFICIAL_RELATIONSHIP', 118)]	6	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 176, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 176, '25(OH)D')]
S33-PMC5418719	PMC5418719	5/2017	S33-PMC5418719	['we determined the efficacy and SAFETY of early supplementation with 800\xa0iu Vitamin D.\n\noutcome measures\nthe primary outcome measured the proportion of Vitamin D sufficiency (>30\xa0ng/ml) at 32 and 36\xa0weeks pma and was analyzed by Cord Blood 25(Oh)D levels (<10\xa0ng/ml versus\u2009≥\u200910\xa0ng/ml) at Birth.']	[('IMPORTANT_CONSIDERATION', 31)]	1	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('UBERON_0009472', 'axilla', 228, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 239, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 239, '25(OH)D'), ('GO_0007567', 'parturition', 287, 'birth')]
S77-PMC5418719	PMC5418719	5/2017	S77-PMC5418719	['caption (table-wrap): table 2\n\nVitamin D statusvariablecord 25(Oh)D concentrations <10\xa0ng/mlcord 25(Oh)D concentrations ≥10\xa0ng/ml p at Birth\u2003n2029\u2003Serum 25(Oh)D levels8.3\u2009±\u20091.921.4\u2009±\u20098.5<0.001\u2003Vitamin D sufficiency (>30\xa0ng/ml)0 (0%)5 (17%)0.0732\u2009±\u20091\xa0weeks Postmenstrual age\u2003n1318\u2003Serum 25(Oh)d levels15.3\u2009±\u200910.124.1\u2009±\u20099.30.05\u2003Vitamin D sufficiency (>30\xa0ng/ml)3 (23%)4 (22%)1.0036\u2009±\u20091\xa0weeks Postmenstrual age\u2003n1726\u2003Serum 25(Oh)D levels43.1\u2009±\u200920.357.7\u2009±\u200921.90.03\u2003Vitamin D sufficiency (>30\xa0ng/ml)11 (65%)23 (88%)0.12\ndata are presented as n (%), median (range), or mean\u2009±\u2009sd\ntable\xa03presents the levels of Serum calcium, Phosphorous, alkaline phosphatase level at Birth, 32\u2009±\u20091\xa0weeks pma, and 36\u2009±\u20091\xa0weeks pma as MARKERS of Vitamin D status.']	[('SUPERFICIAL_RELATIONSHIP', 710)]	1	[('CHEBI_28384', 'vitamin K', 31, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('GO_0007567', 'parturition', 135, 'birth'), ('UBERON_0001977', 'blood serum', 147, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 153, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 153, '25(OH)D'), ('CHEBI_28384', 'vitamin K', 193, 'Vitamin D'), ('GO_0008283', 'cell proliferation', 256, 'postmenstrual'), ('UBERON_0001977', 'blood serum', 280, 'Serum'), ('CHEBI_63056', 'zinc cation', 286, '25(OH'), ('CHEBI_28384', 'vitamin K', 326, 'Vitamin D'), ('GO_0008283', 'cell proliferation', 390, 'postmenstrual'), ('UBERON_0001977', 'blood serum', 414, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 420, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 420, '25(OH)D'), ('CHEBI_28384', 'vitamin K', 461, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 603, 'serum'), ('CHEBI_30207', 'phosphorus(.)', 618, 'phosphorous'), ('GO_0007567', 'parturition', 661, 'birth'), ('CHEBI_27300', 'vitamin D', 721, 'vitamin D')]
S92-PMC5418719	PMC5418719	5/2017	S92-PMC5418719	['WHILE the use of 800\xa0iu/d of Vitamin D achieved Serum 25(Oh)D concentrations to the ADEQUATE range of 30–80\xa0ng/ml without toxicity at 36\xa0weeks pma, this dose MAY STILL be too low to restore Vitamin D stores for the MAJORITY of infants with 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml at Birth.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 84), ('INCOMPLETE_EVIDENCE', 158), ('IMPORTANT_CONSIDERATION', 162), ('PROBABLE_UNDERSTANDING', 215)]	5	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('UBERON_0001977', 'blood serum', 48, 'serum'), ('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 240, '25(OH)D'), ('GO_0007567', 'parturition', 277, 'birth')]
S119-PMC5426325	PMC5426325	4/2017	S119-PMC5426325	['THUS, we CANNOT RULE OUT WHETHER the Birth cohort results REFLECT a TRUE adverse EFFECT of Vitamin D on bone; one PREVIOUS STUDY did indeed report borderline significant inverse ASSOCIATIONS between maternal late Pregnancy 25(Oh)D concentrations and offspring Forearm fractures(12).']	[('PROBABLE_UNDERSTANDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 25), ('SUPERFICIAL_RELATIONSHIP', 58), ('PROBABLE_UNDERSTANDING', 68), ('SUPERFICIAL_RELATIONSHIP', 81), ('INCOMPLETE_EVIDENCE', 114), ('SUPERFICIAL_RELATIONSHIP', 178)]	8	[('GO_0007567', 'parturition', 37, 'birth'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 223, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 223, '25(OH)D'), ('UBERON_0002386', 'forelimb zeugopod', 260, 'forearm')]
S152-PMC5426325	PMC5426325	4/2017	S152-PMC5426325	['UNFORTUNATELY, we LACK INFORMATION on Vitamin D status among danish women in the Reproductive age during the fortification period, BUT for comparision, a study SHOWED that among 850 Pregnant women recruited from the second-largest city in denmark in 1988–1989 (the period without fortification), only 6·3 of the Pregnant women had a Serum 25(Oh)D concentration ≤25 nmol/l(12); the median concentrations of 76·2 (95 % ci 23·0, 152·1) nmol/l were also above the ‘OPTIMAL level’ as STATED by the us Endocrine society(62,63).']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('INCOMPLETE_EVIDENCE', 160), ('IMPORTANT_CONSIDERATION', 461), ('INCOMPLETE_EVIDENCE', 479)]	7	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0000003', 'reproduction', 81, 'reproductive'), ('GO_0007565', 'female pregnancy', 182, 'pregnant'), ('GO_0007565', 'female pregnancy', 312, 'pregnant'), ('UBERON_0001977', 'blood serum', 333, 'serum'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 339, '25(OH)D'), ('UBERON_0005063', 'left ventricular compact myocardium', 496, 'Endocrine')]
S46-PMC5513133	PMC5513133	7/2017	S46-PMC5513133	['during the course of Pregnancy, EVIDENCE from observational studies SHOWS DIVERGENT data on the concentration of Serum 25(Oh)D levels in different Trimesters of Pregnancy, with EITHER decline [41], increase [42], or absence of change in Vitamin D levels with progression [43,44].']	[('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 177)]	4	[('GO_0007565', 'female pregnancy', 21, 'pregnancy'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 119, '25(OH)D'), ('GO_0043033', 'isoamylase complex', 147, 'trimesters'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]
S130-PMC5513133	PMC5513133	7/2017	S130-PMC5513133	['brazil 2015 [83]↑ frequency of 25(Oh)D deficiency <20\xa0ng/ml in pe compared to healthy non obese controlspe: 52.1% (25 women)non obese controls: 14.9%(7 women)( p \xa0=\xa00.0006)abedi et al., iran, 2014 [84]↑ Vitamin D deficiency (<25.0\xa0nmol/l) in pe casesor\xa0=\xa024.0495% ci: 2.14–285.4achkar et al., canada, 2015 [81]↑ pe in women with 25(Oh)D\xa0<\xa030\xa0nmol/l vs women with at least 50\xa0nmol/ladjusted or: 2.2395% ci: 1.29–3.83anderson et al., usa, 2015 [111]↔ proportion of women with inadequate <30\xa0ng/ml 25(Oh)D levels in htn group vs control group73% (htn/pe group) vs 69% (control group)( p \xa0=\xa00.22)baker et al., 2010 [80]↑ severe pe in women with 25(Oh)D\xa0<\xa050\xa0nmol/l compared to levels of at least 75\xa0nmol/ladjusted or: 5.4195% ci: 2.02–14.52( p \xa0=\xa00.001)bodnar et al., usa, 2007 [18]↑ pe in women with 25(Oh)D\xa0<\xa037.5\xa0nmol/l compared to levels of >37.5\xa0nmol/ladjusted or: 5.095% ci: 1.7–14.1bodnar et al., usa, 2014 [79]↓ severe pe in women with 25(Oh)D\xa0≥\xa050\xa0nmol/l COMPARED to levels <50\xa0nmol/ladjusted rr: 0.6595% ci: 0.43–0.98gidlof s, et al.']	[('ANOMALY_CURIOUS_FINDING', 960)]	1	[('CHEBI_71657', 'versiconol acetate', 31, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 31, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 329, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 329, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 495, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 495, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 641, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 641, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 797, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 797, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 940, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 940, '25(OH)D')]
S132-PMC5513133	PMC5513133	7/2017	S132-PMC5513133	['germany, 2–14 [85]↓ 25(Oh)D levels in pe in summer compared to controls, 1,25(Oh)2D ↓ only in winter25(Oh)D: pe:18.2\xa0±\xa017.1; control: 49.2\xa0±\xa029.2\xa0ng/ml, ( p \xa0<\xa00.001); 1,25(Oh)2D: 291\xa0±\xa0217 vs 612.3\xa0±\xa0455\xa0pmol/ml ( p \xa0<\xa00.05)mohaghegh et al., iran, 2015 [89]↓ mean 25(Oh)D in pe compared to Pregnant controls without pe25(Oh)D:Pe: 37.9\xa0±\xa033.9\xa0nmol/lcontrols: 58.2\xa0±\xa038.2\xa0nmol/l( p \xa0=\xa00.001)powe, usa, 2010 [86]↔ women with pe and controls with 25(Oh)D\xa0<\xa015.0\xa0nmol/ladjusted or: 1.3595% ci: 0.40 to 4.50robinson et al., usa, 2010 [25]↑ eospe in women with maternal 25(Oh)D levels <=19.6\xa0nmol/l compared to levels >19.6\xa0nmol/lor: 3.6095% ci: 1.71–7.58( p \xa0<\xa00.001)schneuer et al., australia, 2014 [114]↔ pe or eospe and low 25(Oh)D (< 25\xa0nmol/l)adjusted or- all pe: 0.4695% ci: 0.19–1.10adjusted or- eospe: 1.4095% ci: 0.20 to 9.89singla et al., india, 2015 [87]↓ mean Serum Vitamin D in women with pe vs controlspe: 24.2\xa0±\xa012.4\xa0nmol/l controls: 36.9\xa0±\xa016.7\xa0nmol/l;( p \xa0=\xa00.0001)ullah et al., bangladesh, 2013 [82]↑ pe per 25\xa0nmol/l decrease in 25(Oh)D leveladjusted or: 1.6695% ci: 1.05–3.02wetta et al., uk, 2013 [96]↔ between pe and 25-Oh D\xa0<\xa030\xa0ng/ml and <37.4\xa0nmol/l<30\xa0ng/ml adjusted or: 1.195% ci: 0.6–2.0adjusted or: 1.4 (<37.4\xa0nmol/l)95% ci: 0.7–3.0woodham et al., usa, 2011 [15]↓ severe pe in women with 10\xa0nmol/l increase in maternal 25(Oh)D leveladjusted or: 0.6295% ci: 0.51–0.76xu et al., usa, 2014 [53]↑ pe in women with Vitamin D deficiency (<37.5\xa0nmol/l)or: 4.495% ci: 1.8–10.8yu et al., uk, 2012 [115]↔ Serum Vitamin D raw values in pe and controls25(Oh)D levels: controls: 46.8\xa0nmol/l (27.8–70.0;)early pe: 32.2\xa0nmol/l (22.7–50.4); late pe: 39.2\xa0nmol/l (22.1–63.0) ( p \xa0=\xa00.231)alvarez-fernandez et al., spain, 2014 [90]↑ pe in women with 25(Oh)D levels <50\xa0nmol/l compared TO levels >50\xa0nmol/l after 20\xa0weeks of Gestationor: 4.695% ci:1.4–15( p \xa0=\xa00.010)scholl et al., usa, 2013 [78]↑ pe in women with 25(Oh)D\xa0<\xa049.9\xa0nmol/l and hyperparathyroidismadjusted or: 2.8695% ci: 1.28–6.41burris et al., usa, 2014 [94]↔ Pe and 25(Oh)D levels compared at each 25\xa0nmol/l increase in 25 (Oh)Dadjusted or: 1.1495% ci: 0.77–1.67haugen et al., norway, 2000 [77]↓ pe in women taking 10–15 mcg/d as compared with no supplementsadjusted or: 0.7395% ci: 0.58–0.92shand et al., canada, 2010 [37]↔ pe and 25(Oh)D levels <37.5\xa0nmol/ladjusted or: 0.9195% ci: 0.31–2.62wei et al., canda 2012 [60]↔ Pe and 25(Oh)D\xa0<\xa050\xa0nmol/ladjusted or: 1.2495% ci: 0.58–2.67( p \xa0=\xa00.58)wei, canada, 2013 [14]↑ pe and women with ↓ pigf levels and maternal 25(Oh)d\xa0<\xa050\xa0nmol/ladjusted or: 2.9795% ci: 1.23–7.20zhou, china, 2014 [116]↔ pe and 25(Oh)D levels25(Oh)D levelsgroup a ( n \xa0=\xa013): 41.4\xa0±\xa06.5\xa0nmol/l; group b ( n \xa0=\xa036): 62.1\xa0±\xa07.0\xa0nmol/l; group c ( n \xa0=\xa025): 89.6\xa0±\xa013.0\xa0nmol/l; ( p \xa0=\xa00.900)\na case-cohort study of women from 12 different united states (us) sites whose vitamin D levels were measured at ≤26\xa0weeks of Gestation SHOWED that 25(Oh)D levels greater than 50\xa0nmol/l were ASSOCIATED with a 40% reduction in risk for severe pe (0.65 [95% ci 0.43 to 0.98]), although there was no reduction in absolute and relative risk for the milder clinical subtypes of pe when 25(Oh)D levels were greater than 50\xa0nmol/l [79].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 1791), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2293), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2609), ('INCOMPLETE_EVIDENCE', 2914), ('SUPERFICIAL_RELATIONSHIP', 2969)]	5	"[('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('CHEBI_73285', ""3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine"", 75, '25(OH)2D ↓'), ('CHEBI_33010', 'chromide(1-)', 102, '(OH)D'), ('CHEBI_82784', 'PVP38-Ag NP', 168, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 265, '25'), ('PR_000011614', 'opioid growth factor receptor', 268, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 271, 'D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 322, 'OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 327, 'PE'), ('CHEBI_71657', 'versiconol acetate', 444, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 444, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 725, 'OH)D'), ('UBERON_0001977', 'blood serum', 867, 'serum'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1043, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1043, '25(OH ... D'), ('CHEBI_72765', 'verruculogen', 1134, '25-OH D'), ('CHEBI_71657', 'versiconol acetate', 1343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1434, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1519, 'serum'), ('CHEBI_27300', 'vitamin D', 1525, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 1566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1759, 'OH)D'), ('GO_0007565', 'female pregnancy', 1830, 'gestationOR'), ('CHEBI_71657', 'versiconol acetate', 1920, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2030, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2037, '25(OH)D'), ('CHEBI_982', '2-Aceto-2-hydroxybutanoate', 2091, '25 (OH)DAdjusted'), ('CHEBI_71657', 'versiconol acetate', 2303, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2303, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2393, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2400, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 2534, '25(OH'), ('CHEBI_71657', 'versiconol acetate', 2619, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2635, '(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2865, 'D'), ('GO_0007565', 'female pregnancy', 2904, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 2926, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 3159, '25(OH)D')]"
S0-PMC5524288	PMC5524288	7/2017	S0-PMC5524288	['maternal 25(Oh)D concentrations ≥40 ng/ml ASSOCIATED with 60% lower Preterm Birth RISK among general obstetrical patients at an urban medical center\n\nabstract\n\nbackground\nGIVEN the HIGH RATE of Preterm Birth (ptb) nationwide and data from rcts DEMONSTRATING risk reduction with Vitamin D supplementation, the medical university of south carolina (musc) implemented a NEW standard of care for Pregnant women to receive Vitamin D testing and supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('IMPORTANT_CONSIDERATION', 82), ('INCOMPLETE_EVIDENCE', 171), ('IMPORTANT_CONSIDERATION', 181), ('INCOMPLETE_EVIDENCE', 244), ('FULL_UNKNOWN', 367)]	6	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 68, 'preterm birth'), ('GO_0007565', 'female pregnancy', 194, 'preterm birth'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('GO_0007565', 'female pregnancy', 392, 'pregnant'), ('CHEBI_27300', 'vitamin D', 418, 'vitamin D')]
S118-PMC5524288	PMC5524288	7/2017	S118-PMC5524288	['among women with initial 25(Oh)D concentrations <40 ng/ml, the significantly lower ptb rate (60%) for those who achieved ≥40 ng/ml COMPARED TO those who did not reach the target concentration on a follow-up test SUGGESTS that maternal Vitamin D status is a MODIFIABLE RISK FACTOR that CAN be addressed during the Prenatal period.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('INCOMPLETE_EVIDENCE', 212), ('IMPORTANT_CONSIDERATION', 257), ('SUPERFICIAL_RELATIONSHIP', 268), ('INCOMPLETE_EVIDENCE', 285)]	5	[('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 25, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D'), ('GO_0007565', 'female pregnancy', 313, 'prenatal')]
S127-PMC5524288	PMC5524288	7/2017	S127-PMC5524288	['a LIMITATION of THIS STUDY was that nearly two-thirds of the women (63%) had ONLY one 25(Oh)D test during Pregnancy, which PROHIBITED assessment by Trimester and a more thorough analysis of Vitamin D BENEFIT among those with low initial levels.']	[('INCOMPLETE_EVIDENCE', 2), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 77), ('DIFFICULT_TASK', 123), ('IMPORTANT_CONSIDERATION', 200)]	5	[('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 148, 'trimester'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
S150-PMC5537904	PMC5537904	7/2017	S150-PMC5537904	['IT IS POSSIBLE that the differential ASSOCIATIONS between 25(Oh)D and Birthweight according to maternal bmi we OBSERVED are DUE TO VARIATIONS in overall energy intake or OTHER nutritional factors that are concomitant with increased Vitamin D intake and THUS increased 25(Oh)D levels.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 111), ('PROBLEM_COMPLICATION', 124), ('DIFFICULT_TASK', 131), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('PROBABLE_UNDERSTANDING', 253)]	7	[('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 58, '25(OH)D'), ('GO_0007596', 'blood coagulation', 70, 'birthweight'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 268, '25(OH)D')]
S151-PMC5537904	PMC5537904	7/2017	S151-PMC5537904	['OUR finding that the ASSOCIATION between Cord Blood 25(Oh)D and Birthweight varies according to maternal bmi MUST BE REPLICATED in OTHER studies, including intervention trials, TO DETERMINE IF Vitamin D supplementation RECOMMENDATIONS to modify Birthweight SHOULD BE bmi-specific.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 21), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 117), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('QUESTION_ANSWERED_BY_THIS_WORK', 177), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 190), ('FUTURE_WORK', 219), ('FUTURE_WORK', 257)]	9	[('UBERON_0009472', 'axilla', 41, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 52, '25(OH)D'), ('GO_0007596', 'blood coagulation', 64, 'birthweight'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('GO_0007596', 'blood coagulation', 245, 'birthweight')]
S21-PMC5546866	PMC5546866	8/2017	S21-PMC5546866	['several of these Snps have been ASSOCIATED with the Serum 25(Oh)D increase in response to Vitamin D supplementation in SMALL STUDIES (9–11).']	[('SUPERFICIAL_RELATIONSHIP', 32), ('INCOMPLETE_EVIDENCE', 119)]	2	[('SO_0000694', 'SNP', 17, 'SNPs'), ('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 58, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
S96-PMC5634602	PMC5634602	10/2017	S96-PMC5634602	['INITIAL STUDIES of and RECOMMENDATIONS for Vitamin D intake were designed to PREVENT rickets in term infants targeting a Serum 25(Oh)D level of >50 nmol/l [36,37].']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 23), ('SUPERFICIAL_RELATIONSHIP', 77)]	3	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0001977', 'blood serum', 121, 'serum'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 127, '25(OH)D')]
S13-PMC5659607	PMC5659607	10/2017	S13-PMC5659607	['conclusions\nthis combined analysis SHOWS that Vitamin D supplementation during Pregnancy results in a significant reduced risk of asthma/recurrent wheeze in the offspring, ESPECIALLY among women with 25(Oh)D level ≥ 30 ng/ml at randomization, where the risk was almost halved.']	[('INCOMPLETE_EVIDENCE', 35), ('ANOMALY_CURIOUS_FINDING', 172)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 200, '25(OH)D')]
S135-PMC5659607	PMC5659607	10/2017	S135-PMC5659607	['to explore that ISSUE, we performed the combined analyses stratified for the women’s 25(Oh)D level at trial entry, which SHOWED that the Vitamin D supplement resulted in a significantly reduced RISK of asthma/recurrent wheeze in the offspring of women with 25(Oh)D ≥ 30 ng/ml, BUT a much SMALLER and statistically non-significant EFFECT among women with 25(Oh)D < 30 ng/ml.']	[('PROBLEM_COMPLICATION', 16), ('INCOMPLETE_EVIDENCE', 121), ('IMPORTANT_CONSIDERATION', 194), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 277), ('INCOMPLETE_EVIDENCE', 288), ('SUPERFICIAL_RELATIONSHIP', 330)]	6	[('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 91, 'D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 257, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 257, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 354, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 354, '25(OH)D')]
S153-PMC5659607	PMC5659607	10/2017	S153-PMC5659607	['conclusion\nthis combined analysis SHOWS a significant and clinically IMPORTANT 26% PROTECTIVE EFFECT of Vitamin D supplementation during Pregnancy on the RISK of asthma/recurrent wheeze in the offspring, with a more pronounced risk reduction of 46% in women with 25(Oh)D level ≥ 30 ng/ml at trial entry.']	[('INCOMPLETE_EVIDENCE', 34), ('IMPORTANT_CONSIDERATION', 69), ('SUPERFICIAL_RELATIONSHIP', 83), ('SUPERFICIAL_RELATIONSHIP', 94), ('IMPORTANT_CONSIDERATION', 154)]	5	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 263, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 263, '25(OH)D')]
S89-PMC5679631	PMC5679631	11/2017	S89-PMC5679631	['use of multivitamin supplements containing Vitamin D and maternal obesity were ASSOCIATED with maternal 25(Oh)D level during both low and high seasons, WHILE recruitment group was significantly ASSOCIATED with 25(Oh)D concentration ONLY during the high season.10.1371/journal.pone.0188011.t002\n\ncaption (table-wrap): table 2\nmean maternal 25(Oh)D concentration according to season of Blood sampling and use of multivitamin supplements containing Vitamin D.Blood sampling in high season of cutaneous Vitamin D productionblood sampling in low season of cutaneous Vitamin D production maternal use of multivitamin supplement containing Vitamin Dmaternal Plasma 25(Oh)d nmol/lmaternal Plasma 25(Oh)D nmol/l no (mean (sd))45.2 (17.0)30.1 (13.5)yes (mean (sd))53.3 (17.8)40.9 (16.1)p value&p = 0.000p = 0.000model # beta (95% ci)beta (95% ci) constant52.7 (47.7, 57.7)34.6 (29.5, 39.7)maternal use of multivitamin supplement containing Vitamin D (yes vs .']	[('SUPERFICIAL_RELATIONSHIP', 79), ('ANOMALY_CURIOUS_FINDING', 152), ('SUPERFICIAL_RELATIONSHIP', 194), ('INCOMPLETE_EVIDENCE', 232)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 104, '25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 210, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 210, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 339, '25 ... OH ... D'), ('UBERON_0000178', 'blood', 384, 'blood'), ('CHEBI_27300', 'vitamin D', 446, 'vitamin D'), ('UBERON_0000178', 'blood', 456, 'Blood'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 561, 'vitamin D'), ('CHEBI_61716', 'alpha-Kdo-CH2OH-(2->4)-alpha-Kdo', 633, 'vitamin DMaternal'), ('UBERON_0001969', 'blood plasma', 651, 'Plasma'), ('CHEBI_63056', 'zinc cation', 658, '25(OH'), ('UBERON_0001969', 'blood plasma', 681, 'Plasma'), ('CHEBI_71657', 'versiconol acetate', 688, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 930, 'vitamin D')]
S92-PMC5679631	PMC5679631	11/2017	S92-PMC5679631	['conventional recruitment group -4.6 (-7.8, -1.4) -3.1 (-6.4, 0.3)\nhigh season = april–october, low season = november–march; overweight = body mass index > 90thpercentile;\n&unpaired t-test;\n#regression coefficients (beta) from multivariable linear regression analysis INDICATE the difference in maternal Plasma 25(Oh)D in nmol/l between the group of mothers taking multivitamin supplement containing Vitamin D and those who did not while controlling for the other factors in the model\n\nmaternal Vitamin D intake through use of multivitamin supplements containing Vitamin d\nmaternal use of multivitamin supplements containing Vitamin D was not associated with the prevalence of any of the bacteria in both the unadjusted and adjusted analyses (data not shown).']	[('INCOMPLETE_EVIDENCE', 267)]	1	[('UBERON_0001969', 'blood plasma', 303, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 310, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 310, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 399, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 494, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 562, 'vitamin'), ('CHEBI_27300', 'vitamin D', 624, 'vitamin D')]
S130-PMC5679631	PMC5679631	11/2017	S130-PMC5679631	['ALTHOUGH Vitamin D promotes Immune tolerance, adequate Adaptive Immune Response, as measured by Igg Production in response to infection or vaccination, HAS BEEN observed in patients with relatively high Serum 25(Oh)D levels, SUGGESTING that Vitamin D maintains Immune stability by preventing excessive Immune Responses in EITHER direction [26].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 152), ('INCOMPLETE_EVIDENCE', 225), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 322)]	5	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('UBERON_0002405', 'immune system', 28, 'immune'), ('GO_0002250', 'adaptive immune response', 55, 'adaptive immune response'), ('UBERON_0002405', 'immune system', 64, 'immune'), ('GO_0032608', 'interferon-beta production', 96, 'IgG production'), ('GO_0071735', 'IgG immunoglobulin complex', 96, 'IgG'), ('UBERON_0001977', 'blood serum', 203, 'serum'), ('CHEBI_71657', 'versiconol acetate', 209, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 209, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('UBERON_0002405', 'immune system', 261, 'immune'), ('GO_0006955', 'immune response', 302, 'immune responses'), ('UBERON_0002405', 'immune system', 302, 'immune')]
S93-PMC5706533	PMC5706533	11/2017	S93-PMC5706533	['estimated mean change in effective Vitamin D dose for every 20 nmol/l increase in baseline mean 25(Oh)D concentration was increase of 208 iu/day (p=0.54)\n\nEFFECTS on maternal and Cord Blood 25-Hydroxyvitamin D concentrations\nwe performed meta-analyses for 11 maternal and 27 neonatal/infant outcomes (tables 2 and 3).']	[('SUPERFICIAL_RELATIONSHIP', 155)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 96, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 179, 'cord'), ('UBERON_0000178', 'blood', 184, 'blood'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 190, '25-hydroxyvitamin D')]
S96-PMC5706533	PMC5706533	11/2017	S96-PMC5706533	['higher regular dose regimens (≥2000 iu/day) LED TO a greater average increment in Maternal Delivery and Cord 25(Oh)D than lower doses (tables s1 and s2 in appendix 10); HOWEVER, the linear dose-response curves for maternal and Cord Blood INDICATED modest EFFECTS of increasing Vitamin D doses on the increment in 25(Oh)D concentrations (fig s2 and s4 in Appendix 10).']	[('SUPERFICIAL_RELATIONSHIP', 44), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 169), ('INCOMPLETE_EVIDENCE', 238), ('SUPERFICIAL_RELATIONSHIP', 255)]	4	[('GO_0007618', 'mating', 82, 'maternal'), ('GO_0007567', 'parturition', 91, 'delivery'), ('UBERON_0002240', 'spinal cord', 104, 'cord'), ('CHEBI_71657', 'versiconol acetate', 109, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 109, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 227, 'cord'), ('UBERON_0000178', 'blood', 232, 'blood'), ('CHEBI_27300', 'vitamin D', 277, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 313, '25(OH)D'), ('UBERON_0001154', 'vermiform appendix', 354, 'appendix')]
S159-PMC5706533	PMC5706533	11/2017	S159-PMC5706533	['the INTERPRETATION of Micronutrient intervention trials, HOWEVER, is COMPLEX BECAUSE all Individuals have some Vitamin D intake or Endogenous production.35the EFFECT of a given dose depends on the difference between the intervention and control doses (or the difference in mean 25(Oh)D in the intervention versus control group at/near delivery) as well as baseline Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 4), ('PROBABLE_UNDERSTANDING', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 57), ('DIFFICULT_TASK', 69), ('PROBABLE_UNDERSTANDING', 77), ('SUPERFICIAL_RELATIONSHIP', 159)]	6	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 22, 'micronutrient'), ('NCBITaxon_1', 'root', 89, 'individuals'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0009790', 'embryo development', 131, 'endogenous'), ('CHEBI_71657', 'versiconol acetate', 278, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 278, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 365, 'vitamin D')]
S164-PMC5706533	PMC5706533	11/2017	S164-PMC5706533	['we CONSIDERED the weak ASSOCIATION between dose and 25(Oh)D to reflect the overall low quality of many of the trials, which TEMPERED expectations of finding dose DEPENDENT EFFECTS of Vitamin D on clinical outcomes.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('SUPERFICIAL_RELATIONSHIP', 162), ('SUPERFICIAL_RELATIONSHIP', 172)]	5	[('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 52, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D')]
S35-PMC5827025	PMC5827025	2/2018	S35-PMC5827025	['influence of demographic characteristics on Gestational Serum 25(Oh)D concentration\nthe demographic characteristics for INFLUENCING Gestational Vitamin D status were analyzed.']	[('SUPERFICIAL_RELATIONSHIP', 120)]	1	[('GO_0007565', 'female pregnancy', 44, 'gestational'), ('UBERON_0001977', 'blood serum', 56, 'serum'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 62, '25(OH)D'), ('GO_0007565', 'female pregnancy', 132, 'gestational'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
S29-PMC5941617	PMC5941617	5/2018	S29-PMC5941617	['in literature, several cut-offs HAVE BEEN PROPOSED for Vitamin D deficiency with respect to Serum 25(Oh)D levels measured with a RELIABLE assay.']	[('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 42), ('IMPORTANT_CONSIDERATION', 129)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('UBERON_0001977', 'blood serum', 92, 'serum'), ('CHEBI_71657', 'versiconol acetate', 98, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 98, '25(OH)D')]
S67-PMC5941617	PMC5941617	5/2018	S67-PMC5941617	['other italian data are present in literature, ALTHOUGH they SHOW SOME LIMITATIONS, regarding SMALL populations, analytic methods for 25(Oh)D, the season of recruitment, the prevalence of overweight/obesity, Vitamin D supplements, sunscreens, ethnicity, and uncovered areas of latitude.']	[('ANOMALY_CURIOUS_FINDING', 46), ('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 70), ('PROBLEM_COMPLICATION', 70), ('INCOMPLETE_EVIDENCE', 93)]	6	[('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 133, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]
S162-PMC5941617	PMC5941617	5/2018	S162-PMC5941617	['supplementation at 400\xa0iu/day for variable length (up to 12\xa0months) was USUALLY INSUFFICIENT in raising Serum 25(Oh)D levels >\u200930\xa0ng/ml [78,147–149,151–153,160–162], particularly in subjects with Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 72), ('PROBLEM_COMPLICATION', 80)]	2	[('UBERON_0001977', 'blood serum', 104, 'serum'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 110, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D')]
S163-PMC5941617	PMC5941617	5/2018	S163-PMC5941617	['a RECENT rct performed during winter SHOWED that a Vitamin D intake up to 800\xa0iu/day was REQUIRED by white danish children (4–8\xa0years) to maintain Serum 25(Oh)D\u2009>\u200920\xa0ng/ml.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 37), ('IMPORTANT_CONSIDERATION', 89)]	3	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('UBERON_0001977', 'blood serum', 147, 'serum'), ('CHEBI_71657', 'versiconol acetate', 153, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 153, '25(OH)D')]
S181-PMC5941617	PMC5941617	5/2018	S181-PMC5941617	['subsequent italian cross sectional studies enrolling children and adolescents living in the north-western area of tuscany, central italy (latitude between 43°n and 44°n) not receiving Vitamin D supplementation CONFIRMED seasonal variability in Serum 25(Oh)D levels, with lower concentrations during late winter-early spring months (february–april), with negligible amount of Vitamin D obtained from diet [50,79], ACCORDING TO OTHER italian pediatric studies [70,76–78,83].']	[('INCOMPLETE_EVIDENCE', 210), ('INCOMPLETE_EVIDENCE', 413), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 426)]	3	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0001977', 'blood serum', 244, 'serum'), ('CHEBI_71657', 'versiconol acetate', 250, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 250, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 375, 'vitamin D')]
S211-PMC5941617	PMC5941617	5/2018	S211-PMC5941617	['a RECENT GLOBAL CONSENSUS RECOMMENDATIONS on prevention and management of nutritional rickets DEFINED Vitamin D deficiency AS Serum 25(Oh)D\u2009<\u2009\xa012\xa0ng/ml, CONSIDERING the increased incidence of rickets with Serum 25(Oh)D levels under this THRESHOLD [28].']	[('INCOMPLETE_EVIDENCE', 2), ('IMPORTANT_CONSIDERATION', 9), ('PROBABLE_UNDERSTANDING', 16), ('FUTURE_WORK', 26), ('INCOMPLETE_EVIDENCE', 94), ('PROBABLE_UNDERSTANDING', 94), ('PROBABLE_UNDERSTANDING', 123), ('IMPORTANT_CONSIDERATION', 153), ('PROBABLE_UNDERSTANDING', 237)]	9	[('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('UBERON_0001977', 'blood serum', 126, 'serum'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 132, '25(OH)D'), ('UBERON_0001977', 'blood serum', 205, 'serum'), ('CHEBI_71657', 'versiconol acetate', 211, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 211, '25(OH ... D')]
S264-PMC5941617	PMC5941617	5/2018	S264-PMC5941617	['HOWEVER, the EFFECT of supplementation became significant on total body bmc and Lumbar Spine bmd by dividing the sample into two groups, depending on Vitamin D status [25(Oh)D levels <\u200914\xa0ng/ml vs. ≥ 14\xa0ng/ml], SUGGESTING that Vitamin D supplementation MAY result in a clinically significant increase in bone mass in subjects with Vitamin D deficiency.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 211), ('INCOMPLETE_EVIDENCE', 253)]	4	[('UBERON_0006074', 'lumbar region of vertebral column', 80, 'lumbar spine'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 168, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 168, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 331, 'vitamin D')]
S292-PMC5941617	PMC5941617	5/2018	S292-PMC5941617	['camargo et al., after adjusting for season of Birth, FOUND that newborns with Vitamin D Cord Blood levels <\u200910\xa0ng/ml had a two-fold (odds ratio: 2.16; 95% ci 1.35–3.46) increased risk of Respiratory infections by 3\xa0months of age as COMPARED TO newborns with 25(Oh)D concentrations >\u200930\xa0ng/ml [252].']	[('INCOMPLETE_EVIDENCE', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 232)]	2	[('GO_0007567', 'parturition', 46, 'birth'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 88, 'cord'), ('UBERON_0000178', 'blood', 93, 'blood'), ('UBERON_0001004', 'respiratory system', 187, 'respiratory'), ('CHEBI_71657', 'versiconol acetate', 258, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 258, '25(OH)D')]
S333-PMC5941617	PMC5941617	5/2018	S333-PMC5941617	['an italian rct was performed TO TEST WHETHER Vitamin D3Supplementation (oral 100000\xa0iu every 3\xa0months for 4 doses) COULD improve Vitamin D status and AFFECT the t-Cell phenotype in hiv-infected patients aged 8 to 26\xa0years with Serum 25(Oh) D\u2009<\u200930\xa0ng/ml.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 37), ('INCOMPLETE_EVIDENCE', 115), ('SUPERFICIAL_RELATIONSHIP', 150)]	4	[('CHEBI_52915', 'phosphatediyl group', 45, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CL_0000622', 'acinar cell', 162, '-cell'), ('UBERON_0001977', 'blood serum', 227, 'serum'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 233, '25(OH) D')]
S450-PMC5941617	PMC5941617	5/2018	S450-PMC5941617	['finally, a single age DEPENDENT high-dose oral Vitamin D3(the SO-CALLED stoss therapy; <\u20093\xa0years: 200000\xa0iu; 4–12\xa0years 400000\xa0iu; >\u200912\xa0years 800000\xa0iu) was SAFE and efficacious in achieving and maintaining Serum 25(Oh)D levels >\u200920\xa0ng/ml during a 6-month period in ibd children with Vitamin D deficiency [412].']	[('SUPERFICIAL_RELATIONSHIP', 22), ('INCOMPLETE_EVIDENCE', 62), ('IMPORTANT_CONSIDERATION', 157)]	3	[('CHEBI_33279', 'vitamin D5', 47, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 47, 'vitamin D3'), ('UBERON_0001977', 'blood serum', 207, 'serum'), ('CHEBI_71657', 'versiconol acetate', 213, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 213, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 284, 'vitamin D')]
S560-PMC5941617	PMC5941617	5/2018	S560-PMC5941617	['SUGGESTED that a Vitamin D intake of AT LEAST 4000\xa0iu/day SHOULD BE CONSIDERED in all Pregnant women to maintain Serum 25(Oh)D levels ≥40\xa0ng/ml [513,514].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 37), ('FUTURE_WORK', 58), ('FUTURE_WORK', 68)]	4	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnant'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 119, '25(OH)D')]
S577-PMC5941617	PMC5941617	5/2018	S577-PMC5941617	['daily administration of 2000\xa0iu of Vitamin D3For 16\xa0weeks was EFFECTIVE in increasing Serum 25(Oh)D levels >\u200930\xa0ng/ml also in black adolescents (14–18\xa0years) with Vitamin D deficiency [151].']	[('SUPERFICIAL_RELATIONSHIP', 62)]	1	[('CHEBI_27364', 'zinc molecular entity', 35, 'vitamin D3for'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 92, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
S582-PMC5941617	PMC5941617	5/2018	S582-PMC5941617	['a RECENT 1-year-RCT compared three different regimens for asymptomatic children and adolescents with Vitamin D deficiency and insufficiency (400\xa0iu/day, 45000\xa0iu weekly for 2\xa0months then 400\xa0iu daily, 2000\xa0iu/day for 3\xa0months then 1000\xa0iu/day), SUGGESTING that low loading dose with high maintenance dose is PREFERRED to achieve steady increase in Serum 25(Oh)D levels avoiding hypercalcemic side effects [521].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 245), ('PROBABLE_UNDERSTANDING', 308)]	3	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0001977', 'blood serum', 348, 'serum'), ('CHEBI_71657', 'versiconol acetate', 354, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 354, '25(OH)D')]
S615-PMC5941617	PMC5941617	5/2018	S615-PMC5941617	['DEPENDING ON 25(Oh)D levels, Vitamin D status can be defined as follows:\nsufficiency ≥30\xa0ng/ml\ninsufficiency 20–29\xa0ng/ml\ndeficiency <\u200920\xa0ng/ml\nsevere deficiency <\u200910\xa0ng/ml\nthe term hypovitaminosis D refers to Serum 25(Oh)D levels <\u200930\xa0ng/ml.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 197, 'D'), ('UBERON_0001977', 'blood serum', 209, 'serum'), ('CHEBI_71657', 'versiconol acetate', 215, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 215, '25(OH)D')]
S125-PMC5956785	PMC5956785	5/2018	S125-PMC5956785	['2009 52°n [59]pediatric arthralgia n \u2009=\u2009730 25(Oh)D n \u2009=\u200973<\u20091859.9significantly more reported fall and winter as season of onset – more referrals from northern sk 40%\u2009<\u200950\xa0nmol/l 42% 50–75\xa0nmol/l ASSOCIATION between psychological stress, school absenteeism Vitamin D insufficiency and arthralgia.helinski, finland valta et al.']	[('SUPERFICIAL_RELATIONSHIP', 197)]	1	[('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 44, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]
S29-PMC6011374	PMC6011374	6/2018	S29-PMC6011374	['using a robust, validated chemiluminescent-based assay to measure Serum 25(Oh)D [27], we AIMED TO INVESTIGATE the DIFFERENCES between Vitamin D status in early Pregnancy in two distinct populations of Nulliparous women from australia and new zealand.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 89), ('QUESTION_ANSWERED_BY_THIS_WORK', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114)]	3	[('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 72, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy'), ('GO_0046662', 'regulation of oviposition', 201, 'nulliparous')]
S30-PMC6011374	PMC6011374	6/2018	S30-PMC6011374	['we also AIMED TO EXAMINE the RELATIONSHIP between Serum 25(Oh)D at 15\u2009±\u20091\xa0weeks’ Gestation and the risk of an adverse Pregnancy outcome and included determining the EFFECT modification of fetal sex on the ASSOCIATION between maternal Vitamin D status and Pregnancy outcome.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 29), ('SUPERFICIAL_RELATIONSHIP', 165), ('SUPERFICIAL_RELATIONSHIP', 205)]	5	[('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 56, '25(OH)D'), ('GO_0007565', 'female pregnancy', 81, 'gestation'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy')]
S63-PMC6011374	PMC6011374	6/2018	S63-PMC6011374	['HOWEVER, after adjusting for maternal age, bmi, sei, smoking status and Alcohol consumption at 15\u2009±\u20091\xa0weeks’ Gestation, ethnicity, recreational walking and season, the women recruited in adelaide STILL had significantly lower Serum 25(Oh)D when compared with those in auckland (adelaide: 58.4\u2009±\u200950.3 vs. auckland: 70.2\u2009±\u200954.5\xa0nmol/l, p\u2009<\u20090.001) INDICATING the INFLUENCE of OTHER CONFOUNDERS not measured as part of the study on Vitamin D status.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 196), ('INCOMPLETE_EVIDENCE', 345), ('SUPERFICIAL_RELATIONSHIP', 360), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 373), ('PROBLEM_COMPLICATION', 379)]	6	[('CHEBI_30879', 'alcohol', 72, 'alcohol'), ('GO_0007565', 'female pregnancy', 109, 'gestation'), ('UBERON_0001977', 'blood serum', 226, 'serum'), ('CHEBI_71657', 'versiconol acetate', 232, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 232, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 428, 'vitamin D')]
S64-PMC6011374	PMC6011374	6/2018	S64-PMC6011374	['caption (table-wrap): table 1\n\nparticipant characteristics and comparison of characteristics between women recruited at the adelaide and auckland scope centresall women (n = 2800)adelaide (n = 1156)auckland (n = 1644) p value*age yrs , mean (sd)28 (6)23.73 (5.11)30.44 (4.82)<0.0001bmi kg/m2, mean (sd)25.8 (5.44)27.04 (6.56)24.88 (4.26)<0.0001ethnicity<0.0001\u2003caucasian2449 (87)1060 (92)1389 (84)\u2003non caucasian351 (13)96 (8)255 (16)smoking status, n (%)<0.0001\u2003no2152 (77)704 (61)1448 (88)\u2003quit during Pregnancy306 (11)175 (15)131 (8)\u2003smoking342 (12)277 (24)65 (4)Alcohol consumption, n (%)<0.0001\u2003no1480 (53)708 (61)772 (47)\u2003stopped during pregnancy1185 (42)397 (34)788 (48)\u2003consuming Alcohol135 (5)51 (4)84 (5)fruit intake, n (%)<0.0001\u2003≥1x per day2032 (73)586 (51)1446 (88)\u20033-6x per week405 (14)272 (24)133 (8)\u20031-2x per week223 (8)181 (16)42 (3)\u20031-3x per month or less140 (5)117 (10)23 (1)recreational walking<0.0001\u2003never428 (15)265 (23)163 (10)\u20031-3 times/week1773 (63)668 (58)1105 (68)\u2003≥4 times/week590 (22)221 (19)369 (23)time watching tv<0.0001\u2003<5 hours per day2404 (86)901 (78)1503 (92)\u2003≥5 hours per day387 (14)253 (22)134 (8)season Serum was sampled0.3213\u2003summer636 (23)278 (24)358 (22)\u2003autumn705 (25)273 (24)432 (26)\u2003winter727 (26)300 (26)427 (26)\u2003spring732 (26)305 (26)427 (26)Serum 25(Oh)D nmol/l , mean (sd)68.09 (27.14)60.06 (23.68)73.74 (27.99)<0.0001vitamin D status<0.0001\u2003<25 nmol/l99 (4)48 (4)51 (3)\u200325-50 nmol/l673 (24)375 (32)298 (18)\u200350-75 nmol/l928 (33)422 (37)506 (31)\u2003>75 nmol/l1098 (39)311 (27)787 (48)\n* p values for continuous variables were determined using a welch’s t-test and categorical variables a fisher’s exact test comparing adelaide and auckland women\n\nstandardising Serum 25(Oh)D based on seasonal variation\nAS EXPECTED, there was a seasonal INFLUENCE on Serum 25(Oh)D and THUS, “standardised” Vitamin D concentrations were calculated to account for the month of Serum collection.']	[('INCOMPLETE_EVIDENCE', 1748), ('SUPERFICIAL_RELATIONSHIP', 1782), ('PROBABLE_UNDERSTANDING', 1813)]	3	[('GO_0007602', 'phototransduction', 503, 'pregnancy306'), ('CHEBI_30879', 'alcohol', 565, 'Alcohol'), ('CHEBI_78635', 'fatty alcohol 16:1', 687, 'alcohol135'), ('UBERON_0001977', 'blood serum', 1142, 'serum'), ('UBERON_0001977', 'blood serum', 1289, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 1295, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1375, 'D'), ('UBERON_0001977', 'blood serum', 1706, 'serum'), ('CHEBI_71657', 'versiconol acetate', 1712, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1712, '25(OH)D'), ('UBERON_0001977', 'blood serum', 1795, 'serum'), ('CHEBI_71657', 'versiconol acetate', 1801, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1801, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1834, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1903, 'serum')]
S80-PMC6011374	PMC6011374	6/2018	S80-PMC6011374	['caption (table-wrap): table 2\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaneous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status categorised based on standardised quartiles and clinical definitions of Vitamin D statuspregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci)standardised quartiles**\u2003low711 (25)328 (46)0.95 (0.85, 1.07)46 (6)1.02 (0.66, 1.57))57 (8)0.97 (0.67, 1.42)28 (4)0.79 (0.47, 1.30)36 (5)0.83 (0.54, 1.29)84 (12)1.02 (0.75, 1.39)\u2003low-moderate755 (27)318 (42)1.00 (0.90, 1.12)42 (6)1.07 (0.69, 1.64)65 (9)1.06 (0.74, 1.52)25 (3)0.67 (0.39, 1.16)33 (4)0.87 (0.56, 1.3572 (10)0.98 (0.73, 1.32)\u2003moderate-high702 (25)309 (44)1.0†37 (5)1.0†50 (7)1.0†28 (4)1.0†39 (6)1.0†81 (12)1.0†\u2003high630 (23)258 (41)0.93 (0.82, 1.06)†35 (6)1.24 (0.78, 1.96)40 (6)0.87 (0.58, 1.30)10 (2) 0.47(0.23, 0.96) 30 (5)0.77 (0.48, 1.25)60 (10)0.80 (0.57, 1.11)Vitamin d status\u2003<25 nmol/l99 (4)51 (52)1.10 (0.89, 1.36)8 (8)1.44 (0.68, 3.03))6 (6)0.70 (0.32, 1.52)5 (5)0.98 (0.38, 2.52)7 (7)1.44 (0.68, 3.04)13 (13)1.15 (0.66, 2.01)\u200325-50 nmol/l673 (24)301 (45)0.93 (0.83, 1.03)45 (7)1.18 (0.80, 1.75)59 (9)0.97 (0.71, 1.34)26 (4)0.89 (0.54, 1.47)29 (4)0.75 (0.48, 1.16)74 (11)0.93 (0.69, 1.24)\u2003>50-75 nmol/l928 (33)428 (46)1.0†48 (5)1.0†80 (9)1.0†35 (4)1.0†52 (6)1.0†107 (12)1.0†\u2003>75 nmol/l1098 (39)435 (40)0.95 (0.86, 1.04)60 (5)1.28 (0.87, 1.87)67 (6)0.82 (0.59, 1.12)†26 (2)0.78 (0.48, 1.28)51 (5)0.86 (0.59, 1.26)104 (9)0.86 (0.67, 1.12)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that Serum was sampled based as previously described [34]\n†reference category\n\nSerum 25(Oh)D, Pregnancy outcome and fetal sex\nas THERE IS EVIDENCE to SUGGEST that Vitamin D Metabolism within the Placenta MAY DIFFER with respect to fetal sex [35] THUS, we ASSESSED the EFFECT of “standardised” Vitamin D status on Pregnancy outcome stratified by fetal sex (table\xa03).']	[('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2251), ('INCOMPLETE_EVIDENCE', 2305), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2309), ('PROBABLE_UNDERSTANDING', 2347), ('QUESTION_ANSWERED_BY_THIS_WORK', 2356), ('SUPERFICIAL_RELATIONSHIP', 2369)]	7	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 210, 'preterm birth'), ('GO_0007565', 'female pregnancy', 245, 'gestational'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 1141, 'Vitamin'), ('GO_0007565', 'female pregnancy', 1882, 'gestation'), ('CHEBI_30879', 'alcohol', 1906, 'alcohol'), ('UBERON_0001977', 'blood serum', 2060, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2066, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2066, '25(OH)D'), ('UBERON_0001977', 'blood serum', 2106, 'serum'), ('UBERON_0001977', 'blood serum', 2180, 'Serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 2189, 'OH)D'), ('GO_0007565', 'female pregnancy', 2195, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 2264, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 2264, 'vitamin D metabolism'), ('UBERON_0001987', 'placenta', 2296, 'placenta'), ('CHEBI_27300', 'vitamin D', 2394, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2414, 'pregnancy')]
S86-PMC6011374	PMC6011374	6/2018	S86-PMC6011374	['caption (table-wrap): table 3\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaeous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status and stratified by fetal sexpregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci)standardised quartiles**males\u2003low367 (26)173 (47)1.00 (0.85, 1.18)24 (7)1.24 (0.65, 2.34)31 (8)1.11 (0.64, 1.94)18 (5)1.25 (0.58, 2.68)22 (6)1.09 (0.60, 1.98)43 (12)1.14 (0.73, 1.79)\u2003low-moderate364 (26)163 (45)1.01 (0.86, 1.19))20 (5)1.11 (0.58, 2.12)32 (9)1.25 (0.73, 2.13)13 (4)1.06 (0.48, 2.38)18 (5)0.93 (0.49, 1.76)45 (12)1.23 (0.80, 1.88)\u2003moderate-high359 (25)152 (42)1.0†16 (4)1.0†23 (6)1.0†11 (3)1.0†18 (5)1.0†35 (10)1.0†\u2003high325 (23)111 (34)0.86 (0.71, 1.04)15 (5)1.18 (0.59, 2.36)17 (5)0.90 (0.50, 1.62)4 (1)0.45 (0.15, 1.38)15 (5)0.97 (0.50, 1.88)26 (8)0.77 (0.47, 1.26)females\u2003low380 (28)169 (44)0.91 (0.77, 1.06)23 (6)0.85 (0.47, 1.55)30 (8)0.87 (0.52, 1.45)13 (3)0.51 (0.25, 1.04)14 (4)0.61 (0.31, 1.18)45 (12)0.88 (0.58, 1.35)\u2003low-moderate353 (26)168 (48)0.99 (0.85, 1.15)24 (7)1.03 (0.57, 1.85)31 (9)0.92 (0.57, 1.50)9 (3) 0.44(0.20, 0.97) 18 (5)0.79 (0.43, 1.45)33 (9)0.74 (0.48, 1.13)\u2003moderate-high334 (24)149 (45)1.0†19 (6)1.0†28 (8)1.0†17 (5)1.0†21 (6)1.0†31 (9)1.0†\u2003high314 (23)128 (41)1.00 (0.84, 1.19)19 (6)1.29 (0.70, 2.35)20 (6)0.85 (0.49, 1.46)6 (2)0.48 (0.19, 1.23)12 (4)0.60 (0.30, 1.21)29 (9)0.82 (0.53, 1.28)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that serum was sampled based as previously described [34]\n†reference category\n\ndiscussion\nthis study ADDS TO THE current body of LITERATURE on Vitamin D status in a population of Pregnant australian and new zealand women and provides INSIGHT into normal circulating levels of 25(Oh)D in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 2125), ('INCOMPLETE_EVIDENCE', 2258)]	2	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 209, 'preterm birth'), ('GO_0007565', 'female pregnancy', 244, 'gestational'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1805, 'gestation'), ('CHEBI_30879', 'alcohol', 1829, 'alcohol'), ('UBERON_0001977', 'blood serum', 1983, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 1989, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1989, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 2167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2203, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 2300, '25(OH)D'), ('GO_0007565', 'female pregnancy', 2317, 'pregnancy')]
S98-PMC6011374	PMC6011374	6/2018	S98-PMC6011374	['as INDICATED by the seasonal variation in Serum 25(Oh)D, amongst women recruited in adelaide, Vitamin D status declined significantly from february to april WHILST in the women recruited in auckland, Serum 25(Oh)D in march and april remained elevated before declining.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 157)]	2	[('UBERON_0001977', 'blood serum', 42, 'serum'), ('CHEBI_71657', 'versiconol acetate', 48, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 48, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0001977', 'blood serum', 200, 'serum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 206, '25(OH)D')]
S111-PMC6011374	PMC6011374	6/2018	S111-PMC6011374	['lack of statistically significant associations with other Pregnancy complications MAY reflect the fact that this was a largely Vitamin D-replete population (>\u200972% with Serum 25(Oh)D\u2009>\u200950\xa0nmol/l) LIKELY DUE TO their residence latitude as low Serum 25(Oh)D was found in the scope ireland cohort [52].']	[('INCOMPLETE_EVIDENCE', 82), ('PROBABLE_UNDERSTANDING', 195), ('PROBLEM_COMPLICATION', 202)]	3	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('UBERON_0001977', 'blood serum', 168, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 177, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 180, 'D'), ('UBERON_0001977', 'blood serum', 241, 'serum'), ('CHEBI_71657', 'versiconol acetate', 247, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 247, '25(OH)D')]
